<html lang="en"><head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1, shrink-to-fit=no">
    <link rel="shortcut icon" href="./favicon.png">
    <link rel="preload" href="./static/media/SourceSansPro-Regular.DZLUzqI4.woff2" as="font" type="font/woff2" crossorigin="">
    <link rel="preload" href="./static/media/SourceSansPro-SemiBold.sKQIyTMz.woff2" as="font" type="font/woff2" crossorigin="">
    <link rel="preload" href="./static/media/SourceSansPro-Bold.-6c9oR8J.woff2" as="font" type="font/woff2" crossorigin="">

    <title>app</title>

    <!-- initialize window.prerenderReady to false and then set to true in React app when app is ready for indexing -->
    <script>
      window.prerenderReady = false
    </script>
    <script type="module" crossorigin="" src="./static/js/index.BlylrL8P.js"></script>
    <link rel="stylesheet" crossorigin="" href="./static/css/index.DpJG_94W.css">
  <style media=""></style><style data-emotion="st-emotion-cache-global" data-s=""></style><style data-emotion="st-emotion-cache" data-s=""></style><link rel="modulepreload" as="script" crossorigin="" href="https://pieree369-olmocr.hf.space/static/js/index.BqlD3NTA.js"><link rel="modulepreload" as="script" crossorigin="" href="https://pieree369-olmocr.hf.space/static/js/index.DW_MHI2K.js"><link rel="modulepreload" as="script" crossorigin="" href="https://pieree369-olmocr.hf.space/static/js/FormClearHelper.UtDFKbpT.js"><link rel="modulepreload" as="script" crossorigin="" href="https://pieree369-olmocr.hf.space/static/js/FileHelper.DV2KuUj6.js"><link rel="modulepreload" as="script" crossorigin="" href="https://pieree369-olmocr.hf.space/static/js/ProgressBar.BtMHwdZZ.js"><link rel="modulepreload" as="script" crossorigin="" href="https://pieree369-olmocr.hf.space/static/js/Hooks.YZgOFmbn.js"><link rel="modulepreload" as="script" crossorigin="" href="https://pieree369-olmocr.hf.space/static/js/UploadFileInfo.C-jY39rj.js"></head>
  <body>
    <noscript>You need to enable JavaScript to run this app.</noscript>
    <div id="root"><div class=""><div class="withScreencast" data-testid="stScreencast"><div class="stApp stAppEmbeddingId-t7tp1bcmwpmq st-emotion-cache-1r4qj8v ee4bbma0" data-testid="stApp" data-test-script-state="notRunning" data-test-connection-state="CONNECTED"><header tabindex="-1" class="stAppHeader st-emotion-cache-12fmjuu e4hpqof0" data-testid="stHeader"><div class="stDecoration st-emotion-cache-1dp5vir e4hpqof1" data-testid="stDecoration" id="stDecoration"></div><div class="stAppToolbar st-emotion-cache-15ecox0 e4hpqof2" data-testid="stToolbar"><div class="stToolbarActions st-emotion-cache-1p1m4ay e1i26tt72" data-testid="stToolbarActions"></div><span id="MainMenu" class="stMainMenu st-emotion-cache-czk5ss ev04twb8" data-testid="stMainMenu" aria-haspopup="true" aria-expanded="false"><button kind="headerNoPadding" data-testid="stBaseButton-headerNoPadding" aria-label="" class="st-emotion-cache-l1ktzw em9zgd018"><svg viewBox="0 0 24 24" aria-hidden="true" focusable="false" fill="currentColor" xmlns="http://www.w3.org/2000/svg" class="e144pc0f1 st-emotion-cache-1pbsqtx ex0cdmw0"><path fill="none" d="M0 0h24v24H0V0z"></path><path d="M12 8c1.1 0 2-.9 2-2s-.9-2-2-2-2 .9-2 2 .9 2 2 2zm0 2c-1.1 0-2 .9-2 2s.9 2 2 2 2-.9 2-2-.9-2-2-2zm0 6c-1.1 0-2 .9-2 2s.9 2 2 2 2-.9 2-2-.9-2-2-2z"></path></svg></button></span></div></header><div class="stAppViewContainer appview-container st-emotion-cache-1yiq2ps eht7o1d0" data-testid="stAppViewContainer" data-layout="narrow"><section tabindex="0" class="stMain st-emotion-cache-bm2z3a eht7o1d1" data-testid="stMain"><div class="stMainBlockContainer block-container st-emotion-cache-mtjnbi eht7o1d4" data-testid="stMainBlockContainer"><div data-testid="stVerticalBlockBorderWrapper" data-test-scroll-behavior="normal" class="st-emotion-cache-0 eu6p4el5"><div class="st-emotion-cache-b95f0i eu6p4el4"><div class="stVerticalBlock st-emotion-cache-1n76uvr eu6p4el3" data-testid="stVerticalBlock" width="704"><div class="stElementContainer element-container st-emotion-cache-kj6hex eu6p4el1" data-testid="stElementContainer" data-stale="false" width="auto"><div class="stHeading" data-testid="stHeading"><div data-testid="stMarkdownContainer" class="st-emotion-cache-1104ytp e1icttdg0"><div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 id="olmocr">OLMOCR<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#olmocr" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div></div></div></div><div class="stElementContainer element-container st-emotion-cache-kj6hex eu6p4el1" data-testid="stElementContainer" data-stale="false" width="auto"><div class="st-emotion-cache-8atqhb e1mlolmg0"><div class="stFileUploader st-emotion-cache-0 e17y52ym15" data-testid="stFileUploader" width="704"><label data-testid="stWidgetLabel" aria-hidden="true" class="st-emotion-cache-1s2v671 e1dx5vew0"><div data-testid="stMarkdownContainer" class="st-emotion-cache-wq5ihp e1icttdg0"><p>Upload a PDF or Image</p></div></label><section role="presentation" data-testid="stFileUploaderDropzone" aria-label="Upload a PDF or Image" class="st-emotion-cache-1gulkj5 e17y52ym0" tabindex="0"><input data-testid="stFileUploaderDropzoneInput" accept="application/streamlit,.pdf,.png,.jpg,.jpeg" type="file" style="border: 0px; clip: rect(0px, 0px, 0px, 0px); clip-path: inset(50%); height: 1px; margin: 0px -1px -1px 0px; overflow: hidden; padding: 0px; position: absolute; width: 1px; white-space: nowrap;" tabindex="-1"><div data-testid="stFileUploaderDropzoneInstructions" class="st-emotion-cache-u8hs99 e17y52ym1"><span class="st-emotion-cache-nwtri e17y52ym2"><svg viewBox="0 0 24 24" aria-hidden="true" focusable="false" fill="currentColor" xmlns="http://www.w3.org/2000/svg" class="e144pc0f1 st-emotion-cache-6rlrad ex0cdmw0"><path fill="none" d="M0 0h24v24H0V0z"></path><path d="M19.35 10.04A7.49 7.49 0 0012 4C9.11 4 6.6 5.64 5.35 8.04A5.994 5.994 0 000 14c0 3.31 2.69 6 6 6h13c2.76 0 5-2.24 5-5 0-2.64-2.05-4.78-4.65-4.96zM19 18H6c-2.21 0-4-1.79-4-4 0-2.05 1.53-3.76 3.56-3.97l1.07-.11.5-.95A5.469 5.469 0 0112 6c2.62 0 4.88 1.86 5.39 4.43l.3 1.5 1.53.11A2.98 2.98 0 0122 15c0 1.65-1.35 3-3 3zM8 13h2.55v3h2.9v-3H16l-4-4z"></path></svg></span><div class="st-emotion-cache-j7qwjs e17y52ym4"><span class="st-emotion-cache-9ycgxx e17y52ym3">Drag and drop file here</span><small class="st-emotion-cache-1rpn56r ejh2rmr0">Limit 200MB per file • PDF, PNG, JPG, JPEG</small></div></div><button kind="secondary" data-testid="stBaseButton-secondary" aria-label="" class="st-emotion-cache-ocsh0s em9zgd02">Browse files</button></section><div class="st-emotion-cache-fis6aj e17y52ym5"><ul class="st-emotion-cache-14m29r0 e17y52ym6"><li class="st-emotion-cache-1l95nvm e17y52ym7"><div class="stFileUploaderFile st-emotion-cache-12xsiil e17y52ym10" data-testid="stFileUploaderFile"><div class="st-emotion-cache-10ix4kq e17y52ym12"><svg viewBox="0 0 24 24" aria-hidden="true" focusable="false" fill="currentColor" xmlns="http://www.w3.org/2000/svg" class="e144pc0f1 st-emotion-cache-4mjat2 ex0cdmw0"><path fill="none" d="M0 0h24v24H0V0z"></path><path d="M14 2H6c-1.1 0-1.99.9-1.99 2L4 20c0 1.1.89 2 1.99 2H18c1.1 0 2-.9 2-2V8l-6-6zM6 20V4h7v5h5v11H6z"></path></svg></div><div class="stFileUploaderFileData st-emotion-cache-1l4firl e17y52ym8"><div class="stFileUploaderFileName st-emotion-cache-1uixxvy e17y52ym9" data-testid="stFileUploaderFileName" title="Chapters_6-10.pdf">Chapters_6-10.pdf</div><small class="st-emotion-cache-1rpn56r ejh2rmr0">13.3MB</small></div><div data-testid="stFileUploaderDeleteBtn"><button kind="minimal" data-testid="stBaseButton-minimal" aria-label="" class="st-emotion-cache-8ccstr em9zgd06"><svg viewBox="0 0 24 24" aria-hidden="true" focusable="false" fill="currentColor" xmlns="http://www.w3.org/2000/svg" class="e144pc0f1 st-emotion-cache-1pbsqtx ex0cdmw0"><path fill="none" d="M0 0h24v24H0V0z"></path><path d="M19 6.41L17.59 5 12 10.59 6.41 5 5 6.41 10.59 12 5 17.59 6.41 19 12 13.41 17.59 19 19 17.59 13.41 12 19 6.41z"></path></svg></button></div></div></li></ul></div></div></div></div><div class="stElementContainer element-container st-emotion-cache-kj6hex eu6p4el1" data-testid="stElementContainer" data-stale="false" width="auto"><div class="stButton st-emotion-cache-8atqhb e1mlolmg0" data-testid="stButton"><button kind="secondary" data-testid="stBaseButton-secondary" aria-label="" class="st-emotion-cache-ocsh0s em9zgd02"><div data-testid="stMarkdownContainer" class="st-emotion-cache-1hyd1ho e1icttdg0"><p>Submit</p></div></button></div></div><div class="stElementContainer element-container st-emotion-cache-kj6hex eu6p4el1" data-testid="stElementContainer" data-stale="false" width="auto"><div class="stMarkdown" data-testid="stMarkdown"><div data-testid="stMarkdownContainer" class="st-emotion-cache-1104ytp e1icttdg0"><p><strong>Processing file:</strong> Chapters_6-10.pdf</p></div></div></div><div class="stElementContainer element-container st-emotion-cache-kj6hex eu6p4el1" data-testid="stElementContainer" data-stale="false" width="auto"><div class="stMarkdown" data-testid="stMarkdown"><div data-testid="stMarkdownContainer" class="st-emotion-cache-1104ytp e1icttdg0"><p>CHAPTER 6</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="phototherapy">Phototherapy<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#phototherapy" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>Cynthia Rena Heaton • Margaret Hirsch • Angela Hamilton</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="learning-objectives">LEARNING OBJECTIVES<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#learning-objectives" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>After studying this chapter, the reader will be able to:</p>
<ul>
<li>Identify skin disorders that would be appropriate for phototherapy and desired outcomes.</li>
<li>Describe the differences between ultraviolet radiation A (UVA) and ultraviolet radiation B (UVB) light.</li>
<li>Identify the different types of lights and metering equipment.</li>
<li>Describe the different protocols for UVA and UVB therapy.</li>
<li>Identify the appropriate patients for the different therapies.</li>
<li>Describe the different ways to manage side effects of phototherapy.</li>
<li>Understand the purpose of shielding and ways to shield.</li>
<li>Understand the importance of proper use of topical therapy in combination with phototherapy.</li>
<li>Counsel patients that each individual responds differently to phototherapy.</li>
<li>Counsel patients regarding proper and safe care during phototherapy.</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="key-points">KEY POINTS<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#key-points" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<ul>
<li>Phototherapy is an important health care intervention and should be administered with the same precautions as a drug using specialized equipment. A prescription is needed before a treatment is given.</li>
<li>Patient education regarding the importance of home care, protecting against extra ultraviolet light, and consistency of treatments are the keys to success.</li>
<li>The maximum amount of ultraviolet light a patient can receive is measured by risk versus benefit and quality of life.</li>
<li>Documentation of patient education, treatments, and missed treatments is required, as well as patient concerns.</li>
<li>Multiple regulations and guidelines must be considered including state and federal</li>
</ul>
<p>guidelines, Centers for Disease Control, Food and Drug Administration, Joint Commission, and manufacturer recommendations and guidelines.</p>
<ul>
<li>Treatments are determined by the prescriber, previous dose given, patient response to previous dose, and unit lamp output.</li>
<li>Understand that when switching from UVA to UVB, there is no crossover protection.</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="i-overview">I. OVERVIEW<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#i-overview" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>Phototherapy is the exposure of nonionizing radiation for therapeutic benefit; ultraviolet light (UVL) is not visible and is classified by wavelength—UVC, UVB, and UVA; UVB and UVA are used in treating dermatologic diseases. Phototherapy is the use of UVL to clear skin diseases. This is also referred to as photomedicine. Phototherapy is prescribed by dermatologists and other physicians, nurse practitioners, and/or physician assistants.</p>
<p>A. Evolution of phototherapy</p>
<ol>
<li>Broadband (BB) UVB—first used in the 1920s (290 to 320 nm).</li>
<li>Full-body cabinets—first used in the 1970s.</li>
<li>Narrowband (NB) UVB—first used in the 1980s (311 to 313 nm).</li>
<li>Psoralen plus UVA (PUVA) gets Food and Drug Administration (FDA) approval in 1982 (320 to 400 nm).</li>
<li>Ultraviolet A1 (UA1), the long-wavelength band of UVA—first used in the 2000s (340 to 400 nm).</li>
</ol>
<p>B. Ultraviolet light (Figure 6-1)</p>
<ol>
<li>Phototherapy terms</li>
</ol>
<p>a. Wavelength—the distance measured along the wave from any given point to the next similar point, as from crest to crest (peaks).
b. Nanometer (nm)—the unit of measurement used to describe the distance between wavelengths. One billion nanometers equals 1 m or 39.37 inches.
c. Photons—the energy emitted from the UVL wavelength.
d. Joules (J)—the dosing unit for UVA. One joule equals 1,000 millijoules.
e. Millijoules (mJ)—the dosing unit for UVB.</p>
<p>C. Facts about UVL</p>
<ol>
<li>Longer wavelengths produce fewer photons, resulting in less energy.</li>
<li>Shorter wavelengths produce more photons, resulting in more energy.</li>
<li>UVL can do one of three things. It can be reflected, transmitted, or absorbed. When UVL is absorbed, photons activate specific cells in the dermis and epidermis called chromophores, resulting in a biological response.</li>
<li>Most natural sunlight exposure occurs in the first 18 to 20 years of life, and phototherapy adds to total lifetime accumulation. Overexposure to UVL increases the risk of skin damage. Therefore, risks versus benefits of therapy must be considered.</li>
<li>UVL's therapeutic physiological effects are immune function manipulation, decreased DNA synthesis, and selective cytotoxicity.</li>
</ol>
<p>D. Common diseases treated with phototherapy</p>
<p>The most common dermatological diseases treated with phototherapy are psoriasis, vitiligo, various types of dermatitis, and cutaneous T-cell lymphoma (CTCL). The goals of phototherapy are different depending on the disease being treated (Table 6-1).</p>
<ol>
<li>Psoriasis: goal is to depress the immune system and slow down T-cell activity, which will then result in thinning of plaques, decreased pruritus, decreased scaling, and induction of remission.</li>
<li>Vitiligo: goal is repigmentation, which will occur in  <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>50</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">50\%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">50%</span></span></span></span></span>  to  <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>80</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">80\%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">80%</span></span></span></span></span>  of patients.</li>
<li>Dermatitis: goal is to depress the immune system resulting in elimination or reduction of pruritus. Improvement of the rash is secondary. This group includes atopic dermatitis, eczema, folliculitis, IRBD or papular dermatitis, and lichen planus.</li>
<li>CTCL: goal is to slow the systemic progression of the disease as evidenced by flattening of plaques and normalization of skin pigmentation.</li>
</ol>
<p><img src="assets/images/image-20251225-623e79c8.jpeg" alt="img-0.jpeg">
FIGURE 6-1. UVL spectrum.</p>
<p>TABLE 6-1 Photoresponsive Diseases</p>
<table><thead><tr><th>Photoresponsive Diseases</th><th>BB-UVB</th><th>NB-UVB</th><th>UVA</th><th>UVA-1</th><th>PUVA</th></tr></thead><tbody><tr><td>Alopecia</td><td></td><td></td><td></td><td></td><td>X</td></tr><tr><td>Atopic dermatitis/other eczemas</td><td>X</td><td>X</td><td>X</td><td>X</td><td>X</td></tr><tr><td>Folliculitis</td><td>X</td><td>X</td><td>X</td><td></td><td>X</td></tr><tr><td>Graft vs. host disease</td><td></td><td></td><td></td><td>X</td><td>X</td></tr><tr><td>Granuloma annulare</td><td></td><td>X</td><td></td><td>X</td><td>X</td></tr><tr><td>IRBD ("itchy red bump disease")</td><td>X</td><td>X</td><td>X</td><td></td><td>X</td></tr><tr><td>Lichen planus</td><td></td><td>X</td><td></td><td></td><td>X</td></tr><tr><td>Localized scleroderma</td><td></td><td></td><td></td><td>X</td><td></td></tr><tr><td>Mycosis fungoides (CTCL)</td><td>X</td><td>X</td><td></td><td>X</td><td>X</td></tr><tr><td>Parapsoriasis</td><td>X</td><td>X</td><td>X</td><td></td><td>X</td></tr><tr><td>Photosensitivity</td><td>X</td><td>X</td><td>X</td><td></td><td>X</td></tr><tr><td>Pityriasis rosea</td><td>X</td><td>X</td><td></td><td></td><td></td></tr><tr><td>Prurigo, pruritus</td><td></td><td></td><td></td><td>X</td><td></td></tr><tr><td>Psoriasis</td><td>X</td><td>X</td><td>X</td><td></td><td>X</td></tr><tr><td>Uremic pruritus</td><td>X</td><td>X</td><td>X</td><td></td><td></td></tr><tr><td>Urticaria pigmentosa</td><td></td><td></td><td></td><td>X</td><td></td></tr><tr><td>Vitiligo</td><td></td><td>X</td><td></td><td></td><td>X</td></tr></tbody></table>
<p>BB, broadband; NB, narrowband; UVA, ultraviolet A; UVB, ultraviolet B; PUVA, methoxsalen + ultraviolet A.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="ii-phototherapy">II. PHOTOTHERAPY<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#ii-phototherapy" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>UVL waves found in sunlight have a therapeutic effect. The types of UVL used to treat skin diseases are UVB and UVA (Figure 6-2).</p>
<p><img src="assets/images/image-20251225-926afa36.jpeg" alt="img-1.jpeg">
FIGURE 6-2. Energy of UVL.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="a-uvb">A. UVB<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#a-uvb" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>UVB is referred to as the sunburn ray. It is 1,000 times more capable of producing erythema than UVA and is dosed in millijoules (mJ). It has shallow penetration into the epidermis, takes a short time to develop erythema (4 to 6 hours), and the erythema resolves quickly (18 to 24 hours). Skin protection against UVB is referred to as hyperplasia, thickening of the top layer of skin.</p>
<ol>
<li>Broadband UVB (BB-UVB) wavelength 290 to  <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>320</mn><mrow><mi mathvariant="normal">n</mi><mi mathvariant="normal">m</mi></mrow></mrow><annotation encoding="application/x-tex">320\mathrm{nm}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6444em;"></span><span class="mord">320</span><span class="mord"><span class="mord mathrm">nm</span></span></span></span></span></span></li>
</ol>
<p>a. Must wear goggles, as corneal burns can occur (Figure 6-3).
b. Sunburning spectrum of light, therefore potentially the most damaging.
c. Potential carcinogenesis following long-term exposure.
d. No medications needed as epidermis has sufficient chromophores to absorb UVB. When phototherapy truly indicated in pregnant women, UVB is frequently the type chosen because no additional medications are used with this treatment.</p>
<ol start="2">
<li>Excimer laser UVB-wave length of  <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>308</mn><mtext>&nbsp;</mtext><mrow><mi mathvariant="normal">n</mi><mi mathvariant="normal">m</mi></mrow></mrow><annotation encoding="application/x-tex">308~\mathrm{nm}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6444em;"></span><span class="mord">308</span><span class="mspace nobreak">&nbsp;</span><span class="mord"><span class="mord mathrm">nm</span></span></span></span></span></span></li>
</ol>
<p>a. Treatment twice a week.
b. Emits light that is monochromatic and coherent.
c. Handheld device with a fiber-optic arm allows for targeted application of light while avoiding unaffected skin.
d. Uses a spot diameter of 14 to  <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>30</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">m</mi></mrow></mrow><annotation encoding="application/x-tex">30\mathrm{mm}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6444em;"></span><span class="mord">30</span><span class="mord"><span class="mord mathrm">mm</span></span></span></span></span></span></p>
<ol start="3">
<li>
<p>Narrowband UVB (NB-UVB) wavelength of 311 to 313 nm.
a. Clears lesions faster than BB-UVB.
b. Fewer treatments necessary.
c. Treatment Schedule.
(1) Clearing phase: three to five treatments per week until disease clears.
(2) Maintenance phase: every 9 to 11 days to maintain clearance.</p>
</li>
<li>
<p>Indications (BB-UVB and NB-UVB).
a. Treatment of photosensitive dermatoses.
b. Pregnant women and children may be treated since there are no drugs needed for UVB to be effective.
c. Used for patients with UVA contraindications, such as previous arsenic or x-ray therapy.</p>
</li>
<li>
<p>Absolute contraindications (BB-UVB and NB-UVB).
a. Xeroderma pigmentosum
b. Albinism
c. Porphyria</p>
</li>
<li>
<p>Relative contraindications (BB-UVB and NB-UVB).
a. Can exacerbate photodermatoses.
b. Previous nonmelanoma skin cancers or family history of melanoma.
c. Inability of patient to stand due to physical limitations.
d. Noncompliance with regular treatment schedule.
e. Physically or mentally unstable, debilitated, or intoxicated patients.</p>
</li>
<li>
<p>Dosing (BB-UVB and NB-UVB).
a. Skin type—estimate of patient's ability to tolerate UVL (Table 6-2).
b. Intensity and dosage length are increased as tolerated per a specific protocol designated by the prescribing provider (Tables 6-3 through 6-5; Boxes 6-1 through 6-2).
c. Minimal erythema dose (MED)—smallest amount of UVL needed to produce mild erythema.
(1) Small sections of the patient's skin are exposed to increasing doses of UVB.
(2) Results are read within 18 to 24 hours.</p>
</li>
<li>
<p>Nursing considerations (BB-UVB and NB-UVB).
a. Always evaluate extent of erythema prior to each treatment.
b. Arms and legs may require extra dosing; if so, all other areas must be shielded.
c. Always question the patient regarding new medications as they may be photosensitizing.
d. Protective goggles must be worn during treatment, genital shields for males.
e. Do not increase dose if it has been 7 days since last treatment (or per facility protocol).</p>
</li>
</ol>
<p>B. UVA
UVA is referred to as the suntanning ray. It is 1,000 times less effective in producing erythema than UVB and is dosed in joules (J). UVA penetrates deep into the dermis, takes a longer time for erythema to develop (12 to 36 hours) and can take days to resolve. Skin</p>
<p>protection against UVA is referred to as melanogenesis, which leads to hyperpigmentation (tanning).</p>
<ol>
<li>UVA</li>
</ol>
<p>a. Wavelength 320 to 400 nm; to be effective, must be given with UVB or a photosensitizing medication.
b. UVA at this wavelength may enhance the photobiologic effects of UVB.
c. May cause retinal and lens damage leading to cataracts, so goggles are required.</p>
<ol start="2">
<li>UVA-1</li>
</ol>
<p>a. Wavelength 340 to 400 nm.
b. Long wavelength penetrates deep into the reticular layer of the dermis.
c. Induces T-cell apoptosis and activates fibroblasts, which lead to the breakdown of excess collagen.
d. See immediate hyperpigmentation, but the patient is at lower risk for burning.
e. Dosing regimen is one of three protocols: low, medium, and high.
f. Treatment times are longer, ranging from 10 to 40 minutes per visit.
g. A course of therapy can range from 10 to 40 treatments.
h. Continued improvement can be noted for up to several months after completion of therapy.</p>
<ol start="3">
<li>Psoralen/UVA (PUVA). This is the interaction and absorption of the drug psoralen (methoxsalen) and UVA by specific chromophores in the dermis to produce a therapeutic effect.</li>
</ol>
<p>a. Methoxsalen, a photosensitizing drug from the psoralen family, is administered topically or systemically to be effective. PUVA can be more effective than UVB, but it also has more potential side effects. Patients are at increased risk for malignant melanoma, squamous cell carcinoma, skin aging, actinic keratosis, and lentigines.</p>
<p>(1) Topical methoxsalen (paint PUVA)</p>
<p>(a) Useful for localized lesions and is very potent.
(b) Higher risk of burning or blistering than with systemic methoxsalen.
(c) Application must be done meticulously 15 to 90 minutes prior to UVA exposure (or per facility protocol).
(d) After treatment with topical methoxsalen, site must be washed with soapless cleanser; moisturizing sunscreen and/or appropriate clothing must be worn over site for 8 hours.</p>
<p>(2) Systemic methoxsalen</p>
<p>(a) Methoxsalen is available in 10-mg capsules, and dosing is weight based. Patients ingest a prescribed dose of methoxsalen approximately 1½ to 2 hours before being treated with UVA.</p>
<p>b. Dosage.</p>
<p>(1) MED or skin type dosing is done to establish the baseline dose.
(2) Intensity and dosage length are increased as tolerated per a specific protocol designated by the prescribing provider (Table 6-6 and Box 6-3).</p>
<p>c. Treatment schedule.</p>
<p>(1) Clearing phase: three times per week on alternate days until clearing of disease is</p>
<p>noted.</p>
<p>(2) Maintenance phase: usually once every 2 to 3 weeks. This is individualized, but should be often enough to prevent flare-ups.</p>
<p>d. Indications.</p>
<p>(1) Failure of topical steroids, tar, anthralin, or UVB
(2) Extensive skin involvement
(3) Nail disease
(4) Geographic, social, or occupational factors that necessitate keeping treatments to a minimum
(5) Photosensitivity to UVB</p>
<p>e. Absolute contraindications.</p>
<p>(1) Xeroderma pigmentosum
(2) Lupus
(3) Lactation
(4) Porphyria cutanea tarda, erythropoietic porphyria, variegate porphyria
(5) Albinism
(6) Pregnancy/lactation
(7) No longer approved by the American Academy of Pediatrics for use in children</p>
<p>f. Relative contraindications.</p>
<p>(1) Age and infirmity
(2) Pemphigus and pemphigoid exacerbated by UVA/UVB
(3) Uremia or severe hepatic failure
(4) History or family history of melanoma
(5) Past history of nonmelanoma skin cancer
(6) Extensive solar damage
(7) Previous treatment with ionizing radiation or arsenic
(8) Patients with cataracts or who are aphakic
(9) Dysplastic nevus syndrome
(10) Photosensitizing medications
(11) Severe cardiac disease
(12) Immunosuppression</p>
<p>g. Complete an individualized patient assessment prior to making a therapy decision (Box 6-4).</p>
<p>h. Nursing considerations.</p>
<p>(1) Review prescription and over-the-counter medications every treatment.
(2) Review time methoxsalen was ingested or applied.
(3) Review response to last treatment.</p>
<p><img src="assets/images/image-20251225-c38331fa.jpeg" alt="img-2.jpeg">
FIGURE 6-3. Eye light absorption.</p>
<p>TABLE 6-2 Skin Typing</p>
<table><thead><tr><th>Type*</th><th>Characteristic</th><th>Example</th></tr></thead><tbody><tr><td>I</td><td>Always burns, never tans</td><td>Celtic or Irish, often blue eyes, red hair, freckles</td></tr><tr><td>II</td><td>Burns easily, tans slightly</td><td>Fair skin, often blonde hair; many whites</td></tr><tr><td>III</td><td>Sometimes burns, then tans gradually, and moderately</td><td>Mediterranean's and some Hispanics</td></tr><tr><td>IV</td><td>Burns minimally, always tans well</td><td>Asians and darker Hispanics</td></tr><tr><td>V</td><td>Burns rarely, tans deeply</td><td>Middle Easterners, Asians, dark brown-black skin, African American</td></tr><tr><td>VI</td><td>Almost never burns, deeply pigmented</td><td>Black skin, African American</td></tr></tbody></table>
<p>*Reflects color of unexposed buttock skin. Skin types I to III are white, type IV is white or faint brown, type V is brown, and type VI have dark brown or black buttock skin.</p>
<p>TABLE 6-3 Comparison of Ultraviolet B Narrowband and Broadband Protocols</p>
<table><thead><tr><th>Skin Type</th><th>Broadband</th><th>Narrowband (NBC protocol)</th></tr></thead><tbody><tr><td>I</td><td>10 mJ</td><td>120 mJ</td></tr><tr><td>II</td><td>20 mJ</td><td>220 mJ</td></tr><tr><td>III</td><td>30 mJ</td><td>260 mJ</td></tr><tr><td>IV</td><td>40 mJ</td><td>330 mJ</td></tr><tr><td>V</td><td>50 mJ</td><td>350 mJ</td></tr><tr><td>VI</td><td>60 mJ</td><td>400 mJ</td></tr></tbody></table>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="table-6-4-narrowband-treatment-protocol">TABLE 6-4 Narrowband Treatment Protocol<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#table-6-4-narrowband-treatment-protocol" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<table><thead><tr><th>Skin Type</th><th>Initial Dose</th><th>Subsequent Dose</th></tr></thead><tbody><tr><td>I</td><td>120 mJ</td><td>15–25 mJ</td></tr><tr><td>II</td><td>220 mJ</td><td>25–40 mJ</td></tr><tr><td>III</td><td>260 mJ</td><td>40–45 mJ</td></tr><tr><td>IV</td><td>330 mJ</td><td>45–60 mJ</td></tr><tr><td>V</td><td>350 mJ</td><td>60–65 mJ</td></tr><tr><td>VI</td><td>400 mJ</td><td>65–100 mJ</td></tr></tbody></table>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="table-6-5-broadband-treatment-protocol">TABLE 6-5 Broadband Treatment Protocol<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#table-6-5-broadband-treatment-protocol" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<table><thead><tr><th>Skin Type</th><th>Initial Dose</th><th>Subsequent Dose</th></tr></thead><tbody><tr><td>I</td><td>10 mJ</td><td>5–10 mJ</td></tr><tr><td>II</td><td>20 mJ</td><td>5–20 mJ</td></tr><tr><td>III</td><td>30 mJ</td><td>5–30 mJ</td></tr><tr><td>IV</td><td>40 mJ</td><td>5–40 mJ</td></tr><tr><td>V</td><td>50 mJ</td><td>5–50 mJ</td></tr><tr><td>VI</td><td>60 mJ</td><td>5–60 mJ</td></tr></tbody></table>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="table-6-6-ultraviolet-radiation-a-protocol">TABLE 6-6 Ultraviolet Radiation A Protocol<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#table-6-6-ultraviolet-radiation-a-protocol" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<table><thead><tr><th>Skin Type</th><th>Initial Joules</th><th>Joule Increments</th></tr></thead><tbody><tr><td>I</td><td>0.5 jl</td><td>0.5 jl</td></tr><tr><td>II</td><td>1.0 jl</td><td>0.5 jl</td></tr><tr><td>III</td><td>1.5 jl</td><td>0.5–1.0 jl</td></tr><tr><td>IV</td><td>2.0 jl</td><td>0.5–1.0 jl</td></tr><tr><td>V</td><td>2.5 jl</td><td>1.0–1.5 jl</td></tr><tr><td>VI</td><td>3.0 jl</td><td>1.0–1.5 jl</td></tr></tbody></table>
<p>PATIENT EDUCATION</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="phototherapy">Phototherapy<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#phototherapy" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<ul>
<li>Explain objective of treatment.</li>
<li>Stress that individuals respond differently to phototherapy and that some may not respond at all; 100% clearing is usually not attainable.</li>
<li>Explain possible side effects of treatment.</li>
<li>Emphasize the importance of patient reporting any new medications—prescription or OTC—to avoid potential photosensitization.</li>
<li>Reinforce the importance of compliance with treatment regimen including any topical medications prescribed or recommended prior to therapy.</li>
<li>Instruct patient to use emollients frequently, but especially after treatment, to prevent dryness and pruritus.</li>
<li>Patients with psoriasis should prepare skin at home prior to treatment by soaking and then gently debriding plaques.</li>
<li>Instruct patients about interventions for erythema or other common side effects. Emphasize the need for regular sunscreen use and avoidance of additional UVL exposure.</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="box-6-1-narrowband-treatment-flow-sheet">BOX 6-1. Narrowband Treatment Flow Sheet<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#box-6-1-narrowband-treatment-flow-sheet" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="skin-type-iv">Skin Type IV<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#skin-type-iv" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>Starting dose: 330 mJ
Increase by: 45 mJ
Treatment #1: 330 mJ
Treatment #2: 375 mJ
Treatment #3: 420 mJ
Treatment #4: 465 mJ</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="box-6-2-broadband-treatment-flow-sheet">BOX 6-2. Broadband Treatment Flow Sheet<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#box-6-2-broadband-treatment-flow-sheet" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="skin-type-iv">Skin Type IV<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#skin-type-iv" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>Starting dose: 40 mJ</p>
<p>Increase by: 20 mJ
Treatment #1: 40 mJ
Treatment #2: 60 mJ
Treatment #3: 80 mJ
Treatment #4: 100 mJ</p>
<hr>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="box-6-3-uva-treatment-flow-sheet">BOX 6-3. UVA Treatment Flow Sheet<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#box-6-3-uva-treatment-flow-sheet" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h3 level="3" id="skin-type-ii">Skin Type II<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#skin-type-ii" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h3></div>
<p>Starting dose: 2 joule
Increase by: 5.1 joule
Treatment #1: 2.0 jl
Treatment #2: 2.5 jl
Treatment #3: 3.0 jl
Treatment #4: 4.0 jl</p>
<hr>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="box-6-4-assessment-prior-to-initiating-puva-photochemotherapy">BOX 6-4. Assessment Prior to Initiating PUVA Photochemotherapy<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#box-6-4-assessment-prior-to-initiating-puva-photochemotherapy" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h3 level="3" id="subjective-data">Subjective Data<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#subjective-data" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h3></div>
<ol>
<li>Motivation to adhere to regimen</li>
<li>Ability to alter work and personal schedule to adhere to therapy schedule</li>
<li>Financial needs/concerns regarding prescribed drug and treatment, physicians' fees, and transportation</li>
</ol>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h3 level="3" id="objective-data">Objective Data<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#objective-data" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h3></div>
<ol>
<li>Determine skin type.</li>
<li>Perform thorough assessment of skin area to be treated.</li>
<li>Obtain results of patient's initial ophthalmology exam.</li>
<li>Obtain complete history of other medications patient is taking—prescription and over the counter. Pay particular attention to any that may cause photosensitivity.</li>
<li>Obtain complete health history—particularly in regard to liver problems, skin cancer, heart problems, hypertension, and lupus erythematosus.</li>
</ol>
<p>The nurse will notify physician of inability to initiate therapy if a problem exists with the patient's ability to begin PUVA therapy.</p>
<p>From Galloway, G. A., &amp; Lawson, G. B. (1995). Photochemotherapy (PUVA) protocol. Dermatology Nursing, 7(6), 348–351.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="iii-phototherapy-equipment">III. PHOTOTHERAPY EQUIPMENT<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#iii-phototherapy-equipment" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="a-phototherapy-units">A. Phototherapy units<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#a-phototherapy-units" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<ol>
<li>There are many manufacturers and a variety of models available (Figure 6-4).
a. Full-body cabinets.
b. Panels.
c. Hand and foot units.
d. Handheld units for treating the scalp and selective treatment of body lesions.
e. Models for professional use.
f. Models for home use.
g. Models are designated for a single UVL wavelength or for a combination of UVL wavelengths.</li>
</ol>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="b-safety">B. Safety<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#b-safety" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<ol>
<li>Equipment should be maintained and operated following manufacturer guidelines and facility policy.</li>
<li>All state and federal applicable regulations should be adhered to including the FDA.</li>
<li>Phototherapy units are considered radiology devices. Standards set by the Joint Commission, OSHA, and other agencies must be followed. Only authorized staff should operate the equipment.</li>
</ol>
<p>Each phototherapy unit should have an individual breaker box in the event of fire.</p>
<ol start="4">
<li>Routine cleaning should be done to keep unit functioning at maximum level and for infection control purposes.</li>
</ol>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="c-uvl-lamps-figure-6-5">C. UVL lamps (Figure 6-5)<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#c-uvl-lamps-figure-6-5" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<ol>
<li>
<p>New lamps contain maximum energy and cannot be recharged.
a. Lamps will only lose power when illuminated.
b. Unused lamps do not have expiration dates or a limited shelf-life.</p>
</li>
<li>
<p>Power is gradually lost with use resulting in less energy.
a. Longer treatments occur as time to complete session increases to compensate for lower energy. Long treatments may:
(1) Increase patient fatigue
(2) Result in reduction of patient scheduling</p>
</li>
<li>
<p>Lamps should be changed when burnt out or damaged.
a. Replace lamps in an even distribution pattern to avoid "hot spots"—uneven energy output that could result in patient injury.
b. Ensure the correct UVL lamp is placed in the corresponding socket, that is, NB-UVB lamps should not be placed in sockets made for UVA lamps. Doing so may lead to treatment error and harm the patient.
c. Keep a record of lamp installation, lamp removal, lamp life (per manufacturer), and energy output.</p>
</li>
<li>
<p>Lamps are designated by wave length and are either fluorescent or metal halide.
a. Broadband UVB (290 to 320 nm)
(1) Low-pressure mercury vapor fluorescent lamp.
(2) Red lettering is a visual indicator of this wavelength.</p>
</li>
</ol>
<p>b. Narrowband UVB (311 to 313 nm)
(1) Low-pressure mercury vapor fluorescent lamp.
(2) Gold lettering is a visual indicator of this wavelength.</p>
<p>c. UVA (320 to 400 nm)
(1) Low-pressure mercury vapor fluorescent lamp.
(2) Black lettering is a visual indicator of this wavelength.</p>
<p>d. UVA-1 (340 to 400 nm)
(1) Metal halide high-pressure lamp.
(2) Special optical filters are required for use with these lamps.
(3) A heat removal system is required for UVA-1 units as metal halide lamps generate more heat than fluorescent lamps.</p>
<p>D. Metering
Metering determines the lamp energy/power as output declines over time. Treatments are determined by the energy/power output and past treatment dose (Figures 6-6 and 6-7).</p>
<ol>
<li>
<p>There are no FDA standards for metering.</p>
</li>
<li>
<p>Phototherapy units have either integrated dosimetry or require external dosimetry.
a. Integrated dosimetry is a term used to describe phototherapy units with a built-in meter or sensor.
(1) The meter located inside the cabinet internally monitors the lamp energy.
(2) Unit will self-adjust the treatment time resulting in automatic shut off when the desired dose is reached.
b. Nondosimetry equipment refers to phototherapy units without a built-in meter or sensor.
(1) An external meter is a portable device used to measure the lamp energy.
(2) Meter reading is used along with desired dose to determine treatment time.</p>
</li>
<li>
<p>External metering.
a. Meter new lamps daily until readings stabilize (approximately 2 weeks).
b. Metering once a week is standard after readings are stable.
c. Cold lamps emit less energy.
(1) A warm-up of 5 to 10 minutes prior to metering allows for lamps to reach maximum output.
(a) Refer to manufacturer recommendation for specific warm-up time.
d. Consistency is critical for accurate results.
(1) Only use the meter that is recommended by the unit's manufacturer.
(2) Use the same warm-up time prior to each meter reading.
(3) Place the meter sensor at the same location and distance from the lamps per manufacturer recommendation.</p>
</li>
<li>
<p>Care of portable meters.
a. Clean and protect the sensor lens on the meter.
b. Send meter to manufacturer annually for recalibration.
c. Investigate sudden or rapid changes in readings. Send to manufacturer if meter is dropped or damaged in any way.</p>
</li>
</ol>
<p><img src="assets/images/image-20251225-68cbb9dd.jpeg" alt="img-3.jpeg">
FIGURE 6-4. Phototherapy equipment.</p>
<p><img src="assets/images/image-20251225-2713cf7f.jpeg" alt="img-4.jpeg">
FIGURE 6-5. Phototherapy lamps.</p>
<p>LAMP SELECTION UVB</p>
<table><thead><tr><th>ENERGY</th><th>TIME</th></tr></thead><tbody><tr><td>6:00</td><td></td></tr><tr><td>MJ</td><td></td></tr><tr><td>cm²</td><td>2:23</td></tr><tr><td>4.2</td><td></td></tr><tr><td>mw</td><td></td></tr><tr><td>cm²</td><td>ADJ 00:00</td></tr></tbody></table>
<p>TREATMENT</p>
<table><thead><tr><th>1</th><th>2</th><th>3</th></tr></thead><tbody><tr><td>4</td><td>5</td><td>6</td></tr><tr><td>7</td><td>8</td><td>9</td></tr><tr><td>&lt;</td><td>0</td><td>&gt;</td></tr></tbody></table>
<p>START/STOP</p>
<p>280 MJ cm²</p>
<p><img src="assets/images/image-20251225-01bc1ac4.jpeg" alt="img-5.jpeg">
FIGURE 6-6. Phototherapy control panels.</p>
<p><img src="assets/images/image-20251225-74ca8439.jpeg" alt="img-6.jpeg"></p>
<p><img src="assets/images/image-20251225-3cc1ed16.jpeg" alt="img-7.jpeg">
FIGURE 6-7. Phototherapy meters.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="iv-adverse-effects-of-phototherapy">IV. ADVERSE EFFECTS OF PHOTOTHERAPY<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#iv-adverse-effects-of-phototherapy" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="a-side-effects">A. Side effects<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#a-side-effects" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<ol>
<li>Erythema (Table 6-7)</li>
</ol>
<p>a. BB-UVB: mild erythema is expected and acceptable; pale pink is optimal if no pain and not lasting over 24 hours.
b. NB-UVB: erythema is more intense in color, less painful, and longer lasting.
c. UVB erythema lasting more than 24 hours is a concern. Localized erythema should be shielded. If the patient has generalized erythema, consider holding treatment. Onset of erythema is 2 to 6 hours peaking at 12 to 24 hours, with a normal duration of 24 to 48 hours.
d. PUVA: erythema is not required or desirable with exception of vitiligo and alopecia treatment. Hold treatment until erythema is resolved. Shield localized areas until healed. Onset of erythema is 12 to 36 hours peaking at 48 to 96 hours, with a normal duration of 7 days. Erythema lasting over 48 hours is concerning.
e. UVA-1: Low risk of erythema in UVA-1 compared to other light. Pink is not desirable and would require further evaluation. Immediate hyperpigmentation (tanning) is expected.</p>
<p>f. Nursing considerations:</p>
<p>(1) Document any erythema onset, grade, location, duration, discomfort, itching, and inability to sleep.
(2) Document any changes in prescription and over-the-counter medications.
(3) Document environmental changes, such as golfing, vacation, and outdoor activities.
(4) Treatment—corticosteroids, systemic or topical, aspirin, and cool compresses.</p>
<ol start="2">
<li>Pruritus and xerosis</li>
</ol>
<p>a. Recommend use of an itch scale (0 to 10, 0 being no itch and 10 being severe itch). Ask if the itch has changed intensity, and if constant or intermittent.
b. Treatment: emollients, antipruritics, cool compresses, and antihistamines.</p>
<ol start="3">
<li>Koebnerization</li>
</ol>
<p>a. Process where injury to the skin causes further formation of psoriasis.
b. Treatment: avoid injury, scratching, picking, or aggressive removal of plaques.</p>
<ol start="4">
<li>Lentigines and skin aging</li>
</ol>
<p>a. Lentigines are blemishes of the skin associated with aging and exposure to UVL.
b. Treatment: sunscreens and shielding.</p>
<ol start="5">
<li>Skin cancers and precancers</li>
</ol>
<p>a. Most common types: actinic keratosis or precancers, basal cell carcinoma, squamous cell carcinoma, and melanoma.
b. Treatment: early detection and prevention, topical medications, cryotherapy, and biopsies with follow-up removal.
c. Eye damage</p>
<ol>
<li>
<p>Cataracts and keratitis (corneal burns)</p>
</li>
<li>
<p>Treatment: surgical removal of cataracts
d. Exacerbation of other medical conditions</p>
</li>
<li>
<p>Lupus, herpes simplex, rosacea, and polymorphous light eruption.</p>
</li>
<li>
<p>Treatment: usual course of treatment for the exacerbated condition may be needed.</p>
</li>
</ol>
<p>B. Protection from adverse effects: shielding (Table 6-8)</p>
<ol>
<li>Methods, materials, and devices used to shield can vary depending on unit resources.</li>
</ol>
<p>a. Shielding is the protection of unaffected skin or eyes from UVL.
b. The goal of shielding is to protect the unaffected skin and prevent skin/eye damage from UVL.
c. Material used for shielding should be thick enough to block all UVA. Meter these items to ensure protection. UVB is easily blocked, and shielding material does not require metering.
d. Eyewear is a must for the patient during treatment and the staff during metering of the phototherapy unit. Sunscreen, broad-spectrum UVA/UVB lip protection, and face and genital shielding are strongly recommended if not affected by disease.</p>
<p>TABLE 6-7 Erythema Grading</p>
<table><thead><tr><th>Grade</th><th>Description of Erythema</th></tr></thead><tbody><tr><td>0</td><td>No erythema or pinkness</td></tr><tr><td>1+</td><td>Slightly pink</td></tr><tr><td>2+</td><td>Marked erythema, no edema</td></tr><tr><td>3+</td><td>Fiery erythema with edema</td></tr><tr><td>4+</td><td>Fiery erythema with edema/blisters</td></tr></tbody></table>
<p>TABLE 6-8 Shielding</p>
<table><thead><tr><th>Areas</th><th>Items Used for Shielding</th></tr></thead><tbody><tr><td>Eyes</td><td>UVA/UVB goggles, glasses</td></tr><tr><td>Face/head</td><td>Face shields, bags, sunscreens, glasses, and towels</td></tr><tr><td>Body</td><td>Gowns, towels, bathing suits, sunscreens or sunblocks</td></tr><tr><td>Hands</td><td>Sunscreens or sunblocks, gloves</td></tr><tr><td>Male genitals</td><td>Shorts, jockstraps, socks</td></tr></tbody></table>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="v-phototherapy-pearls">V. PHOTOTHERAPY PEARLS<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#v-phototherapy-pearls" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>Phototherapy can be the last resort for the treatment of some skin diseases. Two primary goals of phototherapy are to provide safe treatment and to ensure the patient is well educated (Box 6-5). Explanation of the procedure, desired effects, and possible complications should be discussed and documented. See Patient Education Points Related To Phototherapy.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="box-6-5-patient-education-objectives-for-puva-treatment">BOX 6-5. Patient Education Objectives for PUVA Treatment<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#box-6-5-patient-education-objectives-for-puva-treatment" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="the-patient-will">The patient will:<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#the-patient-will" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<ol>
<li>Verbalize understanding of PUVA therapy.</li>
<li>Verbalize understanding of action and side effects of oral methoxsalen.</li>
<li>Demonstrate adherence to correct regimen for PUVA therapy.</li>
</ol>
<p>a. Take methoxsalen as directed—1.5 to 2 hours prior to scheduled PUVA treatment. Treatment will be held if medication is not taken.
b. Instruct the patient on PUVA therapy regimen and necessary precautions while taking photosensitizing medication. Patient should protect his or her skin and eyes from sunlight and artificial UVA light sources for 24 hours following ingestion of psoralens and following the light treatment.</p>
<ol start="4">
<li>Demonstrate physical signs of therapeutic response to PUVA without side effects as evidenced by:</li>
</ol>
<p>a. Light-to-medium pink erythemal response 24 to 48 hours following each treatment.
b. Tolerance of methoxsalen by no complaints of nausea and vomiting.
c. Lab values maintained within normal limits.</p>
<p>d. Ophthalmologic exams saw no evidence of cataract formation.</p>
<p>From Galloway, G. A., &amp; Lawson, G. B. (1995). Photochemotherapy (PUVA) protocol. Dermatology Nursing, 7(6), 348–351.</p>
<p>A. Set realistic expectations by discussing the following with each patient prior to the onset of phototherapy:</p>
<ol>
<li>Response to phototherapy is not immediate.</li>
<li>Individuals respond differently to phototherapy, and some may not respond at all.</li>
<li>100% clearing is usually not attainable.</li>
<li>Patient must continue with home care of skin to get the best benefit from phototherapy.</li>
</ol>
<p>B. The phototherapist’s role in treatment</p>
<ol>
<li>Know and follow the facilities policies and procedures for:</li>
</ol>
<p>a. Safe operation of the phototherapy unit(s)
b. Treatment documentation/charting
c. Treatment protocols
d. Missed treatment protocols
e. Treatment adjustment for potential photosensitizing medications
f. Erythema protocols
g. Reporting of treatment errors or adverse events
h. Management of noncompliant patients</p>
<ol start="2">
<li>Administer phototherapy as one would a medication.</li>
</ol>
<p>a. There should be an order which includes:</p>
<p>(1) Condition being treated
(2) Type of UVL to be given
(3) Skin type
(4) Number of treatments prescribed</p>
<p>b. Follow the “five rights” of phototherapy. These are very similar to the rights emphasized in proper medication administration.</p>
<p>(1) Right patient
(2) Right chart
(3) Right UVL and dose
(4) Right phototherapy unit
(5) Right shielding</p>
<ol start="3">
<li>Assess the patient prior to every treatment and document his or her condition.</li>
</ol>
<p>a. Assess response to previous treatment including:</p>
<p>(1) New erythema
(2) Irritation
(3) Pruritus
(4) Pain</p>
<p>b. Assess if condition has improved, has stayed the same, or is worse.
c. Ask if the patient has taken or used new oral or topical medications, including prescription, over-the-counter, and herbal products.
d. Assess if the patient appears physically unwell or mentally unstable.</p>
<p>e. Assess if the patient appears intoxicated or under the influence of drugs.</p>
<ol start="4">
<li>
<p>Patient instructions
a. Tell the patient how long the treatment will take.
b. Eye protection must be in place before unit is started and is to remain in place the entire treatment.
c. Shielding should be appropriate, consistently placed, and secured.
d. Direct patient to stand in center of the phototherapy unit.
e. Discuss appropriate posturing to expose all affected areas.
f. Instruct the patient to call out or exit unit if any problems.</p>
</li>
<li>
<p>There is a professional obligation to ensure patient safety during treatments.
a. One of the primary staff responsibilities in phototherapy is to ensure the safe entry into and exit from all phototherapy equipment.
b. Many potential issues may occur during treatment:
(1) Removal of goggles
(2) Removal of shielding
(3) Position change so patient is standing too close to the lamps
(4) Fainting
(5) Claustrophobia
(6) Seizure
(7) Cardiac arrest
c. Booth timers can fail. It is recommended to have a backup timer as a precautionary measure.</p>
</li>
</ol>
<p>C. Treatment failures</p>
<ol>
<li>Disorder is simply nonresponsive.</li>
<li>Monotherapy is often less effective. At each visit, reinforce continued use of topical or oral medications as prescribed.</li>
<li>Wrong type of UVL used.</li>
<li>Side effects too troublesome.
a. Pruritus
b. Persistent erythema
c. Nausea</li>
<li>Patient is noncompliant.</li>
</ol>
<p>D. Important points to remember</p>
<ol>
<li>Recognize that patient outcomes will vary.</li>
<li>Aggressive treatment is sometimes required to achieve desired outcome.</li>
<li>The number one fear in phototherapy is overtreatment.</li>
<li>The number one error in phototherapy is undertreatment.</li>
<li>The ultimate goal of phototherapy is to provide safe and effective treatment.</li>
</ol>
<p>BIBLIOGRAPHY</p>
<p>Abdulla, F., Breneman, C., Adams, B., &amp; Breneman, D. (2010). Standards for genital protections in phototherapy units.</p>
<p>Journal of the American Academy of Dermatology, 62(2), 223–226.</p>
<p>Dahl, M. V. (2012). UVA1 is often A1. Journal Watch Dermatology. doi: 10.1056/JD201204270000001</p>
<p>Galloway, G. A., &amp; Lawson, G. B. (1995). Photochemotherapy (PUVA) protocol. Dermatology Nursing, 7(6), 348–351.</p>
<p>Habif, T. P. (2010). Clinical dermatology: A color guide to diagnosis and therapy. Mosby Elsevier.</p>
<p>Hearn, R. M. R., Kerr, A. C., Rahim, K. F., Ferguson, J., &amp; Dawe, R. S. (2008). Incidence of skin cancers in 3867 patients treated with narrow-band ultraviolet B phototherapy. British Journal of Dermatology, 159(4), 931–935. doi: 10.1111/j.1365-2133.2008.08776.x</p>
<p>Herr, H., Cho, H. J., &amp; Yu, S. (2007). Burns caused by accidental overdose of photochemotherapy (PUVA). Burns, 33(3), 372–375. doi: 10.1016/j.burns.2006.07.005</p>
<p>Kerr, A. C., Ferguson, J., Attili, S. K., Beattie, P. E., Coleman, A. J., Dawe, R. S., ..., Sarkany, R. P. E. (2012). Ultraviolet A1 phototherapy: A British photodermatology group workshop report. Clinical and Experimental Dermatology, 37(3), 219–226. doi: 10.1111/j.1365-2230.2011.04256.x</p>
<p>Koh, M. J., &amp; Chong, W. (2014). Narrow-band ultraviolet B phototherapy for mycosis fungoides in children. Clinical and Experimental Dermatology, 39(4), 474–478. doi: 10.1111/ced.12364</p>
<p>Krutmann, J., &amp; Moriat, A. (2012). UVA1 phototherapy. <a href="http://www.uptodate.com/contents/uva1-phototherapy" target="_blank" rel="noopener noreferrer">http://www.uptodate.com/contents/uva1-phototherapy</a>? source=search_result&amp;search=UVA1&amp;selectedTitle=1~19</p>
<p>Lapolla, W., Yentzer, B. A., Bagel, J., Halvorson, C. R., &amp; Feldman, S. R. (2011). A review of phototherapy protocols for psoriasis treatment. Journal of the American Academy of Dermatology, 64(5), 936–949.</p>
<p>Leach, E. E., McClelland, P. B., Morgan, P., &amp; Shelk, J. (1996). Basic principles of photobiology and photochemistry for nurse phototherapists and phototechnicians. Dermatology Nursing, 8(4), 235–241, 258.</p>
<p>Majid, I. (2014). Efficacy of targeted narrowband ultraviolet B therapy in vitiligo. Indian Journal of Dermatology, 59(5), 485. doi: 10.4103/0019-5154.139892</p>
<p>Martin, J. A., Laube, S., Edwards, C., Gambles, B., &amp; Anstey, A. V. (2007). Rate of acute adverse events for narrow-band UVB and Psoralen-UVA phototherapy. Photodermatology, Photoimmunology &amp; Photomedicine, 23(2–3), 68–72. doi: 10.1111/j.1600-0781.2007.00278.x</p>
<p>Menter, A., &amp; Bhushan, R. (2010). Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 5. Guidelines of care for the treatment of psoriasis with phototherapy and photochemotherapy. Journal of the American Academy of Dermatology, 62(1), 114–135.</p>
<p>Morita, A. (2010). Ultraviolet (UV) A and (UV) B phototherapy (pp. 87–91). Berlin/Heidelberg: Springer. doi: 10.1007/978-3-540-78814-0_9</p>
<p>Mysore, V. (2009). Targeted phototherapy. Indian Journal of Dermatology, Venereology and Leprology, 75(2), 119–125. doi: 10.4103/0378-6323.48655</p>
<p>Osorio, F., &amp; Magina, S. (2011). Phototherapy and photopheresis: Old and new indications. London, UK: Expert Reviews, Ltd. doi: 10.1586/edm.11.71</p>
<p>Percivalle, S., Piccinno, R., Caccialanza, M., &amp; Forti, S. (2012). Narrowband ultraviolet B phototherapy in childhood vitiligo: Evaluation of results in 28 patients. Pediatric Dermatology, 29(2), 160–165. doi: 10.1111/j.1525-1470.2011.01683.x</p>
<p>Syed, Z. U., &amp; Hamzavi, I. H. (2011). Photomedicine and phototherapy considerations for patients with skin of color. Photodermatology, Photoimmunology &amp; Photomedicine, 27(1), 10–16. doi: 10.1111/j.1600-0781.2010.00554.x</p>
<p>Tartar, D., Bhutani, T., Huynh, M., Berger, T., &amp; Koo, J. (2014). Update on the immunological mechanism of action behind phototherapy. Journal of Drugs in Dermatology, 13(5), 564.</p>
<p>The Joan Shelk Fundamentals of Phototherapy Workshop, Dermatology Nurses’ Association. Copyright 2011.</p>
<p>Tilkorn, D. J., Schaffran, A., Al-Benna, S., Benna, S. A., Hauser, J., Steinau, H. U., &amp; Ring, A. (2013/2012). Severe burn injuries induced by PUVA chemotherapy. Journal of Burn Care &amp; Research, 34(3), e195. doi: 10.1097/BCR.0b013e318257d932</p>
<p>Verhaeghe, E., Lodewick, E., van Geel, N., &amp; Lambert, J. (2011). Intrapatient comparison of 308-nm monochromatic excimer light and localized narrow-band UVB phototherapy in the treatment of vitiligo: A randomized controlled trial. Dermatology, 223(4), 343–348. doi: 10.1159/000335272</p>
<p>Wallengren, J. (2010). Ultraviolet phototherapy of pruritus (pp. 325–334). London, UK: Springer. doi: 10.1007/978-1-84882-322-8_51</p>
<p>Weichenthal, M., &amp; Schwarz, T. (2005). Phototherapy: How does UV work?. Photodermatology, Photoimmunology &amp; Photomedicine, 21(5), 260–266. doi: 10.1111/j.1600-0781.2005.00173.x</p>
<p>York, N. R., &amp; Jacobe, H. T. (2010). UVA1 phototherapy: A review of mechanism and therapeutic application. International Journal of Dermatology, 49(6), 623–630. doi: 10.1111/j.1365-4632.2009.04427x</p>
<p>Zandi, S., Kalia, S., &amp; Lui, H. (2012). UVA1 phototherapy: A concise and practical review. Skin Therapy Letter, 17(1), 1.</p>
<p>Zhang, A. Y. (2014). Drug-induced photosensitivity. <a href="http://emedicine.medscape.com/article/1049648" target="_blank" rel="noopener noreferrer">http://emedicine.medscape.com/article/1049648</a></p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="study-questions">STUDY QUESTIONS<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#study-questions" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<ol>
<li>
<p>Which of the following statements about metering is false?
a. Metering determines the power/energy output of the phototherapy equipment.
b. Metering is done to adjust the amount of energy being emitted from UVL lamps.
c. There are no FDA standards for metering.
d. Metering should be done consistently and according to manufacturer recommendations.</p>
</li>
<li>
<p>Both old and new lamps can provide effective phototherapy treatment; however, treatment times with older lamps may be longer.
a. True
b. False</p>
</li>
<li>
<p>Which of the following is not a side effect of phototherapy?
a. Erythema
b. Pruritus
c. Nail peeling
d. Skin damage</p>
</li>
<li>
<p>Sunscreens can be used for shielding of unaffected areas.
a. True
b. False</p>
</li>
<li>
<p>Which of the following light spectra is also referred to as the burning ray?
a. UVC
b. UVA
c. UVB
d. Both A and C</p>
</li>
<li>
<p>Which of the following is not a question to ask a patient before administering PUVA?
a. Have you started any new medications?
b. Have you used artificial hair dye since the last treatment?
c. Is there any possibility you could be pregnant?
d. Did you develop erythema with the last dose?</p>
</li>
<li>
<p>Erythema lasting more than 24 hours after narrowband UVB is concerning.
a. True</p>
</li>
</ol>
<p>b. False</p>
<ol start="8">
<li>Diseases such as lupus can be exacerbated by UVL use.</li>
</ol>
<p>a. True
b. False</p>
<ol start="9">
<li>Phototherapy is always effective as a monotherapy, replacing the need for the patient to use topical or oral medications for the condition.</li>
</ol>
<p>a. True
b. False</p>
<ol start="10">
<li>All of the following statements about phototherapy are true except:</li>
</ol>
<p>a. Staff members are responsible for ensuring safe entry into and exit out of the phototherapy unit.
b. A backup timer should always be employed as a precautionary safety measure with each treatment.
c. Patient observation during treatment is only necessary for pediatric and elderly patients.
d. Persistent pruritus, erythema, and nausea can result in treatment failure.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="answers-to-study-questions">Answers to Study Questions<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#answers-to-study-questions" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>1.b
2.a
3.c
4.a
5.c
6.b
7.a
8.a
9.b
10.c</p>
<p>CHAPTER 7</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="psychosocial-effects-and-nursing-interventions-for-dermatological-disease-and-psychodermatoses">Psychosocial Effects and Nursing Interventions for Dermatological Disease and Psychodermatoses<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#psychosocial-effects-and-nursing-interventions-for-dermatological-disease-and-psychodermatoses" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>Fiona Cowdell • Steven J. Ersser</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="objectives">OBJECTIVES<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#objectives" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>After studying this chapter, the reader will be able to:</p>
<ul>
<li>Identify the functions of the skin that are related to psychosocial well-being.</li>
<li>Describe the psychosocial effects of dermatological disease.</li>
<li>Describe the classification of psychodermatological disorders.</li>
<li>Identify holistic approaches to consultation that support recognition of psychodermatoses and enhance the therapeutic nature of dermatological consultations.</li>
<li>Select appropriate measures that assess skin-related psychological status accurately and measure learning and support needs.</li>
<li>Assess when patients have psychodermatological conditions that are amenable to nursing intervention and when specialist psychodermatology referral is required.</li>
<li>Explain the principles of three evidence-based behavioral interventions that may be used by nurses to support patients with psychodermatological conditions with a focus on promoting effective self-management.</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="key-points">KEY POINTS<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#key-points" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<ul>
<li>
<p>The skin is the largest and most visible organ of the body, and changes to the skin can have a major impact on psychosocial well-being.</p>
</li>
<li>
<p>Skin diseases cause alterations in appearance and thereby affect body image.</p>
</li>
<li>
<p>Psychodermatoses or psychocutaneous diseases are skin diseases with a psychological origin.</p>
</li>
<li>
<p>People with skin conditions may suffer physical and psychosocial discomfort as well as being stigmatized by others because of their appearance.</p>
</li>
<li>
<p>It is important to integrate psychosocial assessment into dermatological consultations.</p>
</li>
<li>
<p>Patients presenting with dermatological symptoms should be assessed for dermatological and systemic disease before a psychological or psychiatric cause is diagnosed.</p>
</li>
<li>
<p>A long-term skin condition can be very challenging for patients to cope with, and poor self-management can increase psychodermatological suffering and the quality-of-life impact.</p>
</li>
<li>
<p>Many psychodermatological issues are amenable to nursing intervention, while others need specialist referral.</p>
</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="introduction">INTRODUCTION<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#introduction" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>This chapter is divided into four sections. The first section examines the effects of dermatological disease on health and well-being. The second provides a summary of psychodermatological disease classification. The third examines how assessment of psychodermatological health and well-being can be integrated into nursing consultation and offers some measurement tools for assessment and evaluation. Recognition of conditions that are responsive to nursing intervention and those that require specialist referral is also considered in section 2. The final section outlines three evidence-based approaches for psychodermatological disorders that are amenable to nursing intervention through promotion of health and well-being and effective self-management.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="effects-of-dermatological-disease-on-health-and-well-being">EFFECTS OF DERMATOLOGICAL DISEASE ON HEALTH AND WELL-BEING<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#effects-of-dermatological-disease-on-health-and-well-being" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="i-psychosocial-functions-and-impacts-of-the-skin">I. PSYCHOSOCIAL FUNCTIONS AND IMPACTS OF THE SKIN<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#i-psychosocial-functions-and-impacts-of-the-skin" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>A. The skin is the largest and most visible organ of the body that serves as the barrier between the individual and the external environment, including the interpersonal and social environment.</p>
<ol>
<li>As a society, we tend to place a high value on flawless skin and can be quick to judge people on their appearance.</li>
<li>The visual appearance of skin disease may lead to the development of disruption of normal interpersonal relationships.</li>
<li>Rejection by others frequently occurs.</li>
<li>Interpretation of outside stimuli is adversely affected.</li>
<li>Expression of enjoyment from outside stimulation is adversely affected.</li>
<li>Sensory pleasure is adversely affected.</li>
</ol>
<p>B. The skin affects the mind.</p>
<ol>
<li>The skin acts as a sense organ for touch, cold, heat, and pain and is an exogenous organ.</li>
<li>The skin separates us from the outside world but provides an interface with the psychosocial environment.</li>
<li>The skin may be a source of anxiety and stress.</li>
<li>Early experiences of skin contact may have far-reaching impact on physical and emotional development.</li>
<li>The skin's condition is influenced by the "look good–feel good" factor. If the skin has imperfections, this can have a detrimental effect on psychosocial well-being and body image, depending on the individual reaction.</li>
</ol>
<p>C. The mind affects the skin.</p>
<ol>
<li>The skin acts as a facade that displays us and serves as a means of nonverbal communication with the outside world.</li>
<li>The skin involuntarily communicates to others some of our emotional states.</li>
<li>The skin acts as an intermediary between the individual's inner self and the external environment.</li>
<li>The skin is an organ of emotional expression.</li>
<li>The skin conveys varied external stimuli, including temperature differences, pain, affection, tenderness, and sexual identity and stimulation.</li>
<li>There is complex interplay between stress, anxiety, and depression in the skin; these factors can precipitate or worsen skin conditions. Living with skin conditions can cause or exacerbate stress, anxiety, and/or depression.</li>
</ol>
<p>D. The skin is one of the most important psychosomatic organs.</p>
<ol>
<li>The impression an individual makes on another person depends partly on their skin condition/health.</li>
<li>Unsightly skin typically provokes negative feelings in the observer.</li>
<li>Unsightly the skin may trigger feelings of revulsion, shame, and inferiority.</li>
</ol>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="classification-of-psychodermatological-disorders">CLASSIFICATION OF PSYCHODERMATOLOGICAL DISORDERS<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#classification-of-psychodermatological-disorders" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h3 level="3" id="i-overview">I. OVERVIEW<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#i-overview" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h3></div>
<p>A. The skin has multiple functions and plays a crucial role in psychological and social well-being.
B. The concepts of psychological and social well-being are two distinct but related states but are often unhelpfully merged.
C. Psychological well-being refers to issues related to the mind, how the person copes with their experiences and surroundings.
D. Social well-being is concerned with how effectively the person interacts with others in society.</p>
<p>E. Several factors can precipitate psychodermatological disorders including stress, the impact of mood and anxiety, the presence or absence of social support, and, in some cases, mental ill health.</p>
<p>F. The visibility of the skin conditions can have a negative impact on body image, that is, the mental picture of how individuals view their bodies including their perception of how their body looks and the feelings, attitudes, and their emotions toward it.</p>
<p>G. If body image becomes very negative, the person may become obsessional about the appearance of their skin; this may lead to misperceptions of delusional proportion. People with dermatological conditions and those undergoing dermatological treatments often experience uncomfortable and unsightly skin.</p>
<p>H. Treatment for skin conditions may be time consuming and require expensive and unpleasant topical medications.</p>
<p>I. Dermatological treatments may be slow to show an effect, and their use may be required over prolonged periods of time; this may impact on motivation and thus well-being.</p>
<p>J. There is often a high self-management burden when living with chronic dermatoses.</p>
<p>K. While skin conditions present physical problems, they elicit emotional reactions as well, both for the person living with the disease and their significant others.</p>
<p>L. Significant others and the public often do not understand skin diseases and are typically repulsed at the site of their appearance.</p>
<p>M. A common fear is that the diseases are contagious and communicate their thoughts and feelings, both verbally and nonverbally, to the individuals with the diseases. The public may also misinterpret skin lesions as a sign of poor personal hygiene.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="ii-classification">II. CLASSIFICATION<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#ii-classification" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>A. Primary psychiatric disease presenting to dermatology health care professionals</p>
<ol>
<li>
<p>Delusional disorders
a. Olfactory syndromes
b. Dysmorphic syndromes
c. Others</p>
</li>
<li>
<p>Obsessive-compulsive disorders (OCD)
a. Body dysmorphic disorders
b. Other obsessive-compulsive disorders, for example, excessive hand washing
c. Health anxieties
d. Skin picking disorders
e. Trichotillomania</p>
</li>
<li>
<p>Dysesthesias, for example, burning syndrome, vulvodynia, and scrotal dysesthesias</p>
</li>
<li>
<p>Anxiety disorders
a. General anxiety disorder
b. Specific anxieties
i. Syphilis phobia
ii. Cancer phobia
iii. Others</p>
</li>
<li>
<p>Chronic pruritus
a. Psychogenic pruritus
b. Nodular prurigo</p>
</li>
<li>
<p>Factitious disorders
a. Dermatitis artefacta
b. Factitious and induced illness
c. Malingering
d. Abuse (sexual/emotional)</p>
</li>
</ol>
<p>B. Dermatological disorders with potential psychosocial comorbid conditions: for example, acne, eczema, psoriasis, vitiligo, and others with psychiatric disorders such as anxiety, depression, suicidal ideation, and social phobia
C. Suicidal ideation associated with skin disorders
D. Psychopharmacologically related disorders</p>
<ol>
<li>Medication which dermatologists use that may lead to psychiatric disorders (e.g., isotretinoin and depression)</li>
<li>Psychiatric medication that may lead to skin disorder (e.g., lithium and psoriasis)</li>
</ol>
<p>E. Skin disorders that may be induced by stress (e.g., psoriasis)
F. Site-specific skin disorder that may have a site-specific psychosocial comorbid condition, such as the following:</p>
<ol>
<li>Alopecia areata and hair appearance-related comorbid condition</li>
<li>Genital dysesthesias and psychosexual comorbid condition</li>
</ol>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="iii-clinical-features-of-frequently-seen-dermatological-disorders">III. CLINICAL FEATURES OF FREQUENTLY SEEN DERMATOLOGICAL DISORDERS<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#iii-clinical-features-of-frequently-seen-dermatological-disorders" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>A. The clinical features, etiology, and treatment of the most frequently seen dermatology-related primary psychiatric conditions are summarized in Table 7-1.
B. These psychiatric disorders require more specialized care and are beyond the scope of this chapter.</p>
<p>TABLE 7-1 Clinical Features and Treatment of Common Dermatology-Related Primary Psychiatric Conditions</p>
<table><thead><tr><th>Condition</th><th>Etiology</th><th>Treatment</th></tr></thead><tbody><tr><td>Delusional parasitosis (DP)</td><td></td><td></td></tr><tr><td>Also known as Ekbom syndrome</td><td>Currently unknown</td><td></td></tr><tr><td>Can be associated with dementia in older people, drug and alcohol misuse and rarely neurological disease can mimic DP</td><td>Can be difficult as patients often lack insight. Exclusion of organic cause is essential. Patients should not be accused of false claims as this will breakdown the therapeutic relationship and may trigger the patient seeking alternative medical care. Conventional antipsychotics are sometimes effective.</td><td></td></tr><tr><td>Body dysmorphic disorder (BDD)</td><td></td><td></td></tr><tr><td>Characterized by imagined or exaggerated defect in physical appearance</td><td>May be familial and may be related to obsessive–compulsive disorder</td><td>Patients may lack insight and decline psychological or psychiatric treatment.</td></tr><tr><td>High doses over long periods of seronergenic antidepressants may be effective.</td><td></td><td></td></tr><tr><td>Trichotillomania</td><td></td><td></td></tr><tr><td>Hair pulling</td><td></td><td></td></tr><tr><td>May occur alone or as part of another disorder, for example, schizophrenia, borderline personality disorder, or depression</td><td>Unknown at present</td><td>Comorbid psychiatric disorders should be excluded.</td></tr><tr><td>Patient support groups and general supportive psychotherapy may be helpful in helping patients cope with their condition.</td><td></td><td></td></tr><tr><td>Antidepressant and behavioral therapy have been used with some success.</td><td></td><td></td></tr><tr><td>Dermatitis artefacta</td><td></td><td></td></tr><tr><td>Patient-created skin lesions, may be produced to satisfy a personal psychological need. May include linear tears and bruising</td><td>Many patients have personality disorders and may have experienced physical or sexual abuse</td><td>Dermatological diseases must be excluded.</td></tr><tr><td>Skin lesions must be treated.</td><td></td><td></td></tr><tr><td>Patients should be reviewed regularly in the dermatology clinic to prevent escalations of help-seeking behaviors. Psychiatric treatment may include antidepressants or atypical antipsychotics.</td><td></td><td></td></tr></tbody></table>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="iv-dermatology-related-psychosocial-comorbidities">IV. DERMATOLOGY-RELATED PSYCHOSOCIAL COMORBIDITIES<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#iv-dermatology-related-psychosocial-comorbidities" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>A. Psychological and social experiences in dermatological disease</p>
<ol>
<li>Patients with dermatology-related psychosocial comorbid conditions may encounter one or more of the psychological and/or social experiences listed in Box 7-1.</li>
<li>Any of these experiences and feelings can hinder people’s ability to self-manage effectively; this can lead to a downward spiral, as self-care diminishes skin condition and quality of life deteriorates.</li>
<li>This may result in impaired ability to self-care and ever-worsening skin condition; this in turn can impact on psychosocial well-being and self-care ability.</li>
<li>Experiences listed in Box 7-1 may be considered within the realms of “normal” reactions and are likely to be amenable to nursing intervention.</li>
</ol>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="box-7-1-experiences-of-people-with-dermatology-related-psychosocial-comorbid-conditions">BOX 7-1. Experiences of People with Dermatology-Related Psychosocial Comorbid Conditions<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#box-7-1-experiences-of-people-with-dermatology-related-psychosocial-comorbid-conditions" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>Anger</p>
<p>Anxiety</p>
<p>Avoidance</p>
<p>Bullying</p>
<p>Concealment</p>
<p>Depression</p>
<p>Embarrassment</p>
<p>Exhaustion</p>
<p>Frustration</p>
<p>Guilt
Helplessness
Increased alcohol intake
Irritability
Low confidence
Low self-esteem
Performance issues
Poor body image
Relationship issues
Resentment
Secretiveness
Self-consciousness
Sexual problems
Sleep deprivation/sleeplessness
Social isolation
Social phobia
Stigmatization
Stress
Suicidal thoughts
Suicide
Teasing
Unemployment
Withdrawal</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="holistic-approaches-to-nursing-consultation-and-assessment">HOLISTIC APPROACHES TO NURSING CONSULTATION AND ASSESSMENT<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#holistic-approaches-to-nursing-consultation-and-assessment" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="i-overview">I. OVERVIEW<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#i-overview" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>A. Dermatology-related psychosocial comorbid conditions are amenable to nursing care through effective assessment, consultation, and psychological interventions.</p>
<p>B. Accurate, holistic patient assessment is essential in identifying and understanding psychosocial health in patients with skin conditions in planning appropriate care and referral.</p>
<p>C. Most nurses will already have an extensive skill set that will inform consultations. There are additional techniques that may be integrated into consultations to enhance communication, develop therapeutic effectiveness, and ensure that psychosocial issues are identified and addressed.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="ii-nursing-consultation">II. NURSING CONSULTATION<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#ii-nursing-consultation" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>In any nursing consultation, the patient must have the opportunity to express their thoughts and feelings. The consultation should take place in a quiet, comfortable environment in which there are no disturbances. This information below is not intended to be a checklist but rather a number of ideas that may be introduced in the course of consultations using a mixture of open and closed questions as appropriate.</p>
<p>A. Objectives of the nursing consultation:</p>
<ol>
<li>To provide support and education to patients with skin disease to aid their adaptation and promote well-being and quality of life.</li>
<li>To enhance their mental health and well-being and so enable patients to manage their condition as effectively as possible.</li>
<li>To identify patients with psychiatric conditions or complex clinical psychological needs who require specialist care and so referral to psychological or psychiatric services.</li>
</ol>
<p>B. The four-stage therapeutic consultation</p>
<p>A four-stage therapeutic consultation approach allows the person to be examined holistically and provides a basis for effective care planning:</p>
<ol>
<li>The clinical observation: global evaluation</li>
</ol>
<p>a. How does the patient behave?—for example, do they appear worried, relaxed, and defensive?
b. How are they talking?—for example, do they provide a concise or a long and complex history?
c. What about nonverbal language?—for example, do they exhibit signs of stress?
d. How do they look?—how are they dressed; what is the first impression of their skin condition?
e. How are they interacting with others?—For example, are they accompanied by a friend or relative, who talks first, and are they able to listen to and understand information?</p>
<ol start="2">
<li>The clinician's thoughts:</li>
</ol>
<p>a. What is the overall impression of the patient (physical and psychosocial presentation)?
b. Is the initial impression of the patient and what they are saying is congruent? For example, does the patient given nonverbal cues that they are distressed but try to discuss their condition in purely physical terms?
c. Is there a sense of reality in what the patient is telling you?</p>
<ol start="3">
<li>Questions—it is always useful to discuss sleep disturbance, appetite, weight change, their quality of life, and how they manage stress.</li>
<li>Validated questionnaires can help to more accurately assess problems with psychosocial well-being and consequence of disease. (See section below on assessment of psychological health and disease-related quality of life.)</li>
</ol>
<p>C. Communication</p>
<ol>
<li>Communication is central in any consultation, and there are three core conditions that need to be met by the nurse within a therapeutic consultation:</li>
</ol>
<p>a. Congruence (genuineness)
b. Empathy</p>
<p>c. Unconditional positive regard (acceptance and support of a person)</p>
<ol start="2">
<li>Critical elements of consultation include the following:</li>
</ol>
<p>a. Establishing rapport
b. Agenda setting (what does each person expect from the consultation)
c. Asking open-ended questions to elicit a fuller picture of how the patient is feeling:</p>
<p>Are you happy with your skin?</p>
<p>What are your feelings about your skin?</p>
<p>Help me to understand how you feel about your skin?</p>
<p>Talk me through ...</p>
<p>d. Using reflective listening—a communication technique with two steps: firstly understanding what the patient is trying to convey and then offering the idea back to the patient to ensure that they have been correctly understood.</p>
<p>Simply paraphrasing what you think they have said</p>
<p>Stating "It sounds like you are feeling ..."</p>
<p>Stating "It sounds like you are having trouble with ..."</p>
<p>Or the more sophisticated approach of tentatively interpreting the emotion of what they have said</p>
<p>Stating "You're not able to ..."</p>
<p>Stating "You're having a problem with ..."</p>
<p>Stating "You're feeling that ..."</p>
<p>e. Adopting a nonjudgmental, nonconfrontational, and nonadversarial position and try to understand what the patient is experiencing.</p>
<p>f. Establishing some of the following on the nature and potential impact of their condition:</p>
<p>i. What patients know about the disease.
ii. How they feel it affects their appearance.
iii. How it impacts on their body image.
iv. How they feel if it affects the texture of their skin.
v. How they feel if it affects their personal odor.
vi. How the condition is affecting their daily lives.
vii. If they are anxious or depressed.
viii. If they can do the things they want to do.
ix. If they obtain and use treatments as agreed.
x. If they feel supported by family and friends.
xi. How it is affecting their interaction and relationships with others.
xii. The impact the condition is having on their work or education.
xiii. How others are reacting to their skin condition and how they are responding to others.
xiv. If they have developed effective coping mechanisms.
xv. What their expectations are for the outcomes of treatment.</p>
<p>In addition to talking with patients, it may be useful to invite them to complete questionnaires</p>
<p>about their well-being and disease-related quality of life. These can be completed prior to the consultation and provide a basis for discussion, which should include considering physical and psychological health, their interrelationship, and self-management strategies. They can also provide a basis for evaluating the impact of support and treatment.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="assessment-tools-used-in-dermatology-self-management">ASSESSMENT TOOLS USED IN DERMATOLOGY SELF-MANAGEMENT<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#assessment-tools-used-in-dermatology-self-management" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="i-overview">I. OVERVIEW<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#i-overview" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>A. There are many validated measures of quality of life, defined as the differences between the person's hopes and expectations and their current experience.</p>
<p>B. Tools may be generic, applying to diseases affecting one system (e.g., skin) or be disease specific.</p>
<p>C. There are also tools that measure self-management ability (e.g., the Person-Centered Dermatology Self-Management Index, Cowdell et al., 2012).</p>
<p>D. Assessment tools can be used as a guide for discussion and when repeated allow the patient and the nurse to see change over time.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="ii-assessment-tools">II. ASSESSMENT TOOLS<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#ii-assessment-tools" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>A. Generic and disease-specific quality-of-life tools</p>
<p>There are many generic and disease-specific quality-of-life impact tools (Table 7-2).</p>
<p>B. The Person-Centered Dermatology Self-Care Index (PeDeSI)</p>
<p>PeDeSI (Figure 7-1) is a validated, behaviorally based tool; the theoretical underpinnings are the self-efficacy construct (the belief that a person has that they are able to successfully undertake a specific behavior) and the concordance model (the process of prescribing and using medications based on a partnership approach between the patient and health professional). This simple, evidence-based questionnaire, which is completed collaboratively between the patient and nurse, identifies education and support needs that, if met, will enhance self-management and concordance with the treatment regimen.</p>
<p>TABLE 7-2 Quality-of-Life Measures Used in Dermatology</p>
<table><thead><tr><th>Tool</th><th>Components</th><th>Authors</th></tr></thead><tbody><tr><td>Dermatology Life Quality Index (DLQI)</td><td>10 items</td><td></td></tr><tr><td>Score range 0–30</td><td></td><td></td></tr><tr><td>Completed by the patient</td><td>Finlay and Khan (1994)</td><td></td></tr><tr><td>Family Dermatology Life Quality Index (FDLQI)</td><td>10 items</td><td></td></tr><tr><td>Score range 0–30</td><td></td><td></td></tr><tr><td>Completed by the parent</td><td>Basra et al. (2007)</td><td></td></tr><tr><td>Children's Dermatology Life Quality Index (CDLQI)</td><td>10 items</td><td></td></tr><tr><td>Score range 0–30</td><td></td><td></td></tr><tr><td>Completed by children aged 5–16 y assisted by parents if needed</td><td></td><td></td></tr><tr><td>Word or cartoon versions available</td><td>Lewis-Jones and Finlay (1995)</td><td></td></tr><tr><td>Infants Dermatology Quality of Life Index (IDQOL)</td><td>1-item dermatitis severity</td><td></td></tr><tr><td>10-items quality of life</td><td></td><td></td></tr><tr><td>Score range 0–30</td><td></td><td></td></tr><tr><td>Completed by parents or carers of children from birth to 4 y</td><td></td><td></td></tr><tr><td>The severity of eczema is scored separately and can be correlated with the IDQOL</td><td>Lewis-Jones et al. (2001)</td><td></td></tr><tr><td>Dermatitis Family Impact Questionnaire (DFI)</td><td>10 items</td><td></td></tr><tr><td>Score range 0–30</td><td></td><td></td></tr><tr><td>Completed by the parent</td><td>Lawson et al. (1998)</td><td></td></tr><tr><td>Skindex-16</td><td>16 items</td><td></td></tr><tr><td>Score range 0–96</td><td></td><td></td></tr><tr><td>Completed by the patient</td><td>Chren et al. (2001)</td><td></td></tr><tr><td>Cardiff Acne Disability Index (CADI)</td><td>5 items</td><td></td></tr><tr><td>Score range 0–15</td><td></td><td></td></tr><tr><td>Completed by the patient</td><td>Motley and Finlay (1992)</td><td></td></tr><tr><td>Psoriasis Disability Index</td><td>15 items</td><td></td></tr><tr><td>Score range 0–45</td><td></td><td></td></tr><tr><td>Completed by the patient</td><td></td><td></td></tr><tr><td>Visual analogue or tick box version available</td><td>Finlay and Kelly (1987)</td><td></td></tr></tbody></table>
<p>Name:</p>
<p>Condition:</p>
<p>Topical treatment(s):</p>
<p>Please score each area of ability in discussion with the person using treatment(s) by ticking the relevant boxes.</p>
<table><thead><tr><th>PeDeSI number:</th><th>Degree of independence</th><th></th><th></th><th></th><th></th></tr></thead><tbody><tr><td>Ability</td><td>0 = No ability</td><td>1 = Some ability</td><td>2 = Sufficient ability</td><td>3 = Full ability</td><td>Agreed Action Plan</td></tr><tr><td>1. Do you have an understanding of your skin condition?</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>2. Do you know what things make your skin condition better and worse?</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>3. What is this treatment(s) used for?</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>4. Are you aware of how long initial treatment will take to be effective?</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>5. Do you know what the common side-effects of your treatment(s) are?</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>6. Do you know how much cream / ointment / lotion should be applied each time and at what time(s)?</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>7. Can you apply the treatment(s) to the affected areas? (demonstrate)</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>8. Do you know how and when to adapt treatment / seek help if condition gets worse?</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>9. Do you know how to obtain a repeat prescription?</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>10. Do you feel confident to use treatment(s) at home yourself?</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>Total Score / 30 (maximum total score) Total scores in range: 0-10 needs intensive education and support to develop knowledge, ability and confidence Total scores in range: 11-20 needs some education and support to develop knowledge, ability and confidence Total scores in range 21-29 needs limited education and support to develop knowledge, ability and confidence Total score of 30 has sufficient knowledge, ability and confidence to manage on their own Signature Date</td><td></td><td></td><td></td><td></td><td></td></tr></tbody></table>
<p>FIGURE 7-1. Person-Centered Dermatology Self-care Index (PeDeSI). (© Ersser, Cowdell, Gradwell &amp; Langford December 2011.)</p>
<p>While none of these tools is a panacea, they can help to understand the impact of the psychosocial state of the patient, which may have a bearing on their ability to cope and engage in their own self-management. In combination with the consultation and clinical judgment, they will help you to identify when referral to specialist psychodermatology care is required.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="iii-specialist-referral">III. SPECIALIST REFERRAL<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#iii-specialist-referral" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>The need for psychological or psychiatric referral is always a matter for clinical judgment; however, there are some specific factors that should alert the nurse to this requirement (Box 7-2).</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="box-7-2-indicators-that-psychological-or-psychiatric-referral-may-be-required">BOX 7-2. Indicators that Psychological or Psychiatric Referral May Be Required<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#box-7-2-indicators-that-psychological-or-psychiatric-referral-may-be-required" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<ul>
<li>High scores in the quality-of-life indices (but not in isolation)</li>
<li>Anxiety and profound preoccupation with a delusional belief (e.g., of parasitical infestation)</li>
<li>Difficult-to-engage patients who recount in minute detail their medical history and treatment failures</li>
<li>Adults exhibiting personality disordered behavior characterized by infantile, dependent, manipulative behavior and poor impulse control</li>
<li>Unusual skin appearance, for example, single or multiple, bilateral or symmetrical, or within easy reach of the dominant hand, which may be self-inflicted</li>
<li>There is a sense of unreality in what the patient is telling you.</li>
<li>Serious deterioration in their condition and self-care ability, which is primarily related to their psychosocial state</li>
</ul>
<p>There are a range of treatment options for patients who need care that is beyond purely nursing intervention. Complex psychological or psychiatric care and counseling are the major treatments. Medication can be helpful and may include, according to condition, antidepressants and occasionally atypical antipsychotics.</p>
<p>If a higher level of specialized psychological or psychiatric care is required, this idea should be put to the patient sensitively as some may resist referral, partly due to perceived stigma. One of the major advantages of having psychological support within or via a dermatology department is that such care may be "normalized" if provided in "normal" health care settings.</p>
<p>Conducting a systematic and thorough consultation with the patient, careful examination of the skin, and completion of measurement tools will help the nurse determine key aspects of the psychosocial health and well-being and care needs of the patient.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="evidence-based-interventions">EVIDENCE-BASED INTERVENTIONS<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#evidence-based-interventions" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="nursing-for-psychodermatological-disorders">NURSING FOR PSYCHODERMATOLOGICAL DISORDERS<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#nursing-for-psychodermatological-disorders" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="i-overview">I. OVERVIEW<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#i-overview" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<ol>
<li>There is overwhelming evidence that changing people’s health-related behavior can have a major favorable impact on physical and psychosocial well-being.</li>
<li>It is essential that behavioral change interventions are built on a strong theoretical base to strengthen their effectiveness and are appropriate for the individual patient.</li>
<li>Following consultation, the nurse will have built up a picture of the patient, their support and education needs, and whether onward referral for psychological or psychiatric care is necessary.</li>
<li>If the patient’s condition is amenable to nursing intervention, it may be helpful to use elements from the following psychological techniques as an adjunct to conventional dermatology treatments during regular consultations. These techniques are particularly useful for people with chronic dermatoses, which they are finding difficult to self-manage and which is having a detrimental impact on their quality of life.</li>
<li>The patient should be assured that behavioral therapies are complementary to other dermatological treatment and that use of a psychological intervention does not imply that they have a mental illness as this can be a common misunderstanding.</li>
</ol>
<p>The intention here is to give an illustrative flavor of these techniques rather than an exhaustive account. Readers will not become experts; however, they will have an understanding of key concepts and how these may practically be applied and provides a basis to guide further more specialist reading.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="5b064e8f">A. Cognitive–Behavioral Therapy<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#5b064e8f" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<ol>
<li>Cognitive–behavioral therapy (CBT) is a form of therapy that aims to change thoughts and behavior to improve mental and emotional health and well-being.</li>
<li>CBT originates from the work of Aaron Beck in the 1970s and has been developed over time.</li>
<li>It is based on the concept that the way we think about things affects how we feel emotionally and physically and how we behave.</li>
<li>The aim of CBT is to help patients focus on changing their unhelpful thinking patterns in order to change their behavior and emotional state. It is categorized as a “talking therapy” but can be delivered face to face or electronically.</li>
<li>CBT concentrates on the present rather than trying to make links with the individual’s past.</li>
<li>Therapy requires a collaborative relationship between the patient and nurse. The patient needs to be motivated to want to change as they are very involved in the process, which takes significant effort, active participation, and willingness to do “homework.”</li>
<li>If the fundamental principles are used skillfully, CBT can help the patient to make sense of problems that may seem insurmountable at the time.</li>
<li>There is a sound evidence base for CBT. It is recommended by NICE for mental ill health such as anxiety and depression and has also been used successfully in a range of long-term conditions including, to a limited extent, in dermatology.</li>
<li>There are several models of CBT; one suggests a six-phase approach. These are outlined</li>
</ol>
<p>and allied activities summarized in Table 7-3.</p>
<p>B. Habit Reversal</p>
<ol>
<li>Habit reversal (HR) therapy is a brief intervention with a strong theoretical underpinning, which is historically linked to behavioral theory.</li>
<li>It was originally developed by Azrin and Nunn as a multicomponent treatment and based on the premise that an old habit can be broken by replacing it with a new more desirable habit.</li>
<li>A habit is defined as a recurrent, often subconscious, or automatic pattern of behavior that is acquired through frequent repetition.</li>
<li>HR has been used successfully in dermatology primarily to manage the itch-scratch cycle for use in conditions such as eczema but also for trichotillomania and skin picking. A clinical intervention model for use with chronic scratching has been developed (Table 7-4).</li>
<li>Prior to attempting HR, it is important that the nurse acknowledges the patient's affect and feelings about health care professionals and treatments including adherence. There should be a review of chronic illness factors and current medications.</li>
</ol>
<p>C. Social Cognitive Theory (SCT) and its relationship to self-management support</p>
<ol>
<li>SCT and in particular the self-efficacy construct underpin many behavioral interventions to enhance self-management of long-term conditions.</li>
<li>Developed by Albert Bandura, the central concept is the development of self-efficacy, that is, the belief that a person has in their ability to successfully initiate and complete the actions required in specific situations to achieve particular outcomes.</li>
<li>Enhanced self-efficacy in self-management ability will help the person to self-manage their skin condition more effectively.</li>
<li>To help people develop a robust sense of self-efficacy, we need to ensure that they acquire sufficient knowledge, skills, and confidence to self-manage their skin condition as effectively as possible.</li>
<li>Self-efficacy is measured using the PeDeSI referred to above.</li>
<li>Self-efficacy is acquired through mastery experience, vicarious experience, social persuasion, and emotional regulation. These elements are explained in detail in Table 7-5.</li>
</ol>
<p>TABLE 7-3 Six Phases in the Cognitive–Behavioral Therapy Process and Allied Activities</p>
<table><thead><tr><th>Phase</th><th>Activity</th></tr></thead><tbody><tr><td>1. Assessment</td><td>Conversation with patients and their families, series of self-reported measures to identify degree of psychosocial impairment and determine appropriate course of action. The patient is helped to appraise the personal meaning and significance of events and consider his or her capacity to cope with the situation. For each situation, there are helpful and unhelpful ways of responding.</td></tr><tr><td>2. Reconceptualization</td><td>The nurse assists the patient to reframe his or her experiences; this may simply require the nurse to draw the negative response to the attention of the patient. For example, "I am a failure in life because I have bad skin." Alternatively could involve: Asking the patient to complete a thought diary to identify antecedents to negative thoughts.</td></tr><tr><td>3. Skills acquisition</td><td>Teach patients how to deal with day-to-day obstacles in their everyday life and how to avoid falling into a pattern of automatic thought. The patient needs to understand the direct connection between thoughts and feelings (having more positive thoughts is likely to lead to more positive feelings) and that physical/bodily feelings can be changed. Techniques may be used to support this: Square breathing (in for a count of two, hold for two, out for two, hold for two) Progressive muscle relaxation Challenging negative automatic thoughts Behavioral strategies (e.g., building up social contact one step at a time)</td></tr><tr><td>4. Skills consolidation</td><td>Patients given "homework" to help them reinforce newly acquired skills. Changing habitual responses takes time and effort, and for those with skin disease, there is the added challenge of coping with the discomfort and complexity of treatment regimes. Example of this are as follows: Activity scheduling (planning achievable and rewarding daily tasks) Replacing maladaptive coping behaviors (e.g., avoidance of situations) with adaptive mechanisms (e.g., challenging negative automatic thoughts) Mindfulness practice (exercises that focus on awareness of the present moment)</td></tr><tr><td>5. Generalization and maintenance</td><td>The patient and the nurse discuss and agree how the patient is going to maintain his or her skills, for example: Diary Support groups</td></tr><tr><td>6. Posttreatment assessment follow-up</td><td>The nurse and the patient monitor and evaluate how CBT skills have been incorporated into everyday life.</td></tr></tbody></table>
<p>CBT, cognitive-behavioral therapy.</p>
<p>TABLE 7-4 Habit Reversal Clinical Intervention Model for Use in Chronic Scratching</p>
<table><thead><tr><th>Stage of Habit Reversal</th><th>Actions</th></tr></thead><tbody><tr><td>Habit concept education</td><td>Provide the patient with a straightforward explanation of what a habit is and why HR may be a useful technique for he or she to learn.</td></tr><tr><td>Itch-scratch cycle education</td><td>Patient's own itch-scratch cycle should be defined and represented diagrammatically; this requires a conversation with the patient and detailed behavioral profile.</td></tr><tr><td>Situation awareness training</td><td>The person needs to become aware of their scratching behavior; this can be achieved by the following: Asking the patient to keep a scratch diary for a fixed time period Learning to recognize early moves to scratch</td></tr><tr><td>Behavioral assessment</td><td>Patients need to learn the difference between itch and scratch (as some use these terms interchangeably). Assessment should include the following: How the patient actually scratches (with what, where, when, frequency, intensity, duration, and bouts of scratching triggers) must be identified (temperature, friction, atmosphere, etc.). Define thoughts after the itch. Define the scratching behavior. Consider the consequences. What makes the problem better and worse? What does the problem prevent the patient from doing? List the goals that the patient wishes to achieve (stop scratching, allow the skin to heal, etc.).</td></tr><tr><td>Design brief</td><td>Based on assessment, a design brief for the competing response exercise can be developed; this may include factors such as the following: Can be done in bed or in public Incompatible with scratching Lasts for at least 1 min Anatomically opposite of scratching compatible with normal activity</td></tr><tr><td>Competing response practice</td><td>The exercise needs to be practiced to teach the patient a competing nondestructive behavior to replace scratching (e.g., patting or stroking the skin) or a proxy (e.g., a chamois leather pad attached to a belt loop). This should be used for at least 10 min per day and also when trigger or to scratch is experienced.</td></tr><tr><td>Symbolic rehearsal</td><td>The patient is asked to describe the itching and scratching in detail while performing the competing response.</td></tr></tbody></table>
<p>TABLE 7-5 Elements and Application of Self-efficacy  <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mrow></mrow><mi>a</mi></msup></mrow><annotation encoding="application/x-tex">{}^{a}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6644em;"></span><span class="mord"><span class="mord"></span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.6644em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mathnormal mtight">a</span></span></span></span></span></span></span></span></span></span></span></span></span></p>
<table><thead><tr><th>Element of Self-efficacy</th><th>Description</th><th>Application to Practice</th></tr></thead><tbody><tr><td>Mastery experience</td><td>Most effective way of creating a strong sense of self-efficacy</td><td></td></tr><tr><td>Enables people to master tasks</td><td></td><td></td></tr><tr><td>Tasks must be pitched at the right level for the individual</td><td></td><td></td></tr><tr><td>If too easy, people will expect instant success and will be discouraged by failure</td><td></td><td></td></tr><tr><td>Essential to avoid early failure as this undermines self-efficacy</td><td></td><td></td></tr><tr><td>To develop resilient self-efficacy, it is important that people learn to overcome obstacles and persevere</td><td>Break tasks down into component parts, for example, if a person needs to learn to apply a range of topical treatments to different areas of the body, they might first be taught how/when to use emollients and then their suitable quantities</td><td></td></tr><tr><td>The person needs to practice this task repeatedly in different environments with the required support, encouragement, and feedback</td><td></td><td></td></tr><tr><td>When person is confident in this element of the task, further actions may be added</td><td></td><td></td></tr><tr><td>Vicarious experience</td><td>Particularly useful in people with little experience or confidence. Watching someone similar to oneself successfully achieving a specific task (modeling) can be a powerful way of convincing individuals that they can master the skills needed to be successful</td><td>Demonstrate the application of medication</td></tr><tr><td>In a group learning situation, more experienced members may be able to demonstrate a particular skill such as applying a topical treatment to a plaque while avoiding healthy skin</td><td></td><td></td></tr><tr><td>Social learning supports the development for self-efficacy</td><td></td><td></td></tr><tr><td>Social persuasion</td><td>People can be persuaded verbally that they are able to master tasks and succeed</td><td></td></tr><tr><td>Through effective communication and social persuasion, the patient may begin to understand and accept how seemingly difficult treatments can be incorporated into his or her lives</td><td>Expose patients to situations where they can succeed and avoid situations too early in which they are likely to fail</td><td></td></tr><tr><td>Emphasize success as a personal gain during consultations</td><td></td><td></td></tr><tr><td>Agree on achievable personalized goals</td><td></td><td></td></tr><tr><td>Those goals developed through a true partnership interaction style and that are written and reviewed are most likely to be achieved</td><td></td><td></td></tr><tr><td>Encourage patients to consider carefully what they really want to achieve; goals may often be quite different to those anticipated by nurses</td><td></td><td></td></tr><tr><td>Emotional regulation</td><td>Teach patients how to interpret their physical and psychological states that may impact on their self-management accurately</td><td></td></tr><tr><td>They may see physiological and emotional reactions such as those of stress as signs of inability to complete certain tasks</td><td></td><td></td></tr><tr><td>Positive mood enhances perceived self-efficacy; despondent mood diminishes it</td><td></td><td></td></tr><tr><td>It is not the degree of emotional and physical reactions that are important but how these are perceived and interpreted</td><td>Identify where responses to stress are maladaptive, for example, the use of alcohol</td><td></td></tr><tr><td>Advise on stress management and relaxation techniques</td><td></td><td></td></tr></tbody></table>
<p>aThese techniques may be a valuable adjunct to other dermatologic therapies. Although they will only work for some patients and under variable conditions, this does not mean that they are not successful. Reinforcement, perseverance, and practice are essential.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="bibliography">BIBLIOGRAPHY<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#bibliography" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>Azrin, N. H., &amp; Nunn, R. G. (1973). Habit-reversal—Method of eliminating nervous habits and tics. <em>Behaviour Research and Therapy</em>, 11(4), 619–628.</p>
<p>Bandura, A. (1997). <em>Self-efficacy: The exercise of control</em>. New York, NY: W.H. Freeman.</p>
<p>Basra, M. K. A., Sue-Ho, R., &amp; Finlay, A. Y. (2007). The Family Dermatology Life Quality Index: Measuring the secondary impact of skin disease. <em>British Journal of Dermatology</em>, 156, 528–538. Erratum: <em>British Journal of Dermatology</em> 2007;156:791.</p>
<p>Bewley, A., Taylor, R., Reichenberg, J., &amp; Magid, M. (2014). <em>Practical psychodermatology</em>. Chichester, UK: John Wiley &amp; Sons, Ltd.</p>
<p>Cowdell, F., Ersser, S., Gradwell, C., &amp; Thomas, P. (2012). 'The Person-Centred Dermatology Self-Care Index: A tool to measure education and support needs of patients with long-term skin conditions. <em>Archives of Dermatology</em>, 148(11), 1251–1256. doi: 10.1001/archdermatol.2012.1892</p>
<p>Cowdell, F., &amp; Ersser, S. J. (2014). Nursing interventions in psychodermatology. In A. Bewley, R. Taylor, J. Reichenberg, &amp; M. Magid (Eds.), <em>Practical psychodermatology</em> (Chapter 9). Chichester, UK: John Wiley &amp; Sons, Ltd.</p>
<p>Chren, M. M., Lasek, R. J., Sahay, A. P., Sands, &amp; L. P. (2001). Measurement properties of Skindex-16: A brief quality-of-life measure for patients with skin diseases. <em>Journal of Cutaneous Medicine and Surgery</em>, 5(2), 105–110.</p>
<p>Dryden, W., &amp; Branch, R. (2012). <em>The CBT handbook</em>. London, UK: Sage.</p>
<p>Ersser, S. J., &amp; Nicol, N. H. (2012). Chapter 3: Educational interventions for the management of children with dry skin. In M. Lodén, &amp; H. Maibach (Eds.), <em>Treatment of dry skin syndrome—The art and science of moisturizers</em>. Berlin/Heidelberg: Springer.</p>
<p>Finlay, A. Y., &amp; Kelly, S. E. (1987). Psoriasis—An index of disability. <em>Clinical and Experimental Dermatology</em>, 12, 8–11.</p>
<p>Finlay, A. Y., &amp; Khan, G. K. (1994). Dermatology Life Quality Index (DLQI): A simple practical measure for routine clinical use. <em>Clinical and Experimental Dermatology</em>, 19, 210–216.</p>
<p>Lawson, V., Lewis-Jones, M. S., Finlay, A. Y., Reid, P., Owens, R. G. (1998). The family impact of childhood atopic dermatitis: The Dermatitis Family Impact Questionnaire. <em>British Journal of Dermatology</em>, 138, 107–113.</p>
<p>Lewis-Jones, M. S., &amp; Finlay, A. Y. (1995). The children’s dermatology life quality index (CDLQI): Initial validation and practical use. <em>British Journal of Dermatology</em>, 132, 942–949.</p>
<p>Lewis-Jones, M. S., Finlay, A. Y., &amp; Dykes, P. J. (2001). The infants’ dermatitis quality of life index. <em>British Journal of Dermatology</em>, 144, 104–110.</p>
<p>Motley, R. J., &amp; Finlay, A. Y. (1992). Practical use of a disability index in the routine management of acne. <em>Clinical and Experimental Dermatology</em>, 17, 1–3.</p>
<p>Nicol, N. H., &amp; Ersser, S. J. (2010). The role of the nurse educator in atopic dermatitis. (Issue Ed: Prof. M. Boguniewicz-University of Colorado.) <em>Immunology and Allergy Clinics of North America</em>, 30, 369–385.</p>
<p>Penzer, R., &amp; Ersser, S. J. (Eds.) (2010). <em>Principles of skin care: A guide for nurses and other health care professionals</em>. Chichester, UK: Wiley Blackwell.</p>
<p>Walker, C., &amp; Papadopoulos, L. (2005). <em>Psychodermatology: The psychological impact of skin disorders</em>. Cambridge, UK: Cambridge University Press.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="study-questions">STUDY QUESTIONS<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#study-questions" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<ol>
<li>Which of the following is one of the most important psychosomatic organs?</li>
</ol>
<p>a. Heart
b. Brain
c. Lungs
d. Skin</p>
<ol start="2">
<li>Which of the following best describes a dermatological disorder with a psychosocial comorbid condition?</li>
</ol>
<p>a. Skin condition precipitated by exposure to allergens
b. Psychiatric disease that presents as a skin disorder
c. Skin condition that precipitated by exposure to irritants
d. Psychological distress due to skin disease</p>
<ol start="3">
<li>John, a 13-year-old male, presents in the dermatology clinic for evaluation of an obvious skin problem. His mother reports difficulties in school, difficulties making friends, and that her son is generally rebellious and uncooperative. John is exhibiting:</li>
</ol>
<p>a. Typical teenage behavior
b. Schizophrenic behavior
c. An emotional reaction to a dermatological condition
d. A neurotic reaction to a dermatological condition</p>
<ol start="4">
<li>Dermatological conditions often heal:</li>
</ol>
<p>a. Readily and easily
b. Slowly with careful treatment</p>
<p>c. Rapidly with the correct treatment
d. Completely without relapse</p>
<ol start="5">
<li>
<p>The public often interprets skin lesions as a sign of which of the following:
a. Poor personal hygiene
b. Good personal hygiene
c. A neurotic condition
d. A psychotic condition</p>
</li>
<li>
<p>Body image is defined as how individuals:
a. View bodies of others
b. View their own bodies
c. Display their bodies in pictures
d. Present their bodies to the public</p>
</li>
<li>
<p>Psychodermatoses are conditions that primarily have which of the following origins:
a. Physiological
b. Sociological
c. Psychological
d. Biological</p>
</li>
<li>
<p>Therapeutic consultations are characterized by:
a. Compliant patient engagement and sympathy
b. Concordant patient engagement and empathy
c. Unconditional positive regard
d. Conditional positive regard</p>
</li>
<li>
<p>Habit reversal has several key stages, some of which include:
a. Situation awareness training and scratching gently.
b. Itch-scratch education only.
c. Competing response practice and distraction.
d. Situation awareness training, itch-scratch education, and competing response practice.</p>
</li>
<li>
<p>Self-efficacy is mastered in part through:
a. Trying to be self-confident
b. Support from a nurse
c. Vicarious experience and social persuasion
d. Deep breathing</p>
</li>
</ol>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="answers-to-study-questions">Answers to Study Questions<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#answers-to-study-questions" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>1.d
2.d
3.c
4.b
5.a
6.b
7.c
8.b
9.d
10.c</p>
<p>CHAPTER 8</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="papulosquamous-diseases">Papulosquamous Diseases<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#papulosquamous-diseases" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>Sarah W. Matthews</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="objectives">OBJECTIVES<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#objectives" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>After studying this chapter, the reader will be able to:</p>
<ul>
<li>Describe the prevalence and epidemiology of psoriasis, lichen planus, pityriasis rosea, keratosis pilaris, and lichen simplex chronicus.</li>
<li>Identify the most common areas of the body affected by each condition.</li>
<li>Discuss the current understanding of the pathophysiology of each condition.</li>
<li>Explain the various challenges in treating them.</li>
<li>Classify the most common treatment modalities.</li>
<li>Utilize teaching points in the education and engagement of patients with these conditions (etiology, triggers, self-care, optimizing treatment modalities, and follow-up).</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="key-points">KEY POINTS<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#key-points" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<ul>
<li>
<p>Understanding the common clinical features and the distinguishing etiologies of these papulosquamous diseases are essential to appropriate assessment and treatment.</p>
</li>
<li>
<p>Assessing and supporting the patient's knowledge of his/her disease and his/her engagement in self-care is key to achieving successful management.</p>
</li>
<li>
<p>Psoriasis is a chronic, lifelong disease with natural exacerbations and remissions that require long-term treatment affecting about 1% to 3% of the population worldwide. Multiple internal and external factors can trigger psoriasis in genetically susceptible people.</p>
</li>
<li>
<p>Psoriasis is a T-lymphocyte-mediated autoimmune disease, and a variety of topical and systemic treatments exist for the management of psoriasis.</p>
</li>
<li>
<p>Lichen planus can be either an acute or a chronic inflammatory disease of the skin, mucous membranes, hair, and nails. It may be idiopathic or caused by a drug, contact allergen, or viral infection (hepatitis B or C).</p>
</li>
<li>
<p>Classic cutaneous lichen planus is often described using the five Ps—purple, polygonal, pruritic, planar, and papules.</p>
</li>
<li>
<p>Pityriasis rosea is a mild acute, self-limiting exanthematous eruption characterized by a distinctive morphology of oval-shaped salmon-colored papules and macules with a collarette of scaling seen on the trunk and proximal extremities.</p>
</li>
<li>
<p>Pityriasis rosea typically begins with a solitary patch on the trunk called the “herald patch.”</p>
</li>
<li>
<p>Keratosis pilaris is a very common chronic condition, which affects nearly 50% to 80% of all adolescents and approximately 40% of adults. It can be very difficult to treat but may resolve in the fourth or fifth decade.</p>
</li>
<li>
<p>Lichen simplex chronicus is a disorder characterized by skin thickening (lichenification) secondary to excessive scratching and rubbing of the skin. Treatment is aimed at reducing pruritus to break the itch-scratch cycle.</p>
</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="introduction">INTRODUCTION<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#introduction" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>Papulosquamous diseases are varied. They have some shared morphologic features, which can lead to challenges in diagnosis. Interestingly though, their etiologies are different. Some of the common diseases in this group are psoriasis, pityriasis rosea (PR), lichen planus (LP), and lichen simplex chronicus (LSC).</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="i-psoriasis">I. PSORIASIS<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#i-psoriasis" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>Psoriasis is a chronic skin condition that presents in a variety of ways among individuals. It is a genetic condition triggered by environmental factors such as infection, medications, and trauma. It is characterized by exaggerated and disordered epidermal cell proliferation and keratinization. Typical lesions are well-defined erythematous, indurated papules, and plaques with white or silvery scale. It may also involve the nails and joints (Figure 8-1).</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="a-definition">A. Definition<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#a-definition" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<ol>
<li>Psoriasis is thought to be a T-lymphocyte-mediated autoimmune disease. The skin lesions of psoriasis are characterized by cells multiplying much more quickly than normal (epidermal hyperproliferation), cells that do not mature normally (abnormal keratinocyte differentiation), and the presence of proinflammatory cells (a lymphocyte inflammatory infiltrate).</li>
</ol>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="b-background-and-etiology">B. Background and etiology<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#b-background-and-etiology" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<ol>
<li>
<p>Affects about 1% to 3% of the population worldwide depending on the study reviewed. It is seen equally in men and women, and people of all races are affected. Prevalence estimates vary in relation to age and geographic region, being more frequent in countries farther from the equator.</p>
</li>
<li>
<p>US prevalence in Caucasians is 3.6%, in African Americans is 1.9%, in Hispanics is 1.6%, and in other groups is 1.4%.</p>
</li>
<li>
<p>Prevalence varies throughout the world. The highest rates are in Norway of 8.5%, and the lowest rates in Asia of less than 0.5%.</p>
</li>
<li>
<p>Age at onset ranges from infancy to the end of life. The incidence of psoriasis commonly peaks at two different times across the life span (the early peak is between 20 and 30 years and the late peak is 50 and 60 years). Early onset usually leads to a more severe course of the disease.</p>
</li>
<li>
<p>Multifactorial and polygenetically inherited disease. The role of hereditary transmission is supported by familial association, twin studies, and correlation with human leukocyte antigens (HLA). Numerous studies have proven that certain antigens are positively associated with psoriasis and that Cw6 antigen has been shown to be the most significant marker for the risk prediction of the disease.</p>
</li>
<li>
<p>On the basis of epidemiological studies, the theory of two distinct disease patterns of psoriasis has been suggested. In type I psoriasis, the disease has an early onset and familial inheritance. Type II psoriasis has a late onset and sporadic familial occurrence.</p>
</li>
<li>
<p>If one parent is affected, 8% of children will develop psoriasis. If both parents are affected, then 41% of children develop psoriasis. Twin studies by Farber et al. showed that monozygotic twin pairs tend to be similar with respect to age of onset and pattern of disease. This was not the case in concordant dizygotic twins. The fact that not all monozygotic twins exhibited the same disease characteristics indicates the influence of environmental triggering factors.</p>
</li>
<li>
<p>Trigger factors. Multiple internal and external factors can trigger psoriasis in genetically susceptible people.</p>
</li>
</ol>
<p>a. Infections: In some cases, bacterial infections are the initial trigger for psoriasis. A correlation between streptococcal infection and psoriasis has been identified using both clinical and epidemiological data. Acute streptococcal infections, often associated with pharyngitis, are the most common and are specifically associated with the guttate form of psoriasis (Figure 8-2). Children and adolescents are the most susceptible, but it may also precipitate pustular psoriasis or exacerbations of plaque psoriasis. HIV and other immune-suppressing infections can significantly worsen psoriasis. Other infections, such as respiratory, gastrointestinal, and genitourinary, may also trigger psoriasis, although less often.</p>
<p>b. Psychological stress: Stress is a well-known trigger for psoriasis. Zachariae et al. found that 66% of patients reported exacerbations of their psoriasis related to stress and 35% reported that the onset of their psoriasis occurred during a time of stress. Those who were the most stressed reported greater disease severity, psoriasis-related stress, and quality-of-life (QOL) impairment. Depression can be a significant barrier to improving the patient's condition. When severe psoriasis is present or the patient expresses distress related to the psoriasis, depression screening should be considered at the initial visit, as well as follow-up visits. The PHQ-2 depression scale can be used as an initial screening tool for undiagnosed depression. It consists of the first two questions on the PHQ-9 depression questionnaire (PHQ-9 Depression Scale. AIMS Center: Advancing Integrated Mental Health Solutions). If the patient answers affirmatively to either question, the other seven questions should be asked. If depression is identified, the nurse or provider should connect the patient to his/her primary care provider or to behavioral health for follow-up. See Chapter 7 for</p>
<p>additional information on psychosocial effects and nursing interventions for psoriasis.</p>
<p>c. Drugs: Multiple medications have been implicated as inducers of psoriasis including beta-blockers, lithium, antimalarials, interferon, NSAIDs, and tetracyclines. The degree of impact from each of these medications varies. Rapid discontinuation of corticosteroids can lead to exacerbations of plaque and pustular psoriasis. This is why oral prednisone is generally advised to be avoided, and topical steroids should be tapered instead of abruptly stopped.</p>
<p>d. Smoking and alcohol: Smoking and alcohol both have effects on psoriasis. Smoking seems to be a more significant trigger in women, while alcohol may have more impact on the evolution of the disease, particularly in men. Smoking is also strongly associated with pustular psoriasis. Helping patients understand the impact of alcohol and smoking on psoriasis has the potential to significantly impact the course of the disease.</p>
<p>e. Trauma: The Koebner phenomenon (Figure 8-3), a condition induced by trauma to the skin, is common in patients with psoriasis. It was first described by Heinrich Koebner in 1876 as the formation of psoriatic lesions in uninvolved skin of patients after cutaneous trauma. It can be triggered by virtually any form of trauma, such as scratching, picking, rubbing, sunburn, drug eruptions, and tattoos. Patient education is important in the prevention of this type of trigger.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="c-immunopathogenesis">C. Immunopathogenesis<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#c-immunopathogenesis" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<ol>
<li>
<p>Studies indicate that psoriasis is a T-lymphocyte-mediated autoimmune disease. Its pathophysiology is complex, involving parts of the innate and adaptive immune systems, genetics, and the environment. This interaction of multiple systemic factors results in an increase in antigen presentation and the activation of T-helper cell type 1 (TH1) and T-helper cell type 17 (TH17), resulting in what we recognize as typical cutaneous plaques of psoriasis.</p>
</li>
<li>
<p>The skin lesions of psoriasis are characterized by cells multiplying much more quickly than normal (epidermal hyperproliferation), cells that do not mature normally (abnormal keratinocyte differentiation), and the presence of proinflammatory cells (a lymphocyte inflammatory infiltrate).</p>
</li>
<li>
<p>The T-lymphocyte subsets seen in the early phase of psoriasis and the response to T-lymphocyte targeting therapies strongly suggest that the T lymphocytes are the main players in the pathogenesis of psoriasis. Activated T cells in psoriasis secrete cytokines, which can account for many characteristics of the psoriasis lesions. See Chapter 5 to learn more about immunology and its influence on psoriasis treatment decisions.</p>
</li>
</ol>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="d-comorbidities">D. Comorbidities<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#d-comorbidities" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<ol>
<li>
<p>Since psoriasis and psoriatic arthritis are immune-mediated inflammatory disorders, they are associated with multiple comorbidities and cardiovascular risk factors. Patients with psoriasis have an increased risk of atherosclerosis, myocardial infarction, stroke, and cardiovascular death. It has been suggested that overlapping mechanisms of systemic inflammation contribute to the connection between psoriasis and cardiovascular disease.</p>
</li>
<li>
<p>An association with metabolic dysfunction, including obesity and metabolic syndrome</p>
</li>
</ol>
<p>(ischemic heart disease, hypertension, nonalcoholic fatty liver disease, diabetes, and obesity), with subsequent effects on morbidity and mortality, has been documented in psoriasis. It is also associated with inflammatory bowel disease (Crohn disease).</p>
<ol start="3">
<li>Psychiatric/psychological comorbidities that are associated with psoriasis include depression, anxiety, suicidal ideation, and poor QOL. Psoriasis often causes significant psychosocial burden affecting all aspects of a person's life—relationships, social activities, work, and emotional well-being. The collective effect may be self-perpetuating social withdrawal. Health-related QOL studies have measured the burden of psoriasis, and some new studies have attempted to assess the significant cumulative disability over a person's lifetime. Psoriasis is known to affect QOL and emotional well-being in a way that is comparable with other major conditions, including diabetes, arthritis, and cancer. It is imperative to support patients to discuss their feelings and how the condition affects their lives.</li>
</ol>
<p>E. Assessment</p>
<ol>
<li>Clinical manifestations and therapeutic modalities: Psoriasis can be classified by its different phenotypes, which include the following:</li>
</ol>
<p>a. Chronic plaque psoriasis: About 90% of psoriasis is the plaque type and is characterized by well-defined red or salmon-colored, scaly plaques that are usually fairly symmetrically distributed (Figure 8-4). The degree of body surface involvement varies from limited to extensive. The scalp, elbows, knees, and low back/sacral area are the most common sites (Figure 8-5). Hands and feet are also frequently involved. In about 30% of people, the genitals are affected. Treatments range from topical medications (e.g., corticosteroids, vitamin D preparations, coal tar, calcineurin inhibitors) to systemic medications (e.g., methotrexate, acitretin, biologics) and phototherapy for widespread and recalcitrant cases. Depending on the location and severity of the disease, the treatment will need to be individualized to meet the patient's needs. In clinical trials, a method call Psoriasis Area and Severity Index (PASI) is used to evaluate the percentage of body involvement and plaque severity evident on the day of the exam. The PASI scores are then evaluated over time. A PASI score is determined based on the amount of erythema, scaling, and thickness of an "average" plaque on the patient and the percentage of body areas affected. The evaluator must be well trained in how to determine the PASI score in order for the assessment to be accurate and consistent throughout the clinic trial. Because of the complexity and tediousness of PASI scoring, it is not typically used in most dermatology clinics.</p>
<p>b. Scalp: Well-demarcated red, scaly plaques on the scalp are usually classic for psoriasis, but it can sometimes be difficult to differentiate from seborrheic dermatitis (Figure 8-6). Posterior or temporal scalp involvement is often suggestive of psoriasis versus a frontal or diffuse scalp flaking that may be more suggestive of seborrheic dermatitis. There is certainly overlap between the two conditions. Scalp psoriasis can be especially distressing to patients due to itching, its visibility, and difficulty in treatment (Figure 8-7). The presence of hair can make application of topical medications very challenging. Solutions and gels are frequently utilized, but if the</p>
<p>person has more course or very curly short hair, then oils, creams, or ointments may be appropriate. Very recalcitrant scalp psoriasis may require phototherapy or another systemic treatment such as methotrexate. When there are thick adherent scales, a keratolytic preparation such as salicylic acid and coal tar may be needed.</p>
<p>c. Guttate: Widespread erythematous papules with scale, which may be preceded by streptococcal infection. For this reason, underlying infection should be suspected and treated if present. Often, a throat culture is done in new cases whether or not patient complains of sore throat. Regardless of culture results, many patients are treated empirically for streptococcal infections in new cases of guttate psoriasis with a course of amoxicillin. Guttate lesions are often too widespread for topical therapy, so most patients are started on phototherapy (narrowband ultraviolet B [UVB]). It usually responds well so it is only occasionally necessary to use a more aggressive second-line therapy (Figure 8-8).</p>
<p>d. Inverse psoriasis: Characterized by plaques in the intertriginous areas (axillae, inframammary area, gluteal cleft, umbilicus, abdominal folds, and genital area). These plaques tend to be red, thinner, and without scale (Figure 8-9). The intertriginous areas are usually treated with mild topical steroids. Because they are more at risk for steroid atrophy and striae long term, continuous use of even mild steroids should be avoided, though short courses are appropriate. Therefore, nonsteroid treatment is often appropriate, such as tacrolimus or pimecrolimus.</p>
<p>e. Erythrodermic: An uncommon but severe and disabling variant of psoriasis occurring in 1.5% of cases characterized by widespread deep erythema and scaling affecting the entire cutaneous surface (Figure 8-10). Withdrawal of systemic steroid therapy, infections, and drugs are frequent causes in erythrodermic exacerbations. Thus, use of systemic steroids in patients with psoriasis should be avoided. Punch biopsies are important to obtain in any erythrodermic patient to rule out erythrodermic T-cell lymphoma and other conditions that can mimic erythrodermic psoriasis. The protective functions of the skin are lost so these patients are susceptible to infection and loss of fluids and nutrients. Cyclosporine is often necessary for rapid control of this form of psoriasis. Methotrexate or biologics are useful for more long-term treatment, but caution is essential given the risk for complications due to immunosuppression and infection.</p>
<p>f. Pustular psoriasis: Localized or generalized noninfectious pustules. It is characterized by pustules, not papules, found on normal or erythematous skin. There are two types, palmoplantar (Figure 8-11) and generalized (Figure 8-12) acute pustular psoriasis. Incidence of palmoplantar is low compared to psoriasis vulgaris and is seen more frequently in smokers. It tends to be chronic with intermittent exacerbations that are limited to the palms and soles. The lesions are sterile, yellow, deep-seated pustules. It is known to be refractory to many therapeutic approaches. Generalized acute pustular psoriasis is rare and life threatening. It is characterized by burning erythema with widespread sterile pustules, fever, malaise, and leukocytosis. These patients are often admitted to the hospital or should be monitored very closely, and a dermatologist should be called to distinguish this entity from a pustular drug eruption.</p>
<p>g. Nail disease: Occurs in about 50% of people with psoriasis and is more common in those with associated psoriatic arthritis. There are a variety of nail abnormalities associated with psoriasis. The most common change is pitting (Figure 8-13). Loosening of the nail plate from the underlying nail bed, onycholysis, is also fairly common (Figure 8-14). Oil spots may also be seen in the nail bed.</p>
<p>h. Psoriatic arthritis: Psoriatic arthritis is associated with cutaneous psoriasis in 7% to 26% of cases. It is a seronegative inflammatory arthritis that is usually asymmetric (60% to 70% of the time) and involves the proximal and distal joints of the fingers or toes (Figure 8-15). It may also manifest as sausage fingers (dactylitis). The axial form involves the vertebra and sacral joints and occurs approximately 5% of the time. It is a destructive arthritis; therefore, early diagnosis and treatment is critical for optimal control and averting joint destruction, functional disability, and reduced QOL.</p>
<ol start="2">
<li>Diagnostic tests</li>
</ol>
<p>a. Diagnosis is most often based on clinical findings.</p>
<p>b. Punch biopsy may be considered if diagnosis is unclear.</p>
<p>F. Nursing considerations</p>
<ol>
<li>Medical intervention overview</li>
</ol>
<p>a. A variety of topical and systemic treatments exist for the management of psoriasis. It is a chronic, lifelong disease with natural exacerbations and remissions that require long-term treatment. There is a range of treatments available to manage the condition, but the response to treatment is unique to each individual. For that reason, finding an effective treatment plan can be a process of trial and error.</p>
<p>b. Eighty percent of psoriasis patients have mild-to-moderate disease, so topical therapies play a central role in the treatment of their psoriasis. Patients usually start with a single type of therapy; however, in more severe cases (&gt;10% body surface area, severely impaired QOL, or recalcitrant psoriatic lesions), multiple treatment approaches may be used as part of combination, successive, or rotational therapeutic regimen.</p>
<p>c. The main treatment options include topical steroids, topical vitamin D, retinoids, phototherapy, oral systemic therapies (methotrexate, acitretin, cyclosporine), and biologic therapies. Recently, laser has been developed as another modality to treat psoriasis.</p>
<p>d. Other topical therapies include the following steroid-sparing agents: coal tar, anthralin, calcineurin inhibitors, keratolytics, and emollients.</p>
<p>e. Therapeutic approaches should take into consideration the main goal of improving the patient's QOL, the individual patient's likelihood of adherence, and promoting a therapeutic relationship with the patient (Table 8-1).</p>
<ol start="2">
<li>Medications</li>
</ol>
<p>a. Topical corticosteroids were first introduced in the early 1950s and have been the most common treatment for psoriasis. They are often the first-line therapy in mild-to-moderate psoriasis but are also used as adjunct therapy in more severe psoriasis. For plaque psoriasis, medium- to high-potency steroids used one to two times a day can</p>
<p>lead to significant improvements. Itching, scale, and inflammation improve quickly. Potent topical corticosteroids (e.g., betamethasone dipropionate) and very high-potency (e.g., clobetasol propionate) topical corticosteroids are most effective. Some studies compared vitamin D products directly with potent or very potent corticosteroids and found that they have comparable effects when applied to the body, but corticosteroids were more effective than vitamin D for scalp psoriasis. Combination therapy with a topical vitamin D with topical corticosteroid is more powerful than either alone. On both the body and the scalp, potent corticosteroids were less likely than vitamin D to cause local adverse events, such as skin irritation or burning, so people were consequently more likely to stop using vitamin D products.</p>
<p>(1) Factors that increase the risk of side effects from corticosteroids include the following:</p>
<p>(a) Potency.</p>
<p>(b) Length of treatment: the longer the topical corticosteroid is applied, especially on a daily basis, the greater the risk.</p>
<p>(c) Surface area of skin being treated: the larger the area treated with a topical corticosteroid, the greater the risk.</p>
<p>(d) Location being treated: more sensitive skin locations such as the face, axillae, and groin are at higher risk than thicker-skinned areas such as the palms and soles.</p>
<p>(e) Patient's age—young children and people aged over 70 have a greater risk because of thinner skin.</p>
<p>(2) Side effects include the following:</p>
<p>(a) Burning or stinging of the skin: usually occurs when first started; improves as skin gets used to the medication.</p>
<p>(b) Atrophy (thinning of the skin): skin may bruise or tear more easily than normal. May cause visible telangiectasias.</p>
<p>(c) Worsening of a preexisting skin infection.</p>
<p>(d) Acne with over use (especially on the face) or worsening of existing acne.</p>
<p>(e) Rosacea: face becomes red and flushed with acne-form lesions.</p>
<p>(f) Hypopigmentation: more common in skin types with more natural pigment.</p>
<p>(g) Contact dermatitis related to allergic reaction to the substances in the topical corticosteroid, which can manifest as worsening or persistent psoriasis.</p>
<p>(h) Striae (stretch marks): due to prolonged application or excessive potency. The highest risk areas are the axilla, groin, and inner thighs.</p>
<p>(i) Tachyphylaxis: steroids work less well over time if they are overused or breaks are not taken (often, "a 2-week on, 2-week off" regimen is recommended for psoriasis).</p>
<p>(3) Prevention of side effects</p>
<p>(a) Prudent use of topical steroids includes using the minimal strength needed to get results, attention to the area of application (e.g., weaker topical steroids should be used on the face and intertriginous areas), duration (usually a</p>
<p>maximum 2 weeks then taking a break or rotating with nonsteroids), and vehicle (e.g., ointments are more potent than creams).</p>
<p>(b) In general, use a potent preparation for short term and weaker preparation for maintenance between flare-ups or nonsteroidal topicals such as tacrolimus or pimecrolimus. Even the application of weaker or safer steroids should be limited to 2 weeks on those sites.</p>
<p>b. Systemic corticosteroids</p>
<p>(1) Can rapidly clear psoriasis, but the psoriasis eventually worsens again requiring higher and higher doses and can lead to a severe rebounding or more severe disease, even erythrodermic or widespread pustular psoriasis.</p>
<p>c. Calcipotriene</p>
<p>(1) Vitamin D products (calcipotriene) affect keratinocyte differentiation. Treatment with calcipotriene (Dovonex) in ointment, cream, or solution is steroid sparing and has been shown to be very effective in the treatment of plaque and scalp psoriasis.</p>
<p>(2) Combination therapy with calcipotriene and high-potency steroids appears to provide greater improvement rates and fewer adverse effects.</p>
<p>(3) Calcipotriene degrades in the presence of UV light, so it should not be used prior to sun exposure or phototherapy. Calcipotriene plus betamethasone dipropionate is more effective than either agent alone. Calcipotriene performs better than tar products.</p>
<p>d. Other topicals: salicylic acid, tar, anthralin, tazarotene, and calcineurin inhibitors</p>
<p>(1) Salicylic acid is used as a keratolytic agent in shampoos, creams, and gels. It helps to chemically exfoliate scale and promote the absorption of other topical agents. Widespread application should be avoided due to potential for salicylate toxicity.</p>
<p>(2) Coal tar is frequently used in over-the-counter shampoos. Oil of cade (pine tar) or birch tar can be compounded into ointments. The odor of tar is often a deterrent to use.</p>
<p>(3) Anthralin is an ancient effective treatment, but it is irritating and stains skin, clothing, and bedding so it is not used very often.</p>
<p>(4) Tazarotene is a retinoid. It treats psoriasis by modulating keratinocyte differentiation and hyperproliferation, as well as by suppressing inflammation. Combining its use with a topical corticosteroid and weekend pulse therapy can decrease irritation.</p>
<p>(5) Topical calcineurin inhibitors such as tacrolimus and pimecrolimus work well on thin lesions in areas prone to atrophy or steroid acne such as the face and body fold areas (axillae, inframammary, abdominal folds, inguinal area, gluteal folds). The burning commonly associated with these agents can be challenging but may be avoided by initial treatment with a corticosteroid and by application to dry skin, not right after bathing. Typically, this burning effect dissipates after several applications.</p>
<p>e. Methotrexate</p>
<p>(1) This folic acid antagonist was approved by the FDA for treatment of psoriasis in 1971.</p>
<p>(2) Commonly used first-line therapy for moderately severe plaque psoriasis, psoriatic arthritis, pustular psoriasis, erythrodermic psoriasis, and palmoplantar psoriasis.</p>
<p>(3) Associated potential side effects limit its use to severe involvement or cases resistant to topical therapies and phototherapy. It is therefore extremely important that methotrexate not be used in patients with contraindications (e.g., pregnancy, breast-feeding, liver disease, alcoholism, immunodeficiency syndromes, leukopenia, anemia, thrombocytopenia) and that screening labs be done prior to the start of the medication, during the initiation of therapy and after dose adjustments.</p>
<p>(4) Usually dosed weekly by mouth or by subcutaneous injections. Liver biopsies are controversial to monitor for liver dysfunction and cirrhosis on methotrexate. Typically, after a cumulative 3 to 4 g of usage, patients are referred to gastroenterology for a discussion about biopsy.</p>
<p>f. Cyclosporine</p>
<p>(1) The therapeutic value of cyclosporine may be related to the downregulation of proinflammatory epidermal cytokines.</p>
<p>(2) It is known to be a highly effective systemic treatment but has a high risk for nephrotoxicity. It is therefore necessary to follow strict monitoring guidelines and to use it ideally under 12 to 18 months. An alternative therapy should be instituted concomitantly, or the psoriasis will recur. When cyclosporine treatment is 6 months or less, it is associated with a low frequency of renal problems, but blood pressure and serum creatinine must be monitored and doses adjusted when indicated.</p>
<p>g. Systemic retinoids (acitretin and etretinate)</p>
<p>(1) Systemic retinoids are an effective treatment for psoriasis, as well as disorders of keratinization and cutaneous lupus.</p>
<p>(2) It decreases inflammation in the epidermis and dermis by interfering with various cytokines.</p>
<p>(3) In contrast to other systemic psoriasis drugs, acitretin is not cytotoxic or immunosuppressive.</p>
<p>(4) The major problem with them is their teratogenicity. Acitretin is converted into etretinate, which has a very long half-life, and a patient cannot become pregnant for 3 years after it is stopped. Therefore, it should not be used in women of childbearing age, unless the woman is absolutely confident that she will not be seeking pregnancy for several years.</p>
<p>(5) Alcohol ingestion can convert acitretin to etretinate and is strongly discouraged.</p>
<p>(6) All of these drugs also have the potential to elevate triglycerides, which may complicate therapy.</p>
<p>(7) Combinations of retinoids with phototherapy can be effective in chronic plaque psoriasis, resulting in lowered cumulative doses of ultraviolet light.</p>
<p>(8) Dose-related side effects include dry lips (or cheilitis), dry skin, pruritus, peeling of the palms and soles, epistaxis, conjunctivitis, and hair loss. All these effects are dose dependent and quickly reversed after drug discontinuation.</p>
<p>(9) The most common systemic effects include headache, arthralgia, myalgia, and fatigue. Skeletal changes after long-term use have been attributed to retinoid, but studies have not supported this theory well.</p>
<p>(10) Elevated liver enzymes are reported in approximately 14% to 35% of patients in US trials. Serum lipid changes (increase in triglycerides, in very low density lipoprotein (VLDL), and in low density lipoprotein (LDL)) are common.</p>
<p>h. Biologics</p>
<p>(1) Biologics work by impeding certain mechanisms in the autoimmune response characteristic of psoriasis.</p>
<p>(2) Biologics are distinct from general immunosuppressants because they do not suppress the entire immune system. Instead, they target the specific immune system chemicals involved in producing psoriasis.</p>
<p>(3) There are multiple biologic agents with unique mechanisms of action used in the treatment of psoriasis. See Chapter 5 to learn more about biologic therapies for psoriasis.</p>
<ol start="3">
<li>Phototherapy</li>
</ol>
<p>a. Phototherapy with UVB and photochemotherapy with ultraviolet A (psoralen ingestion with UVA) is a treatment modality for psoriasis that has been available for decades. See Chapter 6 for more information about phototherapy.</p>
<p>b. Cost-effective but frequently underutilized therapy for psoriasis.</p>
<p>c. For most people (typically, &gt;75%), sunlight improves psoriasis. Conversely, significant sunburns may cause koebnerization (Figure 8-3) and psoriasis exacerbation.</p>
<p>d. Studies have shown that suberythrogenic levels can be very effective for clearing psoriasis, but tanning does occur, and the dose must be gradually increased to achieve effective levels.</p>
<p>e. Maintenance phototherapy after clearing contributes to the length of remission and is necessary for many patients.</p>
<p>G. Patient education and engagement in self-management</p>
<ol>
<li>Nurses play a major role in patient education and engagement in self-management when caring for patients with psoriasis. Patient education is the process by which the nurse produces changes in the patient's knowledge, skills, and attitude necessary for the patient to have the tools they need to address their health condition. Self-management support is defined as the "systematic provision of education and supportive interventions by health care staff to increase patients' skills and confidence in managing their health problems, including regular assessment of progress and problems, goal setting, and problem-solving support." Key issues that nurses should consider addressing with the patient based on individual readiness to learn and engage in self-management are listed in Table 8-2.</li>
</ol>
<p>H. Follow-up</p>
<ol>
<li>At least once a year—every treatment plan should be reevaluated at least once a year to be sure that it is still working well for the patient and to ensure that there are no concerning side effects.</li>
<li>Patients on systemic medications need more frequent follow-up, often every 3 to 6 months with lab checks.</li>
<li>The patient should check back sooner if:</li>
</ol>
<p>a. There is a lack of response to topical or systemic treatments.
b. The treatment was working then stopped.
c. The treatment did not start to work in the time frame that the dermatology provider suggested that it would.
d. If there is rapid worsening of the condition right away (rapidly spreading rash, pustules, redness covering entire body, fever) since it could indicate pustular or erythrodermic psoriasis. It may also indicate a drug reaction that needs to be addressed right away.</p>
<p>TABLE 8-1 Factors to Consider When Choosing Psoriasis Therapies</p>
<table><thead><tr><th>Age</th><th>Associated medical disorders HIV Liver disease Cardiovascular disease Skin cancer</th></tr></thead><tbody><tr><td>Type of psoriasis and severity Guttate Plaque Palmoplantar Generalized pustular Erythrodermic</td><td>Psychosocial factors Engagement in self-care Perceived impact on quality of life Depression Financial challenges Proximity to clinic</td></tr><tr><td>Sites and extent of involvement Localized vs. widespread Localized but on the palms and soles (very debilitating) Scalp (difficult to treat due to hair-impeding topicals) Anogenital area (psychosocial impact) Scattered plaques but &lt;5% involvement Generalized and &gt;30% involvement</td><td>Previous treatments and response to therapy Systemic glucocorticoids (may exacerbate psoriasis) Narrowband UVB phototherapy (did it work well previously?) PUVA (increased skin cancer risk) Cyclosporine (blood pressure and nephrotoxicity issues) Methotrexate (potential liver toxicity) Biologics</td></tr></tbody></table>
<p>HIV, human immunodeficiency virus; PUVA, ; UVB, ultraviolet B.
Adapted from Wolff, K., Johnson, R. A., &amp; Saavedra, A. P. (2013). Fitzpatrick's color atlas (7th ed., pp. 49-57). United States: The McGraw-Hill Companies.</p>
<p>TABLE 8-2 Patient Education and Engagement in Psoriasis Self-care</p>
<table><thead><tr><th>Key Issues</th><th>Teaching Points</th></tr></thead><tbody><tr><td>Comorbidities</td><td>Psoriatic arthritis Associated with the cutaneous psoriasis in 7%-26% of cases. Inflammatory arthritis that can be very destructive to joints. Signs and symptoms include pain and swelling, often in the morning ("morning stiffness"). Mild cases treated with NSAIDs. More significant cases treated with disease modifying agents (e.g., methotrexate) or biologics. Report early so appropriate interventions may be started. Other comorbidities Metabolic dysfunction, including obesity and metabolic syndrome (diabetes and obesity, ischemic heart disease, hypertension, nonalcoholic fatty liver disease). Subsequent effects on morbidity and mortality. Work with primary care provider (PCP) to optimize cardiovascular and metabolic health through healthy eating, exercise, and possible early intervention in elevated lipids, HTN, elevated blood sugar, etc. Minimize alcohol (alcohol can also trigger psoriasis). Psychosocial Depression, anxiety, social isolation, quality-of-life impact. Common in psoriasis. Significant psychosocial burden affecting all aspects of a person's life—relationships, social activities, work, and emotional well-being. The collective effect may be self-perpetuating social withdrawal. Open dialogue about emotional effects. Facilitate healthy emotional and social self-care (e.g., enjoyable activities, support groups, National Psoriasis Foundation, healthy eating and exercise, rest, avoiding excess alcohol and smoking).</td></tr></tbody></table>
<p>Hypertension (HTN); Non-steroidal anti-inflammatory drugs (NSAID); psoralen ultraviolet-A (PUVA); ultraviolet-B (UVB) RPR - rapid plasma reagin.</p>
<p><img src="assets/images/image-20251225-0175c9be.jpeg" alt="img-8.jpeg">
A</p>
<p><img src="assets/images/image-20251225-c6af5a3a.jpeg" alt="img-9.jpeg">
B</p>
<p><img src="assets/images/image-20251225-fcefc57e.jpeg" alt="img-10.jpeg">
C</p>
<p><img src="assets/images/image-20251225-59217b0a.jpeg" alt="img-11.jpeg">
D</p>
<p><img src="assets/images/image-20251225-d5fb4433.jpeg" alt="img-12.jpeg">
E</p>
<p><img src="assets/images/image-20251225-4a8b0543.jpeg" alt="img-13.jpeg">
G</p>
<p><img src="assets/images/image-20251225-21799274.jpeg" alt="img-14.jpeg">
F</p>
<p><img src="assets/images/image-20251225-7b93de1c.jpeg" alt="img-15.jpeg">
H</p>
<p><img src="assets/images/image-20251225-df57983f.jpeg" alt="img-16.jpeg">
FIGURE 8-1. Psoriasis. A:Desquamating erythrodermic. B:Desquamating erythrodermic, hand. C:Hands. D:Abdomen and chest. E:Ear. F:Nail pitting. G:Forehead. H:Knee, plaque form. (From Stedman's Medical Dictionary for the Health Professions and Nursing.)
FIGURE 8-2. Guttate psoriasis associated with a recent group A beta-hemolytic streptococcal infection. (From Goodheart, H. P. (2003). Goodheart's photoguide of common skin disorders (2nd ed.). Philadelphia, PA: Lippincott Williams &amp; Wilkins.)</p>
<p><img src="assets/images/image-20251225-f7387228.jpeg" alt="img-17.jpeg">
FIGURE 8-3. The Koebner phenomenon is localized to the area of sunburn. The region that had been covered by the patient's bathing suit is almost free of lesions. (From Goodheart, H. P. (2003). Goodheart's photoguide of common skin disorders (2nd ed.). Philadelphia, PA: Lippincott Williams &amp; Wilkins.)</p>
<p><img src="assets/images/image-20251225-2cfd711f.jpeg" alt="img-18.jpeg">
FIGURE 8-4. Moderately severe case of psoriasis characterized by sharply defined, erythematous plaques on the trunk. (From Rubin, E., &amp; Farber, J. L. (1999). Pathology (3rd ed.). Philadelphia, PA: Lippincott Williams &amp; Wilkins.)</p>
<p><img src="assets/images/image-20251225-a0e39fd9.jpeg" alt="img-19.jpeg">
FIGURE 8-5. Well-defined plaques with silvery scale on the lower extremities. (From Goodheart, H. P. (2003). Goodheart's photoguide of common skin disorders (2nd ed.). Philadelphia, PA: Lippincott Williams &amp; Wilkins.)</p>
<p><img src="assets/images/image-20251225-e1bce289.jpeg" alt="img-20.jpeg">
FIGURE 8-6. Scalp psoriasis. (From Goodheart, H. P. (2010). Goodheart's same-site differential diagnosis: A rapid method of diagnosing and treating common skin disorders. Philadelphia, PA: Wolters Kluwer.)</p>
<p><img src="assets/images/image-20251225-f766fc4f.jpeg" alt="img-21.jpeg">
FIGURE 8-7. Psoriasis of the scalp and ears. (From Goodheart, H. P. (2003). Goodheart's photoguide of common skin disorders (2nd ed.). Philadelphia, PA: Lippincott Williams &amp; Wilkins.)</p>
<p><img src="assets/images/image-20251225-699463e1.jpeg" alt="img-22.jpeg">
FIGURE 8-8. Papules of various sizes, with small guttate lesions on the abdomen. Scale is not obvious, and there is a perilesional ring of blanching that may be seen in psoriasis before treatment that is common in the late stages of treatment. (From Craft, N., et al. (2010). VisualDx: Essential adult dermatology. Philadelphia, PA: Wolters Kluwer.)</p>
<p><img src="assets/images/image-20251225-c0ab4b0e.jpeg" alt="img-23.jpeg">
FIGURE 8-9. Inverse psoriasis. Close inspection of this patient reveals typical psoriasis on the hands. (From Goodheart, H. P. (2003). Goodheart's photoguide of common skin disorders (2nd ed.). Philadelphia, PA: Lippincott Williams &amp; Wilkins.)</p>
<p><img src="assets/images/image-20251225-e47c392a.jpeg" alt="img-24.jpeg">
FIGURE 8-10. Psoriasis, erythrodermic variant. (From Goodheart, H. P. (2003). Goodheart's photoguide of common skin disorders (2nd ed.). Philadelphia, PA: Lippincott Williams &amp; Wilkins.)</p>
<p><img src="assets/images/image-20251225-df93aa14.jpeg" alt="img-25.jpeg">
FIGURE 8-11. Psoriasis, pustular variant. (From Goodheart, H. P. (2003). Goodheart's photoguide of common skin disorders (2nd ed.). Philadelphia, PA: Lippincott Williams &amp; Wilkins.)</p>
<p><img src="assets/images/image-20251225-53730d95.jpeg" alt="img-26.jpeg">
FIGURE 8-12. Pustular psoriasis. Rapid development of sterile pustules complicated a case of erythroderma. (From Elder, D. E., et al. (2012). Atlas and synopsis of Lever's histopathology of the skin. Philadelphia, PA: Wolters Kluwer.)</p>
<p><img src="assets/images/image-20251225-39e0c880.jpeg" alt="img-27.jpeg">
FIGURE 8-13. In confusing diagnostic cases, the identification of typical psoriasis on other skin surfaces such as the scalp, elbows, or nail pits, such as these, can be very useful. (From Edwards, L., &amp; Lynch, P. J. (2010). Genital dermatology atlas. Philadelphia, PA: Wolters Kluwer.)</p>
<p><img src="assets/images/image-20251225-89d1104c.jpeg" alt="img-28.jpeg">
FIGURE 8-14. Orange-brown coloration appears under the nail plate, presumably the result of psoriasis of the nail bed. (From Goodheart, H. P. (2003). Goodheart's photoguide of common skin disorders (2nd ed.). Philadelphia, PA: Lippincott Williams &amp; Wilkins.)</p>
<p><img src="assets/images/image-20251225-0db5db7e.jpeg" alt="img-29.jpeg">
FIGURE 8-15. Pitting and onycholysis of nails of a patient with psoriatic arthritis. (From Huang, J. J., &amp; Gaudio, P. A. (2010). Ocular inflammatory disease and uveitis manual. Philadelphia, PA: Wolters Kluwer.)</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="ii-lichen-planus">II. LICHEN PLANUS<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#ii-lichen-planus" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="a-definition">A. Definition<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#a-definition" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<ol>
<li>LP can be either an acute or a chronic inflammatory disease of the skin, mucous membranes, hair, and nails that may be idiopathic or caused by a drug, contact allergen, or viral infection. Classic cutaneous LP is characterized by flat-topped lesions that are often described using the five Ps—purple, polygonal, pruritic, planar, and papules.</li>
</ol>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="b-etiology-and-pathology">B. Etiology and pathology<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#b-etiology-and-pathology" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<ol>
<li>Thought to be due to an abnormal immune reaction most often provoked by a viral infection (such as hepatitis B or C) or a drug.</li>
<li>Research indicates that T cells seem to mistake the skin cells as foreign and attack them, damaging the basal keratinocytes that express altered self-antigens on their surface.</li>
</ol>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="c-incidence">C. Incidence<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#c-incidence" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<ol>
<li>
<p>Occurs worldwide and in all races.</p>
</li>
<li>
<p>Equally prevalent in males and females.</p>
</li>
<li>
<p>The exact prevalence is not known. It varies geographically, but the skin disease is reported to affect  <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>0.22</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">0.22\%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">0.22%</span></span></span></span></span>  to  <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>1</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">1\%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">1%</span></span></span></span></span>  of adults, and the oral manifestations affect  <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>1</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">1\%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">1%</span></span></span></span></span>  to  <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>4</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">4\%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">4%</span></span></span></span></span>  of the population.</p>
</li>
<li>
<p>Onset is most often in adulthood.</p>
</li>
</ol>
<p>D. Assessment</p>
<ol>
<li>Clinical manifestations</li>
</ol>
<p>a. Typical LP is characterized by shiny, flat-topped, firm papules varying from a few millimeters to larger plaques (Figure 8-16). They are purple color and frequently have tiny white lines called "Wickham striae."</p>
<p>b. They may be clustered or widespread, or in lines (linear LP) or circles (annular LP).</p>
<p>c. Linear LP can be the result of scratching or injuring the skin (Koebner phenomenon).</p>
<p>d. Most often affects the oral mucosa and the flexor surfaces of the wrists, forearms, and legs.</p>
<p>e. Genital LP is less common. It can be very painful and have a major impact on QOL (Figures 8-17 and 8-18).</p>
<p>f. Skin lesions are most often very pruritic.</p>
<p>g. Oral LP can vary in its presentation but is frequently seen as white, lacy patterns on the buccal mucosa. It may also be seen on the tongue. On the gingiva, it can be atrophic, erosive, or bullous and associated with mild to severe pain (Figure 8-19).</p>
<p>h. Lichen planopilaris is a variant of LP on the scalp with scaly papules and scarring alopecia.</p>
<p>i. Nail bed changes include thin nails with longitudinal lines, dystrophy ("pterygium"), splintering, and destruction of the nail fold.</p>
<p>j. Cutaneous LP may resolve spontaneously within 2 years, but oral LP may persist and be more recalcitrant to treatment.</p>
<ol start="2">
<li>Diagnostic tests</li>
</ol>
<p>a. Most often diagnosed clinically, but 4-mm punch biopsy may be helpful, plus another 4-mm punch biopsy of perilesional skin for direct immunofluorescence when bullous lesions are present.</p>
<p>b. Testing for hepatitis B and C.</p>
<p>c. Patch testing for metal allergies may be helpful for oral LP since it may be a manifestation of an allergy to metallic fillings and other dental restorations.</p>
<p>E. Nursing considerations</p>
<ol>
<li>Medical interventions</li>
</ol>
<p>a. Corticosteroids</p>
<p>(1) High-potency topical, intralesional, and systemic corticosteroids have all been used effectively for LP.</p>
<p>(2) Mild cases may be treated with topical steroids and sedating antihistamines for itching.</p>
<p>(3) Hypertrophic LP may respond to intralesional corticosteroids or category 1 steroids under occlusion.</p>
<p>(4) In severe cases, systemic corticosteroids are typically used. Moderate doses (30 to 60 mg daily) used for 2 to 6 weeks and then tapered over several weeks to avoid rebound and relapses.</p>
<p>(5) Topical corticosteroids twice daily are first-line therapy for mucosal erosive LP.</p>
<p>b. Topical calcineurin inhibitors, such as tacrolimus and pimecrolimus, are second-line</p>
<p>therapies for oral LP.</p>
<p>c. Other nonsteroidal systemic treatments: methotrexate, acitretin, cyclosporine, azathioprine, PUVA, and narrowband UVB have been utilized. Oral metronidazole has been studied as an effective treatment for diffuse LP.</p>
<p>d. Research shows that narrowband UVB may be viewed as an effective treatment for generalized cutaneous LP. It may be especially appropriate when there are contraindications for systemic corticosteroids and other medicines or other immunosuppressive drugs.</p>
<ol start="2">
<li>Patient teaching and engagement: after assessing the patient's readiness to learn and understanding of his/her condition consider offering education on the below topics:</li>
</ol>
<p>a. Avoid scratching: explain the rational for avoiding scratching due to the pathomechanics of scratching and the risk for koebnerization and lichenification that can worsen pruritus.</p>
<p>b. Utilize cold compresses and cool baths with oatmeal to suppress itch sensation.</p>
<p>c. Discuss purpose of systematic approach to optimal use of topical medications.</p>
<p>d. Review steroid precautions.</p>
<p>e. Advise the patient to complete periodic lab screening as directed by provider if utilizing systemic medications.</p>
<p>f. Discuss rational for consistency in phototherapy.</p>
<p>g. Typically, cutaneous LP resolves within 6 months to a year but is prone to recurrence. Conversely, the hypertrophic type tends to last for years.</p>
<ol start="3">
<li>Follow-up</li>
</ol>
<p>a. Follow-up with patient in 14 days to assess treatment effectiveness if using topical therapy.</p>
<p>b. Visits every 4 to 8 weeks until condition controlled.</p>
<p>c. When stable, visits every 6 months for reevaluation.</p>
<p>d. More often for exacerbations.</p>
<p><img src="assets/images/image-20251225-89770e5d.jpeg" alt="img-30.jpeg">
FIGURE 8-16. Lichen planus of the hand and wrist. Note the violaceous color and flat-topped appearance of the lesions. (From McConnell, T. H. (2013). Nature of disease. Philadelphia, PA: Wolters Kluwer.)</p>
<p><img src="assets/images/image-20251225-a1ce3ece.jpeg" alt="img-31.jpeg">
FIGURE 8-17. Nonspecific erosions typically seen in vulvar lichen planus. (From Edwards, L., &amp; Lynch, P. J. (2010). Genital dermatology atlas. Philadelphia, PA: Wolters Kluwer.)</p>
<p><img src="assets/images/image-20251225-f49c0f5e.jpeg" alt="img-32.jpeg">
FIGURE 8-18. Uncircumcised penis with erosive lichen planus. (From Edwards, L., &amp; Lynch, P. J. (2010). Genital dermatology atlas. Philadelphia, PA: Wolters Kluwer.)</p>
<p><img src="assets/images/image-20251225-46677a52.jpeg" alt="img-33.jpeg">
FIGURE 8-19. Oral lichen planus: erythematous, ulcerated, and painful gingival lesions. (Courtesy of Dr. Ralph Arnold, San Antonio, TX.)</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="iii-pityriasis-rosea">III. PITYRIASIS ROSEA<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#iii-pityriasis-rosea" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="a-definition">A. Definition<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#a-definition" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<ol>
<li>PR is a mild, acute, self-limiting exanthematous eruption characterized by a distinctive morphology of an initial "herald patch" followed by the appearance of oval-shaped salmon-colored papules and macules with a collarette of scaling seen on the trunk and extremities, usually sparing the face, scalp, palms, and soles (Figure 8-20).</li>
</ol>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="b-etiology-and-pathology">B. Etiology and pathology<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#b-etiology-and-pathology" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<ol>
<li>The exact cause is still undetermined, but a viral origin is the most popular hypothesis.</li>
<li>Supporters of the viral theory call attention to the prodromal symptoms experienced by some people and the lack of recurrence signifying an immunity being developed.</li>
<li>Studies have reported involvement of human herpesvirus 7 (HHV-7) and HHV-6.</li>
</ol>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="c-incidence">C. Incidence<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#c-incidence" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<ol>
<li>Multiple studies have tried to establish prevalence. It has been estimated to be  <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>1.31</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">1.31\%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">1.31%</span></span></span></span></span> , but considering the atypical forms that have not been appropriately diagnosed, this is conceivably an underestimation.</li>
<li>Typically occurs in otherwise healthy adolescents and young adults (10- to 35-year-olds).</li>
</ol>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="d-assessment">D. Assessment<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#d-assessment" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<ol>
<li>Clinical manifestations</li>
</ol>
<p>a. Typically begins with a solitary patch on the trunk (more rarely on extremities) called the “herald patch,” which is oval, with slightly elevated finely scaling borders (collaret), whereas the center is paler and slightly depressed and it may be the only lesion for about 2 weeks (Figure 8-21).</p>
<p>b. After herald patch begins to fade, a widespread eruption abruptly develops.</p>
<p>c. This secondary phase is characterized by patches that are similar to the initial one, but smaller and symmetrically oriented with their long axes along the cleavage lines of the trunk and proximal extremities typically.</p>
<p>d. Oral lesions are not commonly reported with PR.</p>
<p>e. Usually, there is an absence of significant systemic symptoms. About 5% of people will experience a mild prodromal phase including a headache, fever, arthralgias, or malaise.</p>
<p>f. Spontaneous resolution usually in 8 to 12 weeks. Rarely persists over 5 months.</p>
<p>g. In the typical cases, diagnosis is easy. The differential diagnosis includes guttate psoriasis, secondary syphilis, tinea versicolor, seborrheic dermatitis, nummular eczema, and pityriasis lichenoides chronica.</p>
<ol start="2">
<li>Diagnostic tests</li>
</ol>
<p>a. Testing is usually not necessary after a thorough history and physical are complete, but RPR, KOH, and punch biopsy could be considered.</p>
<ol start="3">
<li>Nursing considerations</li>
</ol>
<p>a. PR is a self-limiting disease, so medical interventions are generally unnecessary.</p>
<p>b. Best treatment is education and reassurance for the patient.</p>
<p>c. Pruritus, if present, is usually mild and tolerable.</p>
<p>d. A Cochrane collaboration article reviewed the literature on various possible treatments used and found the evidence to be inadequate for the efficacy of emollients, topical antihistamines and corticosteroids, sunlight, artificial ultraviolet therapy, systemic antihistamines and corticosteroids, antiviral agents, and intravenous glycyrrhizin.</p>
<p>e. One study found evidence that oral erythromycin may shorten the course of the rash and alleviate pruritus, but a later study did not confirm the results.</p>
<ol start="4">
<li>Patient teaching</li>
</ol>
<p>a. PR is self-limiting and not dangerous.</p>
<p>b. Patient may be completely asymptomatic or have some mild itching.</p>
<p>c. People with darker skin may be at risk of some postinflammatory hyperpigmentation (Figure 8-22).</p>
<ol start="5">
<li>Follow-up</li>
</ol>
<p>a. No follow-up needed unless the condition lasts greater than 5 months or systemic symptoms develop and persist.</p>
<p><img src="assets/images/image-20251225-3c2e84a6.jpeg" alt="img-34.jpeg"></p>
<p><img src="assets/images/image-20251225-63af742f.jpeg" alt="img-35.jpeg">
FIGURE 8-20. Pityriasis rosea. (From Goodheart, H. P. (2010). Goodheart's same-site differential diagnosis: A rapid method of diagnosing and treating common skin disorders. Philadelphia, PA: Wolters Kluwer.)
FIGURE 8-21. Pityriasis rosea. Oval herald patch (arrow) on the abdomen with a more generalized rash. (From Centers for Disease Control and Prevention Public Health Image Library.)</p>
<p><img src="assets/images/image-20251225-9f78532a.jpeg" alt="img-36.jpeg">
FIGURE 8-22. Pityriasis rosea. Eruption is typically distributed on the chest and/or back in a Christmas tree pattern. (From Goodheart, H. P. (2003). Goodheart's photoguide of common skin disorders (2nd ed.). Philadelphia, PA: Lippincott Williams &amp; Wilkins.)</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="iv-keratosis-pilaris">IV. KERATOSIS PILARIS<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#iv-keratosis-pilaris" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="a-definition">A. Definition<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#a-definition" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<ol>
<li>Keratosis pilaris (KP) is a common condition caused by excessive keratinization leading to numerous coarse follicular plugs (Figures 8-23 and 8-24).</li>
</ol>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="b-etiology-and-pathology">B. Etiology and pathology<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#b-etiology-and-pathology" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<ol>
<li>KP is a genetic condition, but the exact cause has not yet been identified.</li>
<li>The hypothesis is that KP is a disorder of keratinization in which the cells that line the hair follicle form a horny plug instead of exfoliating. This enlarges the pores making them appear more obvious than in the normal skin.</li>
<li>Commonly associated with atopic dermatitis.</li>
</ol>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="c-incidence">C. Incidence<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#c-incidence" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<ol>
<li>
<p>KP affects nearly  <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>50</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">50\%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">50%</span></span></span></span></span>  to  <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>80</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">80\%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">80%</span></span></span></span></span>  of all adolescents and approximately  <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>40</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">40\%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">40%</span></span></span></span></span>  of adults.</p>
</li>
<li>
<p>Frequently first diagnosed when people are being seen in dermatology for other conditions such as eczema.</p>
</li>
<li>
<p>Frequently primarily a cosmetic concern but medically harmless and often asymptomatic (minor itching is possible).</p>
</li>
</ol>
<p>D. Assessment</p>
<ol>
<li>
<p>Clinical manifestations
a. Primarily found on the lateral upper arms and anterior thighs but may also be seen on the cheeks, upper back, buttocks, and forearms.
b. May be skin colored, red, or brown.
c. Keratotic papules on the face may be on a red background that is a variant of KP called keratosis rubra faceii (Figure 8-25).
d. Worsens in the winter months due to dry air.
e. Often refractory to treatment.</p>
</li>
<li>
<p>Diagnostic tests
a. Diagnosis is made by clinical assessment.
b. Testing is not necessary but punch biopsy could be considered if diagnosis is unclear.</p>
</li>
</ol>
<p>E. Nursing considerations</p>
<ol>
<li>
<p>Interventions
a. Moisturizers alone only somewhat helpful.
b. Some KP will respond to topical urea or lactic acid creams.
c. Retinoids may be helpful but easily irritate the skin and should be started at only 1 to 2 times per week.
d. Inflamed KP, which is often red and itchy, may be treated with a low-dose topical corticosteroid.</p>
</li>
<li>
<p>Patient teaching
a. KP is genetic and chronic but essentially asymptomatic.
b. Should not scrub KP or it may become inflamed.</p>
</li>
<li>
<p>Follow-up
a. No follow-up needed.</p>
</li>
</ol>
<p><img src="assets/images/image-20251225-968d9797.jpeg" alt="img-37.jpeg">
FIGURE 8-23. Shoulders with keratosis pilaris. (From Lugo-Somolinos, A., et al. (2011). VisualDx: Essential dermatology in pigmented skin. Philadelphia, PA: Wolters Kluwer.)</p>
<p><img src="assets/images/image-20251225-97900e73.jpeg" alt="img-38.jpeg">
FIGURE 8-24. The discrete lesions of keratosis pilaris are often lifelong and lack the inflammation of folliculitis. (From Craft, N., et al. (2010). VisualDx: Essential adult dermatology. Philadelphia, PA: Wolters Kluwer.)</p>
<p><img src="assets/images/image-20251225-81985efb.jpeg" alt="img-39.jpeg">
FIGURE 8-25. KP on the face is frequently red, while lesions on the extremities typically are not. (From Craft, N., et al. (2010). VisualDx: Essential adult dermatology. Philadelphia, PA: Wolters Kluwer.)</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="v-lichen-simplex-chronicus">V. LICHEN SIMPLEX CHRONICUS<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#v-lichen-simplex-chronicus" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>A. Definition</p>
<ol>
<li>LSC is a common disorder characterized by skin lichenification secondary to excessive scratching and rubbing of the skin (Figure 8-26).</li>
</ol>
<p>B. Etiology and pathology</p>
<ol>
<li>The initial pruritus associated with LSC may be from another skin condition such as atopic dermatitis or psoriasis, a compressed nerve leading to the skin (neuropathic pruritus), or in some cases a psychologically related issue.</li>
<li>Also called neurodermatitis.</li>
<li>Once scratching becomes chronic, the skin thickens as a protective mechanism and develops lichenification (similar to callus that forms on the palms and soles following mechanical trauma) (Figures 8-27 and 8-28).</li>
<li>Lichenification results from thickening of both the epidermis and the stratum corneum.</li>
<li>LSC is frequently very tenacious and tends to recur even if it is responsive to initial</li>
</ol>
<p>treatment.</p>
<ol start="6">
<li>
<p>Longevity seems to be related significantly to the psychological component and how much the person continues to scratch.</p>
</li>
<li>
<p>Itch—scratch cycle plays a dominate role in disease persistence.</p>
</li>
<li>
<p>The most common sites are the neck, scalp, shoulder, wrist, genital area, and lower leg/ankle.</p>
</li>
</ol>
<p>C. Incidence</p>
<ol>
<li>
<p>It develops predominantly in mid-to-late adult life, but it can also occur in children. When LSC develops in children, it is slightly more likely to occur in boys; when it occurs in adults, it is slightly more prevalent in women.</p>
</li>
<li>
<p>Recent study finds that having an anxiety disorder is associated with an increased risk of LSC. Researchers recommend combining the management of LSC and psychological disorders to achieve better outcomes.</p>
</li>
<li>
<p>Anogenital LSC is a common disease. Incidence and prevalence statistics have not been determined (Figures 8-29 and 8-30).</p>
</li>
</ol>
<p>D. Assessment</p>
<ol>
<li>Clinical manifestations</li>
</ol>
<p>a. Characterized by the presence of erythematous or hyperpigmented well-defined scaly and thickened papules and plaques with variable degrees of overlying excoriation.</p>
<p>b. Long-standing LSC may also have hyperpigmentation (Figure 8-31) and hypopigmentation.</p>
<p>c. Worsens with stress, anxiety, heat, sweating, and irritation from clothing.</p>
<ol start="2">
<li>Diagnostic tests</li>
</ol>
<p>a. Diagnosis is made by clinical assessment.</p>
<p>b. Testing is not necessary but punch biopsy could be considered if unclear.</p>
<p>E. Nursing considerations</p>
<ol>
<li>Interventions</li>
</ol>
<p>a. Treatment is aimed at reducing pruritus to decrease the urge to scratch since rubbing and scratching cause LSC.</p>
<p>b. Location, lesion morphology, and extent of the lesions influence treatment.</p>
<p>c. High-potency topical corticosteroids, intralesional steroids, and topical calcineurin inhibitors (tacrolimus and pimecrolimus) are frequently used. Unlike other conditions where the use of topical steroids is limited to 2 weeks, it is often advised in LSC to use steroids twice a day until the lesions flatten.</p>
<p>d. Nighttime scratching cannot be controlled with willpower since people are unaware that they are doing it. Using a sedating antihistamine may be very helpful in breaking the itch—scratch cycle (hydroxyzine 10 to 25 mg taken 2 hours before bedtime reduces the risk for morning drowsiness). Increase the dose every 5 to 7 days until nighttime scratching ceases or side effects limit increasing the dose (may require 50 to 75 mg to be effective).</p>
<p>e. Tricyclic antidepressants (doxepin) may work even better due to its sedating effect and treatment of depression and anxiety.</p>
<p>f. Selective serotonin reuptake inhibitors (SSRIs) may also be helpful when stress,</p>
<p>anxiety, or depression is a significant factor.</p>
<p>g. Systemic corticosteroids are warranted if not improving after several weeks of topical steroids—40 mg in AM × 7 days, than 20 mg in AM × 7 days.</p>
<ol start="2">
<li>Patient teaching: after assessing the patient's readiness to learn and understanding of his/her condition, consider offering education on the below topics:</li>
</ol>
<p>a. The most important aspect of treatment is to break the itch-scratch cycle or the condition will not improve. Patients must understand the pathomechanisms of the itch-scratch cycle in order to participate in effective self-care.</p>
<p>b. Untreated LSC will go on indefinitely but may intermittently improve and worsen.</p>
<p>c. Even with very effective treatment, there is a high likelihood of recurrence if the same triggers are present (underlying disease, warm, sweating, irritation, psychological distress).</p>
<p>d. Dryness is also a trigger for pruritus so moisturizing several times daily is essential.</p>
<p>e. Complications include secondary infection, permanent skin color changes, and permanent scarring.</p>
<ol start="3">
<li>Follow-up</li>
</ol>
<p>a. Close follow-up is needed to support consistent follow-through on the treatment plan to break the itch-scratch cycle. People are often much more motivated to optimize treatment when they start to get relief from the condition.</p>
<p>b. See the person back in clinic in 2 weeks, then again in 1 month. Phone follow-up can also be helpful.</p>
<p>c. Once the LSC is improved, then other underlying conditions such as atopic dermatitis, psoriasis, and psychosocial issues should be addressed for a long-term plan. Engagement in self-care is essential for long-term success.</p>
<p><img src="assets/images/image-20251225-03f8b70f.jpeg" alt="img-40.jpeg">
FIGURE 8-26. Lichen simplex chronicus. Lichenified plaques involve the distal pretibial area and ankle. (From Goodheart, H. P. (2003). Goodheart's photoguide of common skin disorders (2nd ed.). Philadelphia, PA: Lippincott Williams &amp; Wilkins.)</p>
<p><img src="assets/images/image-20251225-f46dd74e.jpeg" alt="img-41.jpeg">
FIGURE 8-27. Lichen simplex chronicus. (From Goodheart, H. P. (2010). Goodheart's same-site differential diagnosis: A rapid method of diagnosing and treating common skin disorders. Philadelphia, PA: Wolters Kluwer.)</p>
<p><img src="assets/images/image-20251225-bf731992.jpeg" alt="img-42.jpeg">
FIGURE 8-28. Lichen simplex chronicus. Chronic "rubbing" of the posterior neck led to lichenification characterized by accentuation and thickening of skin markings. (From Elder, D. E., et al. (2012). Atlas and synopsis of Lever's histopathology of the skin. Philadelphia, PA: Wolters Kluwer.)</p>
<p><img src="assets/images/image-20251225-184d1c0a.jpeg" alt="img-43.jpeg">
FIGURE 8-29. Lichen simplex chronicus of the labia. Lichenification with excoriations due to scratching. (From Rubin, R., et al. (2011). Rubin's pathology. Philadelphia, PA: Wolters Kluwer.)</p>
<p><img src="assets/images/image-20251225-5500ca4c.jpeg" alt="img-44.jpeg">
FIGURE 8-30. Lichen simplex chronicus of the testes. (From Goodheart, H. P. (2010). Goodheart's same-site differential diagnosis: A rapid method of diagnosing and treating common skin disorders. Philadelphia, PA: Wolters Kluwer.)</p>
<p><img src="assets/images/image-20251225-b3cee57e.jpeg" alt="img-45.jpeg">
FIGURE 8-31. Lichen simplex chronicus with accentuated skin markings and hyperpigmentation. (From Lugo-Somolinos, A., et al. (2011). VisualDx: Essential dermatology in pigmented skin. Philadelphia, PA: Wolters Kluwer.)</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="bibliography">BIBLIOGRAPHY<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#bibliography" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>Alai, N. N., &amp; Elston, D. M. (2014). Keratosis pilaris. Retrieved from <a href="http://misc.medscape.com/pi/android/medscapeapp//A1070651-business" target="_blank" rel="noopener noreferrer">http://misc.medscape.com/pi/android/medscapeapp//A1070651-business</a>.
Barisic-Drusko, V., Dobric, I., Pasic, A., Palian, D., Jukic, Z., Basta-Juzbasic, A., &amp; Marinovic, B. (1994). Frequency of psoriatic arthritis in general population and among the psoriatics in Department of Dermatology. Acta Dermato Venereologica. Supplementum, 186, 107-108.
Barker, S., &amp; Oakley, A. (2014, April). Retrieved from <a href="http://dermnetnz.org/acne/eosinophilic-folliculitis" target="_blank" rel="noopener noreferrer">http://dermnetnz.org/acne/eosinophilic-folliculitis</a>.
Basavaraj, K. H., Ashok, N. M., Rashmi, R., &amp; Praveen, T. K. (2010). The role of drugs in the induction and/or exacerbation of psoriasis, International Journal of Dermatology, 49, 1351-1361.
Chuh, A. A., Dofitas, B. L., Comisel, G. G., Reveiz, L., Sharma, V., Garner, S. E., &amp; Chu, F. (2007). Interventions for pityriasis rosea. Cochrane Database of Systematic Reviews, (2), CD005068.
Churton, S., Brown, L., Shin, T. M., &amp; Korman, N. J. (2014). Does treatment of psoriasis reduce the risk of cardiovascular disease? Drugs, 74, 169-182.
Corrocher, G., Di Lorenzo, G., Martinelli, N., Mansueto, P., Biasi, D., Nocini, P. F., ..., Pacor, M. L. (2008). Comparative effect of tacrolimus  <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>0.1</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">0.1\%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">0.1%</span></span></span></span></span>  ointment and clobetasol  <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>0.05</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">0.05\%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">0.05%</span></span></span></span></span>  ointment in patients with oral lichen planus. Journal of Clinical Periodontology, 35(3), 244-249.
Curtis, J. R., Beukelman, T., Onofrei, A., Cassell, S., Greenberg, J. D., Kavanaugh, A., ..., Kremer, J. M. (2010). Elevated liver enzyme test among patients with rheumatoid arthritis or psoriatic arthritis with methotrexate and/or leflunomide. Annals of the Rheumatic Diseases, 69(1), 43-47.</p>
<p>Drago, F., Broccolo, F., &amp; Alfredo, R. (2008). Pityriasis rosea: An update with a critical appraisal of its possible herpesviral etiology. Journal of the American Academy of Dermatology, 61(2), 303–318.</p>
<p>Farber, E. M., Nall, L., &amp; Watson, W. (1974). Natural history of psoriasis in 61 twin pairs. Archives of Dermatology, 109(2), 207–211.</p>
<p>Fukamachi, S., Kabashima, K., Sugita, K., Kobayashi, M., &amp; Tokura, Y. (2009). Therapeutic effectiveness of various treatments for eosinophilic pustular folliculitis. Acta Dermato-Venereologica, 89, 155–159.</p>
<p>Gladman, D. D., Thavaneswaran, A., Chandran, V., &amp; Cook, R. J. (2011). Do patients with psoriatic arthritis who present early fare better than those presenting later in the disease? Annals of the Rheumatic Diseases, 70, 2152–2154.</p>
<p>Gorouhi, F., Davari, P., &amp; Fazel, N. (2014). Cutaneous and mucosal lichen planus: A comprehensive review of clinical subtypes, risk factors, diagnosis, and prognosis. The Scientific World Journal, 2014, 1–22.</p>
<p>Gulliver, W. (2008). Long-term prognosis in patients with psoriasis. The British Journal of Dermatology, 159(Suppl 2), 2–9.</p>
<p>Henseler, T., &amp; Christophers, E. (1985). Psoriasis of early and late onset: Characterization of two types of psoriasis vulgaris. Journal of the American Academy of Dermatology, 13(3), 450–456.</p>
<p>Higgins, E. (2000). Alcohol, smoking and psoriasis. Clinical and Experimental Dermatology, 25, 107–110.</p>
<p>Iraji, F., Faqhihi, G., Asilian, A., Siadat, A. H., Larijani, F. T., &amp; Akbari, M. (2011). Comparison of narrow band UVB versus systemic corticosteroids in treatment of lichen planus: A randomized clinical trial. Journal of Research in Medical Sciences, 16(12), 1578–1582.</p>
<p>James, W. D., Berger, T. G., &amp; Elston, D. M. (2011). Andrew’s diseases of the skin: Clinical dermatology (11th ed., pp. 66, 190–198, 248, 410–411). Saunders Elsevier.</p>
<p>Jiaravuthisan, M. M., Sasseville, D., Vender, R. B., Murphy, F., &amp; Muhn, C. Y. (2007). Psoriasis of the nail: Anatomy, pathology, clinical presentation, and a review of the literature on therapy. Journal of the American Academy of Dermatology, 57, 1–27.</p>
<p>Kimball, A. B., Gieler, U., Linder, D., Sampogna, F., Warren, R. B., &amp; Augustin, M. (2010). Psoriasis: Is the impairment to a patient’s life cumulative? Journal of European Academy of Dermatology and Venereology, 24, 989–1004.</p>
<p>Leung, D. Y., Travers, J. B., Giorno, R., Norris, D. A., Skinner, R., Aelion, J., ..., Kotb, M., et al. (1995). Evidence for a streptococcal super antigen-driven process in acute guttate psoriasis. The Journal of Clinical Investigation, 96, 2106–2112.</p>
<p>Lynch, P. J. (2004). Lichen simplex chronicus (atopic/neurodermatitis) of the anogenital region. Dermatologic Therapy, 17, 8–19.</p>
<p>Martin, S. L., McGoey, S. T., Bebo, B. F., &amp; Feldman, S. R. (2013). Patients’ educational needs about topical treatments for psoriasis. Journal of the American Academy of Dermatology, 68(6), e163–e168.</p>
<p>Mason, A. R., Mason, J., Cork, M., Dooley, G., &amp; Hancock, H. (2003). Topical treatments for chronic plaque psoriasis (Review). The Cochrane Collaboration. Published by John Wiley &amp; Sons, Ltd.</p>
<p>Mumoli, N., Vitale, J., Gambaccini, L., Sabatini, S., Brondi, B., &amp; Cei, M. (2013). Erythrodermic psoriasis. Quarterly Journal of Medicine, 107, 4.</p>
<p>Parisi, R., Symmons, D. P., Griffiths, C. E., &amp; Ashcroft, D. M. (2013). Identification and management of psoriasis and associated comorbidity (IMPACT) project team. Global epidemiology of psoriasis: A systematic review of incidence and prevalence. The Journal of Investigative Dermatology, 133(2), 377–385.</p>
<p>Pearson, M., Mattke, S., Shaw, R., Ridgely, M., &amp; Wiseman, S. (2007). Patient self-management support programs: An evaluation. Retrieved from <a href="http://www.ahrq.gov/research/findings/final-reports/ptmgmt/ptmgmt.pdf" target="_blank" rel="noopener noreferrer">http://www.ahrq.gov/research/findings/final-reports/ptmgmt/ptmgmt.pdf</a></p>
<p>PHQ-9 Depression Scale (2015, April 12). AIMS Center: Advancing Integrated Mental Health Solutions. Retrieved from <a href="http://aims.uw.edu/resource-library/phq-9-depression-scale" target="_blank" rel="noopener noreferrer">http://aims.uw.edu/resource-library/phq-9-depression-scale</a></p>
<p>Pongdee, T. (2014). Bleach baths. American Allergy, Asthma &amp; Immunology. Retrieved from <a href="http://www.aaaai.org/conditions-and-treatments/library/allergy-library/Bleach-Bath-Recipe-for-Skin-Conditions.asp" target="_blank" rel="noopener noreferrer">http://www.aaaai.org/conditions-and-treatments/library/allergy-library/Bleach-Bath-Recipe-for-Skin-Conditions.asp</a></p>
<p>Prey, S., Paul, C., Bronsard, V., Puzenat, E., Gourraud, P. A., Aractingi, S., ..., Ortonne, J. P. (2010). Assessment of risk of psoriatic arthritis in patients with plaque psoriasis: A systematic review of the literature. Journal of European Academy of Dermatology and Venereology, 24(2), 31–35.</p>
<p>Rachakonda, T. D., Schupp, CW, &amp; Armstrong, A. W. (2014). Psoriasis prevalence among adults in the United States. Journal of the American Academy of Dermatology, 70, 512–516.</p>
<p>Rapp, S. R., Feldman, S. R., Exum, M. L., Fleischer Jr, A. B., Reboussin, D. M. (1999). Psoriasis causes as much disability as other major medical diseases. Journal of the American Academy of Dermatology, 41, 401–407.</p>
<p>Rajendran, P., High, W. A., &amp; Maurer, R. (2014). Eosinophilic folliculitis. Retrieved from <a href="http://www.uptodate.com/contents/hiv-associated-eosinophilic-folliculitis" target="_blank" rel="noopener noreferrer">http://www.uptodate.com/contents/hiv-associated-eosinophilic-folliculitis</a>? source=machineLearning&amp;search=eosinophilic+folliculitis&amp;selectedTitle=1%7E150&amp;sectionRank=4&amp;anchor=H5#H5</p>
<p>Rasi, A., Tajziehchi, L., &amp; Savabi-Nasab, S. (2008). Oral erythromycin is ineffective in the treatment of pityriasis rosea. Journal of Drugs in Dermatology, 7, 35–38.</p>
<p>Sharma, P. K., Yadav, T. P., Gautam, R. K., Taneja, N., &amp; Satyanarayana, L. (2000). Erythromycin in pityriasis rosea: A double-blind, placebo-controlled clinical trial. Journal of the American Academy of Dermatology, 42, 241–244.</p>
<p>Shiohara, T., &amp; Kano, Y. (2003). Lichen planus and lichenoid dermatoses. In J. Bolgnia, J. Jorizzo, &amp; R. Rapini (Eds.), Dermatology (pp. 175–184). Edinburgh, UK: Mosby.</p>
<p>Szczerkowska-Dobosz, A. (2005). Human leukocyte antigens as psoriasis inheritance and susceptibility markers. Archivum Immunologiae et Therapia Experimentalis, 53(5), 428–433.</p>
<p>Tauber, M., Viguier, M., Alimova, E., Petit, A., Lioté, F., Smahi, A., &amp; Bachelez, H. (2014). Partial clinical response to anakinra in severe palmoplantar pustular psoriasis. The British Journal of Dermatology, 171(3), 646–649.</p>
<p>Usatine, R. P., &amp; Tinitigan, M. (2011). Diagnosis and treatment of lichen planus. American Family Physician, 84(1), 53–60.</p>
<p>Van de Kerkhof, P. C. (2003). Psoriasis. In J. Bolgnia, J. Jorizzo, &amp; R. Rapini (Eds.), Dermatology (pp. 125–149). Edinburgh, UK: Mosby.</p>
<p>Vorwick, L. (2012, October). Folliculitis. Retrieved from <a href="http://www.ncbi.nlm.nih.gov/pubmedhealth/PMH0001826" target="_blank" rel="noopener noreferrer">http://www.ncbi.nlm.nih.gov/pubmedhealth/PMH0001826</a></p>
<p>Wolff, K., Johnson, R. A., &amp; Saavedra, A. P. (2013). Fitzpatrick’s color atlas (7th ed., pp. 49–57). United States: The McGraw-Hill Companies.</p>
<p>Woods, G. S., &amp; Reizner, G. (2003). Other papulosquamous disorders. In J. Bolgnia, J. Jorizzo, &amp; R. Rapini (Eds.), Dermatology (pp. 158–160). Edinburgh, UK: Mosby.</p>
<p>Zachariae, R., Zachariae, H., Blomqvist, K., Davidsson, S., Molin, L., Mork, C., &amp; Sigurgeirsson, B. (2004). Self-reported stress reactivity and psoriasis-related stress of Nordic psoriasis sufferers. Journal of the European Academy of Dermatology and Venereology, 18(1):27–36.</p>
<p>Zeichner, J. A., Lebwohl, M. G., Menter, A., Bagel, J., Del Rosso, J. Q., Elewski, B. E., ..., Tanghetti, E. (2010). Psoriasis Process of Care Consensus Panel. Optimizing topical therapies for treating psoriasis: A consensus conference. Cutis, 86(3), 5–31.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="study-questions">STUDY QUESTIONS<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#study-questions" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<ol>
<li>A patient with a history of psoriasis on her scalp for years presents with new onset of a rapidly developing rash that is widespread and consists of numerous small papules (about 5 to 10 mm size) with scale. She recently had a sore throat and fever. She most likely has what type of psoriasis?</li>
</ol>
<p>a. Plaque
b. Guttate
c. Pustular
d. Inverse</p>
<ol start="2">
<li>Stress, smoking, and alcohol are common triggers for psoriasis.</li>
</ol>
<p>a. True
b. False</p>
<ol start="3">
<li>The Koebner phenomenon is the presence of small bleeding points seen on a psoriatic lesion when the scales are removed.</li>
</ol>
<p>a. True
b. False</p>
<ol start="4">
<li>The lacy white network on the surface of papules, called Wickham striae, is typical and helpful for?</li>
</ol>
<p>a. Lichen planus
b. Lichen simplex chronicus</p>
<p>c. Atopic dermatitis</p>
<ol start="5">
<li>
<p>Where does lichen planus most often present?
a. Scalp
b. Nails and joints
c. Skin and oral mucosa
d. Genital area</p>
</li>
<li>
<p>What is the primary symptom associated with cutaneous lichen planus?
a. Scaling
b. Pain
c. Crusting
d. Severe itching</p>
</li>
<li>
<p>Pityriasis rosea generally begins with a solitary scaly patch on the trunk (herald patch), then 2 weeks later, the eruption abruptly worsens with abundant smaller scaly flat lesions that rapidly spread to the trunk and proximal arms and thighs. Patients and parents are often very concerned. The best treatment is usually:
a. Education and reassurance since pityriasis rosea is self-limiting
b. Topical steroids
c. Oral antihistamines
d. Moisturizer since medications don't really help</p>
</li>
<li>
<p>Your patient has a history of atopic dermatitis since childhood. He is 16 years old now and concerned about small (1 to 2 mm), asymptomatic papules covering both upper arms and thighs. His mom has the same condition. What does he likely have?
a. Seborrheic keratosis
b. Acne
c. Keratosis pilaris
d. Lichen planus</p>
</li>
<li>
<p>Your patient with lichen simplex chronicus is frustrated by her persistent itching. When you are educating her to maximize her ability to self-manage, you emphasize that the most important aspect of treatment is:
a. Applying moisturizer
b. Getting a good night's sleep
c. Breaking the itch—scratch cycle or the condition will not improve
d. Taking her antihistamines</p>
</li>
<li>
<p>Lichenification is a condition that develops once scratching or rubbing becomes chronic. The skin thickens as a protective mechanism and develops common</p>
</li>
</ol>
<p>characteristics of leather-like hypertrophy with exaggerated skin markings (similar to calluses that form on the palms and soles following mechanical trauma). It is always seen in lichen simplex chronicus but may also be seen with atopic dermatitis and psoriasis.</p>
<p>a. True
b. False</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="answers-to-study-questions">Answers to Study Questions<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#answers-to-study-questions" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>1.b
2.a
3.b
4.a
5.c
6.d
7.a
8.c
9.c
10.a</p>
<p>CHAPTER 9</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="dermatitis-eczemas">Dermatitis/Eczemas<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#dermatitis-eczemas" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>Noreen Heer Nicol</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="objectives">OBJECTIVES<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#objectives" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>After studying this chapter, the reader will be able to:</p>
<ul>
<li>Recognize that eczema and dermatitis are terms that describe the same response in the skin.</li>
<li>Define several types of eczemas and their various clinical presentations including atopic dermatitis, seborrheic dermatitis, contact dermatitis (allergic or irritant), and nummular eczema.</li>
<li>Identify the therapeutic interventions frequently used to treat these various eczemas.</li>
<li>Discuss important patient teaching points for managing various eczemas.</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="key-points">KEY POINTS<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#key-points" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<ul>
<li>Dermatitis and eczema are terms that can be used interchangeably to describe a type of inflammatory disease characterized by pruritus and lesions with indistinct borders. They can present in multiple phases including acute, subacute, and chronic.</li>
<li>Atopic dermatitis is a complex, common, chronic, and relapsing skin disorder of infants and children but can affect patients of any age. It is a global health problem.</li>
<li>Seborrheic dermatitis is a common eczematous condition that mainly affects the scalp and other oily areas of the body, such as the face, upper chest, and back.</li>
<li>Contact dermatitis can be divided on the basis of etiology into two types: irritant contact dermatitis and allergic contact dermatitis. Irritant contact dermatitis is more common of the two, accounting for approximately 80% of cases.</li>
<li>Nummular eczema, also called discoid eczema, is a chronic eczematous disorder that causes coin-shaped rashes on the skin.</li>
<li>Good daily skin care, which emphasizes regular use of moisturizers, is the cornerstone to treatment of most eczematous conditions.</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="dermatitis-and-eczema">DERMATITIS AND ECZEMA<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#dermatitis-and-eczema" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="i-overview">I. OVERVIEW<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#i-overview" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>A. Dermatitis and eczema are two general terms that are generally interchangeable and describe a particular type of inflammatory response in the skin.</p>
<p>B. Diseases that are considered eczematous disorders are generally characterized by pruritus, lesions with indistinct borders, and epidermal changes.</p>
<p>C. These lesions can appear as erythema, papules, or lichenification of the skin.</p>
<p>D. The disorder presents in an acute, subacute, or chronic phase.</p>
<p>E. The inflammatory process of eczema or dermatitis takes place primarily at the level of the epidermis; however, the dermis can be involved.</p>
<p>F. There are many different types of eczema or dermatitis (Box 9-1, Figure 9-1).</p>
<p><img src="assets/images/image-20251225-64a4a1d2.jpeg" alt="img-46.jpeg"></p>
<p><img src="assets/images/image-20251225-4ce94f34.jpeg" alt="img-47.jpeg">
B
FIGURE 9-1. Contact dermatitis. A. Allergic contact dermatitis results when a substance comes in direct contact with the skin, leading to a simple inflammatory reaction. B. Irritant contact dermatitis results when the substance causes direct skin damage, pain, or ulceration, such as with tight shoes or prolonged use of latex gloves. (From Cohen, B. J., &amp; DePetris, A. (2013). Medical terminology. Philadelphia, PA: Wolters Kluwer.)</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="box-9-1-types-of-dermatitis-eczema">BOX 9-1. Types of Dermatitis (Eczema)<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#box-9-1-types-of-dermatitis-eczema" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<ul>
<li>Allergic contact dermatitis (allergic contact eczema). A red, itchy, weepy reaction where the skin has initially come into contact with a substance that the immune system recognizes as foreign, such as poison ivy or certain preservatives in creams and lotions. This is a delayed hypersensitivity reaction.</li>
<li>Atopic dermatitis (atopic eczema). A chronic skin disease characterized by itchy, inflamed skin associated with a personal or family history of asthma, allergic rhinitis, or eczema.</li>
<li>Diaper dermatitis (Diaper rash). An inflammatory reaction localized to the area of skin usually covered by the diaper. It can have many causes, including infections (yeast, bacterial, or viral), friction irritation, chemical allergies (preservatives, perfumes,</li>
</ul>
<p>soaps, etc.), sweat, decomposed urine, and plugged sweat glands.</p>
<ul>
<li>Dyshidrotic eczema. Irritation of the skin on the palms of the hands and soles of the feet characterized by clear, deep blisters that itch and burn.</li>
<li>Irritant contact dermatitis (irritant contact eczema). A localized reaction that includes redness, itching, and burning where the skin has come into contact with a substance acting as an irritant such as an acid, a cleaning agent, other chemical, or even water.</li>
<li>Neurodermatitis (lichen simplex chronicus). Scaly patches of the skin on the head, lower legs, wrists, or forearms characterized by skin lichenification secondary to excessive scratching and rubbing of the skin.</li>
<li>Nummular eczema (discoid eczema). Coin-shaped patches of irritated skin—most common on the arms, back, buttocks, and lower legs—that may be crusted, scaling, and extremely itchy.</li>
<li>Seborrheic dermatitis (seborrheic eczema). Yellowish, oily, scaly patches of skin on the scalp, face, and occasionally other parts of the body.</li>
<li>Stasis dermatitis. A skin irritation on the lower legs, generally related to circulatory problems, which often presents with hyperpigmented areas.</li>
<li>Xerotic eczema ("xerotic dermatitis," "eczema craquele," "asteatotic eczema," "Winter itch," and "Winter eczema"). Irritated skin that occurs when the skin becomes abnormally dry, itchy, and cracked. It can appear in red bumpy or scaly.</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="ii-common-therapeutic-modality">II. COMMON THERAPEUTIC MODALITY<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#ii-common-therapeutic-modality" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>Basic Skin Care for All Patients with Dermatitis or Eczema (Boxes 9-2 and 9-3).</p>
<p>A. Methods of skin hydration and moisturization
B. Proper methods of application of medications
C. Ways to incorporate treatments into daily routines</p>
<p>Tips for All Patients with Dermatitis or Eczema to Reduce Skin Irritation (Box 9-4)</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="box-9-2-patient-education-all-types-of-dermatitis-and-eczema">BOX 9-2. Patient Education: All Types of Dermatitis and Eczema<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#box-9-2-patient-education-all-types-of-dermatitis-and-eczema" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<ul>
<li>Spend time listening to the patient and/or the parent.</li>
<li>Individualize treatment.</li>
<li>Explain the nature of the disease and clarify that the goal is control, not cure.</li>
<li>Explain the role and the correct use of each therapy, including risks and benefits.</li>
<li>Demonstrate the technique and how much of various topical agents to apply (e.g., emollients, sealers, medications).</li>
<li>Reinforce the need to use emollients frequently and liberally.</li>
<li>Explain the factors that need to be taken into account to decide whether to prescribe</li>
</ul>
<p>topical corticosteroids, topical calcineurin inhibitors, and other systemic therapies:</p>
<ul>
<li>
<p>Patient's age</p>
</li>
<li>
<p>Site to be treated</p>
</li>
<li>
<p>Previous response to other therapies</p>
</li>
<li>
<p>Extent/severity of disease</p>
</li>
<li>
<p>Explain how skin infection (bacterial or viral) can cause deterioration in condition, and teach the signs and symptoms of skin infection.</p>
</li>
<li>
<p>Provide written recommendations with step care moving up and down regarding all therapies including bathing and/or showering.</p>
</li>
<li>
<p>Include written instructions for prescription as well as over-the-counter products.</p>
</li>
<li>
<p>Distribute patient-education brochures.</p>
</li>
<li>
<p>Recommend individualized environmental measures to avoid skin irritants and proven allergens.</p>
</li>
<li>
<p>Recommend psychosocial support as appropriate.</p>
</li>
</ul>
<p>Adapted from Nicol, N. H. (2005a). Atopic triad: Atopic dermatitis, allergic rhinitis and asthma. American Journal for Nurse Practitioners, (Suppl), 36–40; Nicol, N. H. (2005b). Use of moisturizers in dermatologic disease: The role of healthcare providers in optimizing treatment outcomes. Cutis, 76(Suppl 6), 26–31; Nicol, N. H., &amp; Ersser, S. J. (2010). The role of the nurse educator in managing atopic dermatitis. In M. Boguniewicz (Ed.), Immunology and allergy clinics of North America: Atopic dermatitis (pp. 369–383). Philadelphia, PA: Saunders-Elsevier.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="box-9-3-basic-principles-of-skin-care-for-patients-with-dermatitis-or-eczema">BOX 9-3. Basic Principles of Skin Care for Patients with Dermatitis or Eczema<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#box-9-3-basic-principles-of-skin-care-for-patients-with-dermatitis-or-eczema" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>Intact and healthy skin is the body’s first line of defense. Hydration and moisturization will prevent the breakdown of the skin. “Soak and Seal” is the cornerstone to good daily skin care.</p>
<ol>
<li>Soak by taking at least one bath or shower per day; use warm water, for 10 to 15 minutes.</li>
<li>Use a gentle cleansing bar or wash in the sensitive skin formulation (fragrance-free, dye-free) as needed.</li>
<li>Seal by patting away excess water and immediately (within 3 minutes) apply moisturizer (fragrance-free moisturizers available in one pound jars or large tubes including Aquaphor ointment, Vaniply ointment, Eucerin Creme (various formulations), Vanicream, CeraVe cream, or Cetaphil cream). Vaseline is a good occlusive preparation to seal in but is most effective after bath or shower. Topical maintenance medications may be used in place of moisturizers or sealer when prescribed.</li>
<li>Use moisturizers liberally throughout the day. Moisturizers and sealers should not be applied immediately over any topical medication.</li>
<li>Avoid skin irritants and proven/clinically relevant allergens.</li>
</ol>
<p>Adapted from Nicol, N. H., &amp; Boguniewicz, M. (2008). Successful strategies in AD management. Dermatology Nursing, (Suppl), 3–19.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="box-9-4-tips-for-patients-with-dermatitis-or-eczema-to-reduce-skin-irritation">BOX 9-4. Tips for Patients with Dermatitis or Eczema to Reduce Skin Irritation<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#box-9-4-tips-for-patients-with-dermatitis-or-eczema-to-reduce-skin-irritation" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<ul>
<li>Recognize that skin sensitivity varies among people and according to their health status.</li>
<li>Avoid skin irritants and proven/clinically relevant allergens.</li>
<li>Learn to read product labels carefully and critically.</li>
<li>Use fragrance-free, dye-free products whenever possible. Recognize that even products labeled as for sensitive skin may have a masking or regular fragrance.</li>
<li>Add a second rinse cycle to ensure removal of detergent. Changing to a liquid and fragrance-free, dye-free detergent may be helpful.</li>
<li>Wear garments that allow air to pass freely to your skin. Open weave, loose-fitting, cotton-blend clothing may be most comfortable.</li>
<li>Work and sleep in comfortable surroundings with a fairly constant temperature and humidity level. Humidifiers remain controversial and should be used with great caution and cleaned very routinely when used.</li>
<li>Keep fingernails very short and smooth to help prevent damage due to scratching.</li>
<li>Carry a small tube of moisturizer/sunscreen at all times. Daycare/school/work should have a separate supply of moisturizer.</li>
<li>After swimming in chlorinated pool or using hot tub, shower or bathe using a gentle cleanser to remove chemicals and then apply moisturizer.</li>
</ul>
<p>Adapted from Nicol, N. H., &amp; Boguniewicz, M. (2008). Successful strategies in AD management. <em>Dermatology Nursing</em>, (Suppl), 3–19.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="iii-resources-for-all-types-of-dermatitis-and-eczema-box-9-5">III. RESOURCES FOR ALL TYPES OF DERMATITIS AND ECZEMA (BOX 9-5)<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#iii-resources-for-all-types-of-dermatitis-and-eczema-box-9-5" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="box-9-5-dermatitis-eczema-resources-and-patient-education">BOX 9-5. Dermatitis/Eczema Resources and Patient Education<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#box-9-5-dermatitis-eczema-resources-and-patient-education" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>American Academy of Dermatology</p>
<p><a href="http://www.aad.org" target="_blank" rel="noopener noreferrer">www.aad.org</a></p>
<p>American Academy of Allergy, Asthma, and Immunology</p>
<p><a href="http://www.aaaai.org" target="_blank" rel="noopener noreferrer">www.aaaai.org</a></p>
<p>American Cancer Society</p>
<p><a href="http://www.cancer.org" target="_blank" rel="noopener noreferrer">www.cancer.org</a></p>
<p>American College of Allergy, Asthma, and Immunology</p>
<p><a href="http://www.acaai.org" target="_blank" rel="noopener noreferrer">www.acaai.org</a>
American Skin Association
<a href="http://www.americanskin.org" target="_blank" rel="noopener noreferrer">www.americanskin.org</a>
Centers for Disease Control and Prevention
<a href="http://www.cdc.gov" target="_blank" rel="noopener noreferrer">www.cdc.gov</a>
Food Allergy and Anaphylaxis Network
<a href="http://www.foodallergy.org" target="_blank" rel="noopener noreferrer">www.foodallergy.org</a>
National Eczema Association
<a href="http://www.nationaleczema.org" target="_blank" rel="noopener noreferrer">www.nationaleczema.org</a>
National Eczema Society in the United Kingdom
<a href="http://www.eczema.org" target="_blank" rel="noopener noreferrer">www.eczema.org</a>
National Psoriasis Foundation
<a href="http://www.psoriasis.org" target="_blank" rel="noopener noreferrer">www.psoriasis.org</a>
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
<a href="http://www.niams.nih.gov" target="_blank" rel="noopener noreferrer">www.niams.nih.gov</a>
The Skin Cancer Foundation
<a href="http://www.skincancer.org" target="_blank" rel="noopener noreferrer">www.skincancer.org</a></p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="atopic-dermatitis">ATOPIC DERMATITIS<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#atopic-dermatitis" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="i-overview">I. OVERVIEW<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#i-overview" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h3 level="3" id="a-definition">A. Definition<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#a-definition" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h3></div>
<ol>
<li>AD is the most common chronic, relapsing inflammatory skin disease of children and is a global health problem.</li>
<li>The disorder leads to pruritus and disruption of the skin surface.</li>
<li>The disease is usually associated with a personal or family history of asthma, allergic rhinitis, or eczema.</li>
</ol>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h3 level="3" id="b-etiology">B. Etiology<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#b-etiology" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h3></div>
<ol>
<li>The exact pathogenesis is unknown.</li>
<li>Commonly, there is a family history of AD, asthma, and/or allergic rhinitis and/or food allergy.</li>
<li>Precipitating factors in AD.
a. Genetic predisposition
b. Age
c. Emotional stress</li>
</ol>
<p>d. Lifestyle
e. Irritants including course clothing such as wool and some synthetic fabrics, sweating, drying cleansers, cosmetics, or other topical preparations</p>
<p>f. Climate and extremes in temperature and humidity: hot/humid or cold/dry</p>
<p>g. Proven and clinically relevant environmental allergens (e.g., dust mite, cat, contact allergens including chemicals)</p>
<p>h. Proven and clinically relevant food allergens (e.g., milk, soy, egg, wheat, fish, and nuts)</p>
<p>C. Pathogenesis</p>
<ol>
<li>Skin barrier abnormalities.</li>
<li>T-cell activation.</li>
<li>Th1/Th2 cytokine imbalance.</li>
<li>Increased IgE production.</li>
<li>Staphylococcal aureus and staphylococcal toxins trigger several processes.</li>
</ol>
<p>D. Incidence</p>
<ol>
<li>The prevalence has increased to at least 20% in children and approximately 3% of adults in the United States and other industrialized countries.</li>
<li>Fifty percent of patients with AD go on to develop respiratory manifestations of asthma or allergic rhinitis.
a. Onset of clinical manifestations before 5 years of age in almost 90% of cases
b. Almost 75% of all cases clear by adolescence but can reoccur in adults.</li>
</ol>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="ii-assessment">II. ASSESSMENT<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#ii-assessment" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>A. Clinical manifestations</p>
<ol>
<li>
<p>Characterized by basic diagnostic criteria: patient must have three or more basic features (a to d) listed below.
a. Pruritus
b. Typical morphology and distribution:
(1) Facial and extensor involvement in infants and children. In infants and young children with AD, involvement is commonly present on the scalp, face (cheeks and chin), and extensor surfaces of the extremities (Figures 9-2 and 9-3). Tends to be symmetrical. Is more pronounced in areas not covered by clothing. Diaper area is generally clear in infants.
(2) Flexural lichenification in adults. Older children and adults typically have involvement of the flexor surfaces (antecubital and popliteal fossa), neck, wrists, and ankles (Figures 9-4 and 9-5). In adults, the hands and feet frequently are involved. The flexor surfaces tend to have greater involvement in older patients.
c. Chronic or chronically relapsing dermatitis
d. Personal or family history of atopy (asthma, allergic rhinitis, AD)</p>
</li>
<li>
<p>Other common skin features associated with AD are listed in Box 9-6.</p>
</li>
<li>
<p>Severity ranges from mild to severe and tends to wax and wane with seasonal variation in select patients, often worsening in the winter due increased dryness.</p>
</li>
<li>
<p>Primary lesions.
a. Some believe no primary lesion can be identified and that all visible skin lesions in AD are secondary to scratching.
b. Erythematous papules that may coalesce or dry scaly patches</p>
</li>
<li>
<p>Secondary lesions.
a. Scale
b. Excoriations
c. Lichenification
d. White dermatographism</p>
</li>
<li>
<p>Complications.
a. Secondary bacterial infection usually caused by S. aureus
b. Eczema herpeticum as well as other viral and fungal infections including molluscum and tinea</p>
</li>
</ol>
<p>B. Differential diagnoses</p>
<ol>
<li>Allergic contact dermatitis</li>
<li>Immunodeficiency</li>
<li>Irritant contact dermatitis</li>
<li>Lichen simplex chronicus</li>
<li>Mollusca contagiosa with dermatitis</li>
<li>Mycosis fungoides (cutaneous T-cell lymphoma)</li>
<li>Nummular dermatitis</li>
<li>Plaque psoriasis</li>
<li>Relative zinc deficiency</li>
<li>Scabies</li>
<li>Seborrheic dermatitis</li>
<li>Tinea corporis</li>
</ol>
<p>C. Diagnostic tests</p>
<ol>
<li>Serum IgE tests are frequently elevated but are not helpful diagnostically.</li>
<li>Allergy testing when allergies are suspected. Prick skin testing, patch testing, and in vitro testing can be useful in assessing triggers. Clinical correlation with allergy results and patient's exposure to these triggers are necessary prior to any restrictions.</li>
<li>Skin cultures and sensitivities in cases of suspected secondary infection.</li>
</ol>
<p><img src="assets/images/image-20251225-c4b285df.jpeg" alt="img-48.jpeg"></p>
<p><img src="assets/images/image-20251225-ba5b509d.jpeg" alt="img-49.jpeg">
FIGURE 9-2. Distribution of infant atopic dermatitis occurs primarily on the face and scalp and extensor surfaces of the extremities. Diaper areas are usually clear. (From Nettina, S. M. (2009). Lippincott manual of nursing practice (9th ed.). Philadelphia, PA: Wolters Kluwer.)</p>
<p><img src="assets/images/image-20251225-9bb1a53d.jpeg" alt="img-50.jpeg">
A</p>
<p><img src="assets/images/image-20251225-8801f935.jpeg" alt="img-51.jpeg">
B
FIGURE 9-3. Infantile atopic dermatitis of the head (A) and of the limbs (B). (Courtesy of Schering.)</p>
<p><img src="assets/images/image-20251225-528ee12d.jpeg" alt="img-52.jpeg">
FIGURE 9-4. Distribution of atopic dermatitis in older children and adults typically has involvement of the flexor surfaces (antecubital and popliteal fossa), neck, wrists, and ankles. (Courtesy of Noreen Heer Nicol, PhD, RN.)</p>
<p><img src="assets/images/image-20251225-90921b8a.jpeg" alt="img-53.jpeg">
FIGURE 9-5. Atopic dermatitis of antecubital fossae with lichenification. (From Goodheart, H. P. (2010). Goodheart's same-site differential diagnosis: A rapid method of diagnosing and treating common skin disorders. Philadelphia, PA: Wolters Kluwer.)</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="box-9-6-skin-features-associated-with-atopic-dermatitis">BOX 9-6. Skin Features Associated with Atopic Dermatitis<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#box-9-6-skin-features-associated-with-atopic-dermatitis" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<ul>
<li>Atopic pleat (Dennie-Morgan fold)—extra fold of skin that develops under the eye</li>
<li>Cheilitis—inflammation of the skin on and around the lips
Hyperlinear palms—increased number of skin creases on the palms</li>
<li>Hyperpigmented eyelids—eyelids that have become darker in color from inflammation or hay fever</li>
<li>Ichthyosis—dry, rectangular scales on the skin</li>
<li>Keratosis pilaris—small, rough bumps, generally on the face, upper arms, and thighs</li>
<li>Lichenification—thick, leathery skin resulting from constant scratching and rubbing</li>
<li>Papules—small raised bumps that may open when scratched and become crusty and infected</li>
<li>Urticaria—hives (red, raised bumps) that may occur after exposure to an allergen, at the beginning of flares, or after exercise or a hot bath</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="iii-common-therapeutic-modalities">III. COMMON THERAPEUTIC MODALITIES<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#iii-common-therapeutic-modalities" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="a-treatment">A. Treatment<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#a-treatment" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<ol>
<li>Interventions: see Atopic Dermatitis Action Plan (Box 9-7).</li>
</ol>
<p>a. Relief of xerosis: soak and seal</p>
<p>(1) Soak by taking a bath or shower at least once per day. Use warm, not hot, water for 15 to 20 minutes. Avoid scrubbing skin with a washcloth. Bath time should be relaxing and enjoyable for children and adults alike (Figure 9-6).</p>
<p>(2) Use a gentle cleansing bar or wash such as Dove, Oil of Olay, Eucerin, Basis, Cetaphil, or Aveeno. During a severe flare, limit the use of cleansers to avoid possible irritation. Gentle cleansers are generally perfume-free and dye-free.</p>
<p>(3) Seal by patting gently away excess water after the bath or shower and immediately applying the moisturizer or the special skin medications prescribed onto damp skin. This will seal in the water and make the skin less dry and itchy. Moisturizers should not be applied over the medications. Vaseline is a good occlusive preparation to seal in the water; however, it contains no water, so it only works effectively after a soaking bath. Recommended moisturizers include Aquaphor Ointment, Eucerin Creme, Vanicream, Cetaphil Cream, CeraVe Cream, or Aveeno Cream (Figure 9-7).</p>
<p>(4) Wet wrap therapy twice a day when severe or overnight to treat moderate-to-severe AD with multiple excoriations, crusting, and weeping lesions (Box 9-8, Figure 9-8).</p>
<p>(a) Wet one pair of cotton sleepers, pajamas, or long underwear in warm water, wring out until damp, and put on immediately after applying topical medications.</p>
<p>(b) Special layering when facial wraps required.</p>
<p>(c) Place a dry layer on top of the damp ones.</p>
<p>(d) Not to be used as preventive or maintenance therapy.</p>
<p>(e) To be used in conjunction with prescribed topical medications as well as moisturizers.</p>
<p>b. Decrease inflammation</p>
<p>(1) Mild-to-moderate strength topical corticosteroids or topical calcineurin inhibitors twice a day as needed. The two topical calcineurin inhibitors drugs, tacrolimus (Protopic) ointment and pimecrolimus (Elidel) cream, are effective in both adults and children without the common side effects of topical steroids such as thinning of the skin and increased skin infections.</p>
<p>(2) Some patients with AD are sensitive to the ingredients of topical preparations both over the counter or prescription. Cream or ointment vehicles may be used on face and body with a lotion vehicle to scalp.</p>
<p>(3) Wet wrap therapy may be used with topical corticosteroids in moderate-to-severe AD. They are not to be used as maintenance therapy.</p>
<p>(4) Systemic corticosteroids are likely used too frequently in the treatment of this chronic condition of AD with significant potential of side effects and rebound flaring.</p>
<p>c. Relief of pruritus</p>
<p>(1) Sedating antihistamines such as diphenhydramine (3 to 5 mg/kg/d) or hydroxyzine (1 to 2 mg/kg/d) may help to relieve pruritus.</p>
<p>(2) Use sedating antihistamines at bedtime to decrease itching and to promote more restful sleep.</p>
<p>(3) The relatively low-sedating antihistamine cetirizine may be used to provide relief from pruritus in children as young as 6 months of age during the daytime. The role of nonsedating antihistamines in the treatment of AD remains unclear.</p>
<p>d. Treatment of infections</p>
<p>(1) Topical antibiotic—mupirocin 2% ointment may be applied three times a day to small areas of impetigo. Use three times per day until clearing; never use PRN.</p>
<p>(2) For more widespread infection, use an antistaphylococcal oral antibiotic (e.g., cephalexin 25 to 50 mg/kg/d).</p>
<p>e. Environmental control</p>
<p>(1) Decrease exposure to predisposing factors, which have been evaluated and agreed to by treatment team.</p>
<p>(2) Avoid exposure to anyone with active herpes lesions.</p>
<p>B. Follow-up</p>
<ol>
<li>
<p>First follow-up visit in 7 to 14 days to assess treatment effectiveness with patients who have moderate-to-severe disease.</p>
</li>
<li>
<p>Monthly visits until the patient is using primarily moisturizers.</p>
</li>
<li>
<p>When skin condition is stable, visits every 6 months for re-evaluation.</p>
</li>
<li>
<p>As needed for flairs and failure to respond to treatment.</p>
</li>
<li>
<p>AD is usually a long-term condition. Patients may need many repeated treatments before the symptoms go away. And they may return later.</p>
</li>
</ol>
<p><img src="assets/images/image-20251225-d50387de.jpeg" alt="img-54.jpeg">
FIGURE 9-6. Soak in warm water for 15 to 20 minutes. (Courtesy of Noreen Heer Nicol, PhD, RN.)</p>
<p><img src="assets/images/image-20251225-000f7c47.jpeg" alt="img-55.jpeg">
FIGURE 9-7. Seal with appropriate topicals and moisturizers immediately after bathing. (Courtesy of Noreen Heer Nicol, PhD, RN.)</p>
<p><img src="assets/images/image-20251225-ab63ea18.jpeg" alt="img-56.jpeg">
FIGURE 9-8. Wet wrap therapy in atopic dermatitis and play therapy. (Courtesy of Noreen Heer Nicol, PhD, RN, and Barry Silverstein.)</p>
<p><img src="assets/images/image-20251225-8a71c26c.jpeg" alt="img-57.jpeg"></p>
<p><img src="assets/images/image-20251225-bcb6241b.jpeg" alt="img-58.jpeg"></p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="box-9-7-atopic-dermatitis-action-plan">BOX 9-7. Atopic Dermatitis Action Plan<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#box-9-7-atopic-dermatitis-action-plan" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="basic-or-daily-care-for-patient-with-atopic-dermatitis-soak-and-seal">Basic or Daily Care for Patient with Atopic Dermatitis: "Soak and Seal"<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#basic-or-daily-care-for-patient-with-atopic-dermatitis-soak-and-seal" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<ol>
<li>Soak by taking at least one bath or shower per day; use warm water, for 10 to 15 minutes.</li>
<li>Use a gentle cleansing bar or wash in the sensitive skin formulation (fragrance-free, dye-free) as needed.</li>
<li>Seal by patting away excess water and immediately (within 3 minutes) apply moisturizer (fragrance-free moisturizers available in one pound jars or large tubes. Moisturizers include Aquaphor ointment, Vaniply ointment, Eucerin Creme (various formulations), Vanicream, CeraVe cream or Cetaphil cream). A sealer (Vaseline is a good occlusive preparation to seal in and is most effective after bath or shower), or maintenance medication if directed. Use moisturizers liberally throughout the day. Moisturizers and sealers should not be applied immediately over any topical medication.</li>
<li>Avoid skin irritants and proven/clinically relevant allergens.</li>
</ol>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="mild-to-moderate-atopic-dermatitis">Mild-to-moderate atopic dermatitis<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#mild-to-moderate-atopic-dermatitis" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<ol>
<li>Bathe as above for 10 to 15 minutes in comfortably warm water, one to two times a day.</li>
<li>Use a gentle cleansing bar or wash in the sensitive skin formulation as needed.</li>
<li>Use moisturizers as above to healed and unaffected skin, twice daily especially after baths and at midday total body.</li>
<li>Apply to affected areas of the face, groin, and underarms twice daily especially after baths (low-potency topical corticosteroid), or (topical calcineurin inhibitor), or other topical preparation as directed.</li>
<li>Apply to other affected areas of the body twice daily especially after baths (low- to midpotency topical corticosteroid), or (topical calcineurin inhibitors), or other topical preparation as directed.</li>
<li>Other medications as directed: (e.g., oral sedating antihistamines, topical or oral antimicrobial therapy)</li>
<li>Pay close attention to things that seem to irritate the skin or make condition worse.</li>
</ol>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="moderate-to-severe-atopic-dermatitis">Moderate-to-severe atopic dermatitis<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#moderate-to-severe-atopic-dermatitis" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<ol>
<li>
<p>Bathe as above for 10 to 15 minutes in comfortably warm water, two times a day, in the morning and before bedtime. Your health care provider may recommend dilute bleach baths.</p>
</li>
<li>
<p>Use a gentle cleansing bar or wash in the sensitive skin formulation as needed. May consider an antibacterial cleanser.</p>
</li>
<li>
<p>Use moisturizers as above to healed and unaffected skin, twice daily especially after baths and at midday total body.</p>
</li>
<li>
<p>Apply to affected areas of the face, groin, and underarms twice daily especially after baths (low-potency topical corticosteroid), or (topical calcineurin inhibitors), or other topical preparation as directed.</p>
</li>
<li>
<p>Apply to other affected areas of the body twice daily especially after baths (mid- to high-potency topical corticosteroid), or (topical calcineurin inhibitor), or other topical preparation as directed.</p>
</li>
<li>
<p>Use wet wraps to involved areas selectively as directed per policy and procedure. Wet wraps are left in place at a minimum of 2 hours. If left in place, need to be rewet every 2 to 3 hours. In general, wet wraps should be removed after 4 hours. If patient falls asleep with wet wraps in place, they may be left on overnight. Stop rewetting during the night. Apply moisturizer to total body after wet wraps are removed.</p>
</li>
<li>
<p>Add other medications as directed: (e.g., oral sedating antihistamines, topical or oral antimicrobial therapy).</p>
</li>
<li>
<p>Pay close attention to things that irritate skin or make condition worse.</p>
</li>
<li>
<p>Step down to moderate plan as above as the skin heals.</p>
</li>
</ol>
<p>Adapted from Nicol, N. H., &amp; Boguniewicz, M. (2008). Successful strategies in AD management. Dermatology Nursing, (Suppl), 3-19. This may be modified and used for patient care citing National Jewish Health Atopic Dermatitis Program as source.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="box-9-8-wet-wrap-therapy-procedure">BOX 9-8. Wet Wrap Therapy Procedure<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#box-9-8-wet-wrap-therapy-procedure" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<ul>
<li>Wet wrap therapy is to be used to relieve inflammation, itching, and burning of atopic dermatitis.</li>
<li>Wet wraps facilitate the removal of scale and increase penetration of topical medications in the stratum corneum.</li>
<li>Skin protection provided by the wraps allows healing to take place and cooling of the skin.</li>
<li>Wet wrap therapy should only be used during flares of atopic dermatitis under the supervision of a health care provider. They should not be used as routine maintenance therapy.</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="supplies">Supplies:<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#supplies" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<ol>
<li>Topical medications and moisturizers</li>
<li>Tap water at comfortably warm temperature</li>
<li>Basin for dampening of dressings</li>
<li>Clean dressings of approximate size to cover involved area</li>
</ol>
<ul>
<li>a. Face: 2 to 3 layers of wet Kerlix gauze held in place with SurgiNet.</li>
<li>b. Arms, legs, hands, and feet: 2 to 3 layers of wet Kerlix gauze held in place with Ace bandages or tube socks, or cotton gloves, or wet tube socks followed by dry tube socks. Tube socks may be used for wraps for hands and feet, and larger ones work as leg/arm covers.</li>
<li>c. Total body: Combination of above or wet pajamas or long underwear and turtleneck</li>
</ul>
<p>shirts covered by dry pajamas or sweat suit. Pajamas with feet work well for the outer layer.</p>
<ol start="5">
<li>Blankets to prevent chilling</li>
<li>Nonsterile gloves if desired</li>
</ol>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="procedure">Procedure<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#procedure" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<ol>
<li>Be certain that the patient's room is warm and insure privacy. Gather supplies appropriate to the individual.</li>
<li>If wraps are to be applied to a large portion of the body, work with two people if possible. It is necessary to work rapidly to prevent chilling.</li>
<li>Explain the procedure to the patient and parent.</li>
<li>Fill the basin with warm tap water.</li>
<li>The patient will have had a 15- to 20-minute soaking bath, in warm water without additional additives, prior to this procedure. Pat skin dry with a towel.</li>
<li>Apply the appropriate topical medications to the affected areas and moisturizer to the nonaffected areas immediately after pat drying the skin. Use clean plastic spoons or tongue depressor to avoid contamination of products in jars. This allows large areas to be covered quickly and prevent caregivers from unnecessary exposure to topical medications.</li>
<li>Soak the dressings in very warm water, as they cool quickly in this process. Squeeze out excess water. Dressings should be wet, not dripping.</li>
<li>Cover an area with wet dressing chosen for the area and the patient. Immediately after wrapping, cover with appropriate dry material such as an Ace bandage, socks, or pajamas. Start at the feet and move upward. Use wet, long underwear or wet pajamas covered by dry pajamas or sweat suit with total body involvement in place of wet gauze.</li>
<li>Take steps to avoid chilling. Blanket can be put in a dryer to warm up and cover patient but do not overheat the patient. Wraps can be removed after 2 to 4 hours or can be rewet. A warm blanket and snuggling help pass the time.</li>
<li>If the patient is known or suspected to have an infection of the involved areas, place dressings in the appropriate bag and dispose according to the infection control procedure.</li>
<li>After all dressings are removed, moisturizers may be applied to the entire body.</li>
</ol>
<p>Adapted from Nicol, N. H. (1987). Atopic dermatitis: The (wet) wrap-up. American Journal of Nursing, 87(12), 1560–1563; Nicol, N. H., &amp; Boguniewicz, M. (2008). Successful strategies in AD management. Dermatology Nursing, (Suppl), 3–19; Nicol, N. H., Boguniewicz, M., Strand, M., &amp; Klinnert, M. D. (2014). Wet wrap therapy in children with moderate to severe atopic dermatitis in a multidisciplinary treatment program. Journal of Allergy and Clinical Immunology: In Practice, 2(4), 400–406. This may be modified and used for patient care citing National Jewish Health Atopic Dermatitis Program as source.</p>
<p>PATIENT EDUCATION</p>
<p>Atopic Dermatitis (SEE BOX 9-2,9-3, 9-4,9-5, and 9-7)</p>
<ul>
<li>Methods of skin hydration</li>
<li>Address itch-stratch cycle</li>
<li>Proper methods of application and amounts of medications</li>
<li>Signs of skin infection</li>
<li>Ways to incorporate treatments into daily routines</li>
<li>Sources of psychosocial support</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="seborrheic-dermatitis">SEBORRHEIC DERMATITIS<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#seborrheic-dermatitis" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="i-overview">I. OVERVIEW<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#i-overview" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h3 level="3" id="a-definition">A. Definition<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#a-definition" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h3></div>
<ol>
<li>Common chronic dermatitis occurring primarily in areas of increased sebaceous gland concentration resulting in a papulosquamous disorder</li>
<li>Occurs in multiple age groups—the infant, the adolescent, and the adult</li>
</ol>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h3 level="3" id="b-etiology">B. Etiology<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#b-etiology" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h3></div>
<ol>
<li>The exact pathogenesis is unknown.</li>
<li>Several factors are associated with the condition including hormonal levels, fungal infections, and nutritional deficits.</li>
<li>Occasionally, it may be associated with serious illness and failure to thrive. Rarely, it is an early sign of HIV or other immunodeficiency diseases.</li>
<li>Stress can cause flare-ups.</li>
</ol>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h3 level="3" id="c-pathogenesis">C. Pathogenesis<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#c-pathogenesis" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h3></div>
<ol>
<li>Pathology has been attributed to excessive sebum accumulation on skin surface, but the mechanism for this remains unclear.</li>
<li>Occurrence in the neonate is believed to be related to intrauterine exposure to maternal hormones.</li>
<li>Occurrence may be linked to a type of yeast, Malassezia furfur. While there are normal levels, there is an abnormal immune response.</li>
<li>Immunologic abnormalities linked to T-cell depression and activation of the alternative complement pathway</li>
</ol>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h3 level="3" id="d-incidence">D. Incidence<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#d-incidence" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h3></div>
<ol>
<li>
<p>The incidence in the general population is 2% to 5%.</p>
</li>
<li>
<p>In infants, it tends to regress by 5 to 6 months of age (Figure 9-9).</p>
</li>
<li>
<p>In adolescents and adults, it may improve with age and tends to wax and wane. Most common in adults 30 to 60 years of age (Figure 9-10)</p>
</li>
</ol>
<p><img src="assets/images/image-20251225-55153a57.jpeg" alt="img-59.jpeg">
FIGURE 9-9. Severe seborrheic dermatitis with thick, waxy, yellow scale and underlying erythema in an infant. (From Burkhart, C., Morrell, D., Goldsmith, L. A., Papier, A., Green, B., Dasher, D., &amp; Gomathy, S. (2009). VisualDx: Essential pediatric dermatology. Philadelphia, PA: Wolters Kluwer.)</p>
<p><img src="assets/images/image-20251225-31bc8f57.jpeg" alt="img-60.jpeg">
FIGURE 9-10. Seborrheic dermatitis on an adult face. (From Engleberg, N. C., Dermody, T., &amp; DiRita, V. (2012). Schaechter's mechanisms of microbial disease. Philadelphia, PA: Wolters Kluwer.)</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="ii-assessment">II. ASSESSMENT<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#ii-assessment" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>A. Clinical manifestations</p>
<ol>
<li>Minimal to no pruritus in infancy. Adolescents or adults may complain of pruritus.</li>
<li>Lesions are symmetric and typically red with greasy yellow to salmon-colored scale.</li>
<li>Areas of involvement are primarily the scalp, medial eyebrows, central face, retroauricular area, presternal area, or perineum. Seborrheic dermatitis can also affect oily areas of the body, such as the upper chest and back.</li>
<li>Varies from minimal to widespread involvement</li>
<li>Primary lesions—erythematous papules/patches, poorly marginated</li>
<li>Secondary lesions—greasy scale, excoriations if pruritic</li>
</ol>
<p>B. Differential diagnoses</p>
<ol>
<li>Allergic contact dermatitis</li>
<li>Atopic dermatitis</li>
<li>Cutaneous candidiasis</li>
<li>Discoid lupus erythematosus, rare in children</li>
<li>Drug eruptions</li>
<li>Irritant contact dermatitis</li>
<li>Nummular dermatitis</li>
<li>Perioral dermatitis</li>
<li>Pityriasis rosea</li>
<li>Psoriasis</li>
<li>Rosacea, rare under the age of 25</li>
<li>Systemic lupus erythematosus, rare in children</li>
<li>Tinea infections</li>
</ol>
<p>C. Diagnostic tests</p>
<ol>
<li>Usually diagnosed by physical examination, unless another severe systemic disease is suspected</li>
<li>Fungal, viral, and bacterial cultures, as appropriate</li>
<li>Skin biopsy with disease unresponsive to treatment</li>
</ol>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="iii-common-therapeutic-modalities">III. COMMON THERAPEUTIC MODALITIES<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#iii-common-therapeutic-modalities" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>A. Treatment</p>
<ol>
<li>Low-potency topical corticosteroid creams or topical calcineurin inhibitors applied twice daily for several days will usually clear the dermatitis and then used occasionally will control recurrences.</li>
<li>Frequently in infants, tear-free shampoos are adequate to loosen the scales when allowed to remain on the scalp for several minutes and lightly scrubbed with a soft brush to remove the scale. In more difficult cases, scale may be loosened with mineral oil prior to shampooing.</li>
<li>Keratolytic/antiseborrheic or ketoconazole (Nizoral) shampoos may be helpful for adolescents and adults to control scalp scaling.</li>
</ol>
<p>B. Follow-up</p>
<ol>
<li>One-week visit to evaluate response, if appropriate</li>
<li>Thereafter, the patient is seen only if the dermatitis does not resolve.</li>
<li>Seborrheic dermatitis is usually a long-term condition. Patients may need many repeated treatments before the symptoms go away. And they may return later.</li>
</ol>
<p><img src="assets/images/image-20251225-099a48f6.jpeg" alt="img-61.jpeg"></p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="patient-education">PATIENT EDUCATION<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#patient-education" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h3 level="3" id="seborrheic-dermatitis">Seborrheic Dermatitis<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#seborrheic-dermatitis" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h3></div>
<ul>
<li>
<p>For infants and children with cradle cap</p>
</li>
<li>
<p>Apply baby oil to soften the scale and gently comb out.</p>
</li>
<li>
<p>Follow by shampooing with a mild baby shampoo and longer lathering to gently remove the scale.</p>
</li>
<li>
<p>Use of an antiseborrheic dermatitis shampoo when milder shampoos are ineffective</p>
</li>
<li>
<p>Use prescribed hydrocortisone or an antiyeast cream to areas outside scalp as recommended.</p>
</li>
<li>
<p>For adults</p>
</li>
<li>
<p>Use of an antiseborrheic dermatitis shampoo containing coal tar, selenium sulfide, or zinc pyrithione on a more frequent basis and longer lathering. Brand names include Selsun Blue, Head &amp; Shoulders, and DHS zinc.</p>
</li>
<li>
<p>Use prescribed hydrocortisone or an antiyeast cream to areas outside scalp as recommended.</p>
</li>
<li>
<p>Discontinue use of hairsprays and hair pomades with active scalp involvement.</p>
</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="contact-dermatitis">CONTACT DERMATITIS<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#contact-dermatitis" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h3 level="3" id="i-overview">I. OVERVIEW<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#i-overview" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h3></div>
<p>A. Definition</p>
<ol>
<li>Contact dermatitis can be defined and divided on the basis of etiology into two types: irritant contact dermatitis (ICD) and allergic contact dermatitis (ACD).</li>
</ol>
<p>B. Etiology</p>
<ol>
<li>Irritant nonallergic contact dermatitis results from direct contact with an irritating substance. Possible irritants are numerous, for example, oil products such as fuels and lubricants, corrosives, detergents, bleaches, ammonia, oven cleaners, ingredients in</li>
</ol>
<p>common skin products, and even water or frequent wetting and drying of skin (Figure 9-11).</p>
<ol start="2">
<li>ACD affects a limited number of susceptible individuals and is a manifestation of a sensitivity to a substance to which the patient has had previous contact. Possible allergens are many; common examples include fragrances, dyes, nickel, antibiotic ointments or creams, rubber-containing products, formaldehyde, and poison ivy/oak (Figure 9-12).</li>
</ol>
<p>C. Pathogenesis</p>
<ol>
<li>
<p>ICD from a local irritant is the most common form of contact dermatitis. The intensity of the inflammation is related to the concentration of the irritant and the exposure time.</p>
</li>
<li>
<p>ACD triggers an immunologic event, which is the result of a type IV delayed hypersensitivity reaction to an allergen.</p>
</li>
</ol>
<p>D. Incidence</p>
<ol>
<li>
<p>Anyone at any time could acquire ICD. Suspect patients working with cleaning agents such as ammonia, bleach, and other wet work and health care workers who work with various lotions, alcohol solutions, and repetitive hand washing and drying. Repeated higher concentrates of chemicals can cause a contact dermatitis. Approximately 80% of contact dermatitis is irritant in nature.</p>
</li>
<li>
<p>Individuals must be sensitized to a chemical to acquire contact allergic dermatitis. Patients initially come in contact with a sensitizing agent and have a reaction upon subsequent exposure to the agent. Approximately 20% of contact dermatitis is allergic in nature. Table 9-1 lists some of the most common allergens known to currently cause ACD.</p>
</li>
</ol>
<p><img src="assets/images/image-20251225-4e810a47.jpeg" alt="img-62.jpeg">
FIGURE 9-11. Irritant contact dermatitis on the hands of a health care worker. (Image provided by Stedman's.)</p>
<p><img src="assets/images/image-20251225-1594e2bd.jpeg" alt="img-63.jpeg"></p>
<p>1</p>
<p>FIGURE 9-12. Allergic contact dermatitis secondary to poison ivy. Erythema and vesicle formation in a linear pattern is characteristic of poison ivy. (Courtesy of Darren Fiore, MD.)</p>
<p>TABLE 9-1 Common Causes of Allergic Contact Dermatitis</p>
<table><thead><tr><th>Agent</th><th>Source</th></tr></thead><tbody><tr><td>Bacitracin</td><td>Topical antibiotic</td></tr><tr><td>Balsam of Peru (Myroxylon pereirae)</td><td>Fragrance used in perfumes and skin lotions, derived from tree resin</td></tr><tr><td>Chromium</td><td>Used in tanning of leather Also a component of uncured cement/mortar, facial cosmetics, and some bar soaps</td></tr><tr><td>Cobalt chloride</td><td>Metal found in medical products; hair dye; antiperspirant; objects plated in metal such as snaps, buttons, or tools; and in cobalt blue pigment</td></tr><tr><td>Colophony (rosin)</td><td>Fosin, sap, or sawdust typically from spruce or fir trees</td></tr><tr><td>Formaldehyde</td><td>Preservative with multiple uses, for example, in paper products, paints, medications, household cleaners, cosmetic products, and fabric finishes</td></tr><tr><td>Fragrance mix</td><td>Group of the eight most common fragrance allergens found in foods, cosmetic products, insecticides, antiseptics, soaps, perfumes, and dental products</td></tr><tr><td>Gold (gold sodium thiosulfate)</td><td>Precious metal often found in jewelry</td></tr><tr><td>Isothiazolinone, methylisothiazolinone, methylchloroisothiazolinone</td><td>Preservatives used in many personal care, including wet wipes, household, and commercial products</td></tr><tr><td>Neomycin sulfate</td><td>Topical antibiotic common in first aid creams and ointments, also found occasionally in cosmetics, deodorant, soap, and pet food</td></tr><tr><td>Nickel (nickel sulfate hexahydrate)</td><td>Metal frequently encountered in jewelry and clasps or buttons on clothing</td></tr><tr><td>Quaternium 15</td><td>Preservative found in cosmetic products such as self-tanners, shampoo, nail polish, and sunscreen or in industrial products such as polishes, paints, and waxes</td></tr><tr><td>Poison ivy, poison oak, and poison sumac</td><td>Plants naturally occurring in many parts of the United States; oily coating from plants of Toxicodendron genus</td></tr><tr><td>Pramoxine, diphenhydramine</td><td>Topical anesthetics, for example, after prolonged use</td></tr><tr><td>Thimerosal</td><td>Mercury compound used in local antiseptics and formerly in vaccines</td></tr></tbody></table>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="ii-assessment">II. ASSESSMENT<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#ii-assessment" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="a-clinical-manifestations">A. Clinical manifestations<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#a-clinical-manifestations" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<ol>
<li>Irritant contact dermatitis</li>
</ol>
<p>a. Can be either acute or chronic. In the acute stage erythema, blister formation, erosion, crusting, shedding, and scaling are seen. The distribution is usually isolated or localized; pruritus is always present.
b. In chronic contact dermatitis, thickening of skin, scaling, fissures, and crusting are present. Distribution is usually isolated or localized.</p>
<ol start="2">
<li>Allergic contact dermatitis</li>
</ol>
<p>a. Can be either acute or chronic. In acute allergic dermatitis erythema, papules, vesicles, erosion, crusts, and scaling are seen. The dermatosis is usually confined to the area of exposure but can spread to peripheral areas.
b. In ACD, the patient has been previously exposed to the allergen. This exposure creates a sensitization phase, which results in antigen formation. The resulting sensitized T cells remain in the body. Re-exposure to the antigen in the elicitation phase results in a cutaneous eczematous inflammation. Although these reactions are usually localized, patients who are sensitized to topical medications may develop generalized</p>
<p>eczematous reactions.</p>
<p>B. History and physical examination</p>
<ol>
<li>History of sensitivity to chemicals or substances</li>
<li>Occupation and history of exposure to, for example, neomycin, procaine, benzocaine, sulfonamides, turpentine, balsam of Peru, formalin, chromate, nickel sulfate, cobalt sulfate, <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi>p</mi></mrow><annotation encoding="application/x-tex">p</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.625em; vertical-align: -0.1944em;"></span><span class="mord mathnormal">p</span></span></span></span></span>-phenylenediamine, and many more.</li>
<li>In an acute exposure, erythema, papules, and edema are present and are usually confined to area of exposure.</li>
<li>In chronic exposure, plaques of lichenification with small, firm, round, or flat-topped papules with mild erythema are present.</li>
</ol>
<p>C. Differential diagnoses</p>
<ol>
<li>Asteatotic eczema</li>
<li>Atopic dermatitis</li>
<li>Contact urticaria syndrome</li>
<li>Drug-induced bullous disorders</li>
<li>Drug-induced photosensitivity</li>
<li>Irritant contact dermatitis</li>
<li>Nummular dermatitis</li>
<li>Perioral dermatitis</li>
<li>Phytophotodermatitis</li>
<li>Psoriasis</li>
<li>Scabies</li>
<li>Seborrheic dermatitis</li>
<li>Tinea infections</li>
<li>Transient acantholytic dermatosis</li>
</ol>
<p>D. Diagnostic tests</p>
<ol>
<li>Patch testing: to help determine the responsible allergen in ACD and is considered the gold standard for testing. The goal of patch testing is to reproduce the eczema in a controlled process. Small amounts of suspected chemical are applied to the skin, and subsequent examination will reveal reaction. This process must be done in a standardized format to be reliable. The product T.R.U.E. TEST® offers standardized easy-to-use patch testing. Patient counseling of results is key in management. (See Chapter 3.)</li>
<li>Potassium hydroxide preparation and/or fungal culture: To exclude tinea, these tests are often indicated for dermatitis of the hands and feet.</li>
<li>Repeat open application testing (ROAT): To determine whether a reaction is significant in individuals who develop weak or <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>1</mn><mo>+</mo></mrow><annotation encoding="application/x-tex">1+</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">1</span><span class="mord">+</span></span></span></span></span> positive reactions to a chemical</li>
<li>Dimethylglyoxime test: To determine whether a metallic object contains enough nickel to provoke allergic dermatitis. These tests are available to patients as well as health care providers (i.e., Nickel Alert and Nickel Solution). They are very helpful for nickel-allergic patients to participate in determining safe products.</li>
<li>Skin biopsy: May help to exclude other disorders, particularly tinea, psoriasis, and cutaneous T-cell lymphoma</li>
</ol>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="iii-common-therapeutic-modalities">III. COMMON THERAPEUTIC MODALITIES<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#iii-common-therapeutic-modalities" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>A. Treatment—See Boxes 9-2, 9-3, 9-4, and 9-5</p>
<ol>
<li>Eliminate the irritant or allergen when possible.</li>
<li>Topical corticosteroids are used carefully to avoid side effects. Consider PUVA (psoralen with ultraviolet A) (See Phototherapy Chapter)</li>
<li>In severe cases, a short course of systemic corticosteroids may be required.</li>
</ol>
<p>B. Follow-up</p>
<ol>
<li>First follow-up visit in 7 to 14 days to assess treatment effectiveness with patients who have moderate-to-severe disease.</li>
<li>Monthly visits until the patient is using primarily moisturizers.</li>
<li>When skin condition is stable, visits every 6 months for re-evaluation.</li>
<li>As needed for flairs and failure to respond to treatment.</li>
<li>Contact dermatitis, especially ICD, is usually a long-term condition. Patients may need many repeated treatments before the symptoms go away. And they may return later.</li>
</ol>
<p><img src="assets/images/image-20251225-0ed9a5aa.jpeg" alt="img-64.jpeg"></p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="patient-education">PATIENT EDUCATION<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#patient-education" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h3 level="3" id="contact-dermatitis">Contact Dermatitis<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#contact-dermatitis" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h3></div>
<ul>
<li>Avoid any proven and clinically relevant irritants and allergens: do not eliminate things unnecessarily and make daily routines impossible.</li>
<li>Be sure to have reliable information and sites for proven irritants and allergens.</li>
<li>Methods of skin hydration and moisturization.</li>
<li>Proper methods of application and amounts of medications.</li>
<li>Avoid any activities that dry, heat, or irritate the skin.</li>
<li>Dress in loose clothing or fabrics that are not irritating to the skin.</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="diaper-dermatitis-or-diaper-rash">DIAPER DERMATITIS OR DIAPER RASH<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#diaper-dermatitis-or-diaper-rash" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="i-overview">I. OVERVIEW<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#i-overview" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>A. Definition</p>
<ol>
<li>An inflammatory cutaneous eruption in the diaper area and one of the leading dermatology disorders that result in childhood dermatology visits. The majority of causes are due to ICD; however, ACD, infection, seborrhea, and psoriasis are other causes.</li>
<li>A number of factors are important in this disease including wetness, friction,</li>
</ol>
<p>inappropriate skin care, microorganisms, antibiotics, and nutritional deficiencies.</p>
<p>B. Etiology and pathogenesis</p>
<ol>
<li>ICD in the diaper area is caused by an interaction between several factors and is the most frequent cause of diaper dermatitis or rash in the diaper area. Generally, this is seen on buttocks, lower abdomen, genitals, and upper thighs. The skin folds are not usually affected. Symptoms can vary from mild redness to extremely red, raised, and peeling (Figure 9-13).</li>
</ol>
<p>a. Frequent and prolonged skin wetness from occlusion and urine and feces trapped close to the skin
b. Friction by movement of the skin against skin, the diaper, plastic leg gathers, or fastening tape.
c. Fecal enzymes causing cutaneous irritation
d. Oral antibiotic medication administrated for other disorders may predispose a child to diarrhea, which irritated and causes the development of diaper dermatitis.</p>
<ol start="2">
<li>ACD in the diaper area is far less common than ICD. Itchy, red raised, or scaly areas are present in the areas of the skin that are in contact with the allergen used in the diaper area (Figure 9-14).</li>
</ol>
<p>a. Reported allergens include dyes, fragrances, preservatives, neomycin, bacitracin, lanolin, paraben, and other allergens.
b. Some baby wipes may contain a preservative, methylisothiazolinone (MI), which may also cause an allergic reaction in certain individuals.</p>
<ol start="3">
<li>Infection</li>
</ol>
<p>a. If there is frequent and prolonged skin wetness for a prolonged number of days, there is likely to be a secondary <em>C. albicans</em> infection (yeast infection). This presents as confluent erythema to dark red with or without satellite papules or lesions. Yeast infections are often found in the skin folds between the thigh and body and in the folds of skin around the genitals (Figure 9-15).
b. Impetigo is a bacterial infection that can develop in the diaper area as well as other areas of the body. It is usually caused by bacteria that normally live on the skin including <em>Staphylococcus aureus</em> and group A streptococci; infection can develop when there is a break in the skin. Signs include tiny (1- to 2-mm) raised yellow fluid-filled areas and honey-colored crusted lesions; the lesions may be itchy and/or painful.
c. Other infections include coxsackievirus, human papillomavirus, herpes simplex virus, scabies, and human immunodeficiency virus.</p>
<ol start="4">
<li>Seborrhea or seborrheic dermatitis</li>
</ol>
<p>a. Seborrhea is a skin condition that causes patches of redness and greasy yellow scaly skin in infants. It is commonly located in the skin folds between the thighs and body and is often found in other areas as well, including the scalp (where it is called "cradle cap"), face, neck, or in other skin folds (e.g., in the armpit, in front of the elbow, behind the knees).
b. Seborrhea is a more common cause of diaper rash/dermatitis.</p>
<ol start="5">
<li>Psoriasis</li>
</ol>
<p>a. Psoriasis is considered a rare cause of diaper rash/dermatitis.
b. Psoriasis symptoms often include reddened and silver scaly patches of skin. In the diaper area, the silver scale may be absent (Figure 9-16).</p>
<ol start="6">
<li>Other causes</li>
</ol>
<p>a. Granuloma gluteale infantum
b. Epidermolysis bullosa
c. Ulcerative hemangioma
d. Infantile granular parakeratosis
e. Langerhans cell histiocytosis
f. Nutritional deficiencies
g. Immune deficiencies</p>
<p>C. Incidence</p>
<ol>
<li>Diaper dermatitis is one of the most frequent skin disorders of infancy, with peak incidence between 9 and 12 months of age. It can start as early as the first week of life.</li>
<li>May occur in any child or adult who is incontinent of urine or stool.</li>
</ol>
<p><img src="assets/images/image-20251225-45b71d4e.jpeg" alt="img-65.jpeg">
FIGURE 9-13. Irritant contact dermatitis. The patient has diaper rash with an eruption conforming to the shape of a diaper. (From Goodheart, H. P. (2003). Goodheart's photoguide of common skin disorders (2nd ed.). Philadelphia, PA: Lippincott Williams &amp; Wilkins.)</p>
<p><img src="assets/images/image-20251225-ede972ce.jpeg" alt="img-66.jpeg">
FIGURE 9-14. Allergic contact dermatitis from nickel in pajama snaps in the diaper area. (Courtesy of Noreen Heer Nicol, PhD, RN.)</p>
<p><img src="assets/images/image-20251225-8b842db7.jpeg" alt="img-67.jpeg">
FIGURE 9-15. Diaper dermatitis due to candidal infection. This bright red rash involves the intertriginous folds, with small "satellite lesions" along the edges. (From Fletcher, M. (1998). Physical diagnosis in neonatology. Philadelphia, PA: Lippincott-Raven Publishers.)</p>
<p><img src="assets/images/image-20251225-1b506ed3.jpeg" alt="img-68.jpeg">
FIGURE 9-16. Psoriasis in the diaper area. These plaques easily could be confused with diaper rash or atopic dermatitis. (From Goodheart, H. P. (2003). Goodheart's photoguide of common skin disorders (2nd ed.). Philadelphia, PA: Lippincott Williams &amp; Wilkins.)</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="ii-assessment">II. ASSESSMENT<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#ii-assessment" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>A. Clinical manifestations (see above with etiology)</p>
<ol>
<li>Erythema with or without papules, erosions, scale, and/or maceration on the lower abdomen, groin, perineum, buttocks, labia majora, scrotum, penis, or upper thigh that initially spares skin creases.</li>
<li>Fragile bulla or erosions with a collarette of scale may indicate bullous impetigo.</li>
</ol>
<p>B. Differential diagnoses</p>
<ol>
<li>
<p>Irritant contact dermatitis</p>
</li>
<li>
<p>Atopic dermatitis</p>
</li>
<li>
<p>Cutaneous candidiasis</p>
</li>
<li>
<p>Drug eruptions</p>
</li>
<li>
<p>Allergic contact dermatitis</p>
</li>
<li>
<p>Tinea and bacterial infections</p>
</li>
<li>
<p>Langerhans cell histiocytosis</p>
</li>
<li>
<p>Nummular dermatitis</p>
</li>
<li>
<p>Psoriasis</p>
</li>
<li>
<p>Scabies</p>
</li>
<li>
<p>Seborrheic dermatitis</p>
</li>
<li>
<p>Others, child abuse</p>
</li>
<li>
<p>Human immunodeficiency virus, very rare in infants and children</p>
</li>
</ol>
<p>C. Diagnostic tests</p>
<ol>
<li>Usually diagnosed by physical examination, unless another severe systemic disease is suspected.</li>
<li>KOH preparation to skin scrapings to identify <em>C. albicans</em> infection.</li>
<li>Bacterial, fungal, and viral culture may be needed to rule out secondary infection.</li>
<li>Skin biopsy may be required in dermatitis that is unresponsive to therapy to rule out other associated problems particularly in older children or adults.</li>
<li>Workup for other systemic diseases as warranted.</li>
</ol>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="iii-common-therapeutic-modalities">III. COMMON THERAPEUTIC MODALITIES<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#iii-common-therapeutic-modalities" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h3 level="3" id="a-prevention">A. Prevention<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#a-prevention" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h3></div>
<ol>
<li>Prevention is the single most important intervention. Most diaper dermatitis is self-limited and may resolve or be prevented quickly with the following steps. Take care with any products that contain preservatives, fragrances, or other additives as they may further irritate the skin. It is important to closely read the ingredient label of all diaper products. The use of superabsorbent disposable diapers has decreased the incidence of the disease.
a. Airing of the diaper area or frequent diaper changes
b. Always clean the skin in the diaper area, gently. Use of warm water and a soft cloth is preferable.
c. Applying barrier creams and ointments (such as petrolatum or zinc oxide) as preventive measures. The ointment or paste should be applied thickly at every diaper change and can be covered with petroleum jelly to prevent sticking to the diaper. The ointment or paste should be long lasting and should stick to irritated or broken areas of skin. It is not necessary to completely clean the ointment or paste off the skin at diaper changes.</li>
<li>Always clean the skin in the diaper area, gently. Aggressive cleansing can cause or worsen irritation and delay skin healing. Gentle cleansing with warm water and a soft cloth is usually sufficient. If soap is desired, a mild, fragrance-free product (sample brand names: Dove sensitive or Cetaphil) is recommended. Powders are best avoided.</li>
</ol>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h3 level="3" id="b-treatment">B. Treatment<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#b-treatment" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h3></div>
<ol>
<li>
<p><em>C. albicans</em> diaper dermatitis is treated with a topical antiyeast cream such as nystatin applied TID or with each diaper change. A barrier cream or petrolatum may be placed over the antiyeast cream.</p>
</li>
<li>
<p>In severe dermatitis, hydrocortisone 1% cream twice daily for 1 or 2 days may help to decrease discomfort in between use of other topicals.</p>
</li>
</ol>
<p>C. Follow-up</p>
<ol>
<li>Routine visits for care is sufficient follow-up.</li>
<li>In severe diaper dermatitis, a return visit to assess response is recommended.</li>
</ol>
<p><img src="assets/images/image-20251225-c19bdc40.jpeg" alt="img-69.jpeg"></p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="patient-education">PATIENT EDUCATION<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#patient-education" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="diaper-dermatitis-or-diaper-rash">Diaper Dermatitis or Diaper Rash<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#diaper-dermatitis-or-diaper-rash" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<ul>
<li>Diaper dermatitis or diaper rash treatment is most effective when a combination of measures is used together. The letters ABCDE help to remember all of these measures:</li>
<li>A = air out the skin by allowing the child to go diaper-free or frequent changes</li>
<li>B = barrier; use a paste or ointment to protect the skin.</li>
<li>C = clean; keep the skin clean.</li>
<li>D = disposable diapers; during an episode of diaper rash, consider using disposable rather than cloth diapers.</li>
<li>E = educate; educate yourself about how to prevent a recurrence of diaper rash.</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="nummular-dermatitis-nummular-eczema-or-discoid-eczema">NUMMULAR DERMATITIS (NUMMULAR ECZEMA OR DISCOID ECZEMA)<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#nummular-dermatitis-nummular-eczema-or-discoid-eczema" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="i-overview">I. OVERVIEW<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#i-overview" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>A. Definition: An inflammatory skin disorder with coin-shaped, usually scaly, lesions generally affecting lower extremities, also referred to as discoid eczema</p>
<p>B. Etiology</p>
<ol>
<li>The exact pathogenesis is unknown.</li>
<li>The exudative variant starts acutely and may persist for weeks, months, and rarely years.</li>
<li>Secondary infection is common, and sensitivity to contactants is thought to play a role.</li>
</ol>
<p>C. Pathogenesis</p>
<ol>
<li>The initial plaque may appear at the site of trauma or infection, for example, a thermal burn, scabies infestation, varicose vein surgery, insect bite, or localized ACD site.</li>
<li>Severe, extensive nummular dermatitis can be an "id" reaction or an autoeczematization following another type of severe infectious or inflammatory process.</li>
</ol>
<p>D. Incidence</p>
<ol>
<li>Often appears after a skin injury, such as a abrasion, insect bite, or burn</li>
<li>Affects males more than females</li>
<li>Men tend to have first outbreaks between 55 and 65 years.</li>
<li>Women are likely to have first outbreaks younger between 15 and 25 years.</li>
<li>Children are affected less often.</li>
</ol>
<p>E. Considerations across lifespan</p>
<ol>
<li>The condition is chronic.</li>
<li>Plaques may be lichenified.</li>
</ol>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="ii-assessment">II. ASSESSMENT<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#ii-assessment" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>A. Clinical manifestations</p>
<ol>
<li>Characterized by lesions that are 2 to 10 cm or more, distinct, coin shaped or oval, and often distributed symmetrically on the lower legs, arms, backs of hands, and other sites (Figure 9-17)</li>
<li>Presents in two forms
a. Dry, nummular dermatitis, which is usually subacute with erythema and edema
b. Exudative "wet" nummular dermatitis with vesiculation followed by oozing and scaling</li>
<li>Pruritus may be present; color is usually pink to dull red; plaque may be present.</li>
</ol>
<p>B. History and physical examination
a. History of psoriasis, AD, and contact dermatitis associated with subsequent nummular eczema.
b. Lesions may be present for months to weeks.
c. Change in seasons or excessive cold may initiate nummular eczema.
d. Coin-shaped, small vesicles and papules with regional clusters of lesions.</p>
<p>C. Differential diagnoses</p>
<ol>
<li>Allergic contact dermatitis</li>
<li>Atopic dermatitis</li>
<li>Cutaneous T-cell lymphoma</li>
<li>Drug eruptions</li>
<li>Irritant contact dermatitis</li>
<li>Pityriasis rosea</li>
<li>Plaque psoriasis</li>
<li>Stasis dermatitis</li>
<li>Tinea infections, particularly tinea corporis</li>
</ol>
<p>D. Diagnostic tests</p>
<ol>
<li>Microscopy of skin scrapings to rule out fungal infection.</li>
<li>Bacterial, fungal, and viral culture may be needed to rule out secondary infection.</li>
<li>Skin biopsy may be required in dermatitis that is unresponsive to therapy to rule out other associated problems particularly in older children or adults.</li>
<li>Workup for other systemic diseases as warranted</li>
</ol>
<p><img src="assets/images/image-20251225-100e12ca.jpeg" alt="img-70.jpeg">
FIGURE 9-17. Nummular eczema with thick, adherent scale crust. (From Lugo-Somolinos, A., Lee, I., McKinley-Grant, L., Goldsmith, L. A., Papier, A., Adigun, C. G., ..., Fredeking, A. (2011). VisualDx: Essential dermatology in pigmented skin. Philadelphia, PA: Wolters Kluwer.)</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="iii-common-therapeutic-modalities">III. COMMON THERAPEUTIC MODALITIES<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#iii-common-therapeutic-modalities" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>A. Treatment—See first section on all eczemas and dermatitis.</p>
<ol>
<li>Therapeutic interventions</li>
</ol>
<p>a. Hydration of skin with moisturizing creams and ointments
b. Use of topical corticosteroids or topical calcineurin inhibitors
c. Use of topical tar preparations
d. Use of systemic antibiotics if secondary bacterial infection
e. PUVA or narrow-band ultraviolet B may be used in very difficult cases.
f. Resistant lesions may require intralesional corticosteroid injections.</p>
<p>B. Follow-up</p>
<ol>
<li>
<p>First follow-up visit in 7 to 14 days to assess treatment effectiveness with patients who have moderate-to-severe disease</p>
</li>
<li>
<p>Monthly visits until the patient is using primarily moisturizers</p>
</li>
<li>
<p>When skin condition is stable, visits every 6 months for re-evaluation</p>
</li>
<li>
<p>As needed for flairs and failure to respond to treatment</p>
</li>
<li>
<p>Nummular dermatitis can be a long-term condition. Patients may need many repeated treatments before the symptoms go away. The symptoms may return later.</p>
</li>
</ol>
<p><img src="assets/images/image-20251225-a137fdb4.jpeg" alt="img-71.jpeg"></p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="patient-education">PATIENT EDUCATION<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#patient-education" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h3 level="3" id="nummular-dermatitis-see-boxes-9-2-9-3-9-4-9-5-and-9-7">Nummular Dermatitis (See Boxes 9-2, 9-3, 9-4, 9-5, and 9-7)<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#nummular-dermatitis-see-boxes-9-2-9-3-9-4-9-5-and-9-7" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h3></div>
<ul>
<li>Methods of skin hydration and moisturization</li>
<li>Skip any cleansers or topicals that may be drying.</li>
<li>Proper methods of application and amounts of medications</li>
<li>Avoid any activities that dry, heat, or irritate the skin.</li>
<li>Dress in loose clothing or fabrics that are not irritating to the skin.</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="other-commonly-seen-disorders-in-patients-with-eczema-covered-in-this-textbook">OTHER COMMONLY SEEN DISORDERS IN PATIENTS WITH ECZEMA COVERED IN THIS TEXTBOOK<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#other-commonly-seen-disorders-in-patients-with-eczema-covered-in-this-textbook" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>I. Lichen simplex chronicus: See Papulosquamous Diseases (Chapter 8).
II. Keratosis pilaris: See Papulosquamous Diseases (Chapter 8).
III. Ichthyosis: See Dermatologic Conditions in Children (Chapter 13).</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="bibliography">BIBLIOGRAPHY<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#bibliography" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>Akdis, C. A., Akdis, M., Bieber, T., Bindsley-Jensen, C., Boguniewicz, M., Eigenmann, P., ..., Zuberbier, T. (2006). Diagnosis and treatment of AD in children and adults: European Academy of Allergology and Clinical Immunology/American Academy of Allergy, Asthma and Immunology/PRACTALL Consensus Report. Journal of Allergy and Clinical Immunology, 118, 152–169.</p>
<p>Berger, T. G., Duvic, M., Van Voorhees, A. S., VanBeek, M. J., Frieden, I. J., &amp; American Academy of Dermatology Association Task Force. (2006). The use of topical calcineurin inhibitors in dermatology: Safety concerns. Report of the American Academy of Dermatology Association Task Force. Journal of the American Academy of Dermatology, 54(5), 818–823.</p>
<p>Boguniewicz, M., &amp; Leung, D. Y. M. (2010). Recent insights into AD and implications for management of infectious complications. Journal of Allergy and Clinical Immunology, 125(1), 4–13.</p>
<p>Boguniewicz, M., &amp; Leung, D. Y. M. (2011). Atopic dermatitis: A disease of altered skin barrier and immune dysregulation. Immunological Reviews, 242, 233–246.</p>
<p>Boguniewicz, M., Moore, N., &amp; Paranto, K. (2008). Allergic diseases, quality of life and the role of the dietician. Nutrition Today, 43, 6–10.</p>
<p>Boguniewicz, M., &amp; Nicol, N. (2002). Conventional therapy for atopic dermatitis. Immunology and Allergy Clinics of North America, 22(1), 107–124.</p>
<p>Boguniewicz, M., &amp; Nicol, N. H. (2008). General management of patients with atopic dermatitis. In S. Reitamo, T. A. Luger, &amp; M. Steinhoff (Eds.), Textbook of atopic dermatitis (pp. 147–164). Andover, UK: Informa UK, Ltd.</p>
<p>Boguniewicz, M., Nicol, N., Kelsay, K., &amp; Leung, D. Y. (2008). A multidisciplinary approach to evaluation and treatment of atopic dermatitis. Seminars in Cutaneous Medicine and Surgery, 27(2), 115–127.</p>
<p>Bonamonte, D., Foti, C., Vestita, M., Ranieri, L. D., &amp; Angelini, G. (2012). Nummular eczema and contact allergy: A retrospective study. Dermatitis, 23(4), 153–157.</p>
<p>Devillers, A. C. C., &amp; Oranje, A. P. (2012). Wet-wrap treatment in children with atopic dermatitis: A practical guideline. Pediatric Dermatology, 29(1), 24–27.</p>
<p>Deleo, V. A., Elsner, P., &amp; Marks, J. G. Jr. (2000). Contact &amp; occupational dermatology (3rd ed.). St. Louis, MO: Mosby.</p>
<p>Eichenfield, L. F., Tom, W. L., Chamlin, S. L., Feldman, S. R., Hanifin, J. M., Simpson, E. L., ..., Sidbury, R. (2014). Guidelines of care for the management of atopic dermatitis: Section 1. Diagnosis and assessment of atopic dermatitis. Journal of the American Academy of Dermatology, 70, 338–351.</p>
<p>Fonacier, L., Bernstein, D. I., Pacheco, K., Holness, D. L., Blesing-Moore, J., Khan, D., ..., Wallace, D. (2015). Contact dermatitis: A practice parameter-update 2015. The Journal of Allergy and Clinical Immunology. In Practice, 3(3 Suppl), S1–S39.</p>
<p>Goldsmith, L. A., Katz, S. I., Gilchrest, B. A., Paller, A. S., Leffell, D. J., &amp; Wolff, K. (2012). Fitzpatrick’s dermatology in general medicine (8th ed.). New York, NY: McGraw-Hill.</p>
<p>Greaves, M. W., &amp; Leung, D. Y. M. (Eds.) (2000). Allergic skin disease: A multidisciplinary approach. New York, NY: Marcel Dekker, Inc.</p>
<p>Gutman, A. B., Kligman, A. M., Sciacca, J., &amp; James, W. D. (2005). Soak and smear: A standard technique revisited. Archives of Dermatology, 141(12), 1556–1559.</p>
<p>Iwahira, Y., Nagasao, T., Shimizu, Y., Kuwata, K., &amp; Tanaka, Y. (2015). Nummular eczema of breast: A potential dermatologic complication after mastectomy and subsequent breast reconstruction. <em>Plastic Surgery International</em>. Volume 2015, Article ID 209458, 6 pages.</p>
<p>Kapoor, R., Menon, C., Hoffstad, O., Bilker, W., Leclerc, P., &amp; Margolis, D. J. (2008). The prevalence of atopic triad in children with physician-confirmed atopic dermatitis. Journal of the American Academy of Dermatology, 58, 68–73.</p>
<p>Klunk, C., Domingues, E., &amp; Wiss, K. (2014). An update on diaper dermatitis. Clinics in Dermatology, 32, 477–487.</p>
<p>Leung, D. Y. M. (2013). New insights into atopic dermatitis: Role of skin barrier and immune dysregulation. <em>Allergology International</em>, 62, 151–161.</p>
<p>Marks, J. G., &amp; Miller, J. J. (2006). Lookingbill and Marks’ principles of dermatology (4th ed.). Philadelphia, PA: Saunders-Elsevier.</p>
<p>McCann, S. E., &amp; Huether, S. E. (2014). Structure, function, and disorders of the integument. In S. E. Huether, K. L. McCance, V. L. Brasher, &amp; N. S. Rote (Eds.), Pathophysiology—The biologic basics for disease in adults and children (7th ed., pp. 1616–1652). St. Louis, MO: Mosby-Elsevier.</p>
<p>Moore, J. A., Nicol, N. H., &amp; Ruszkowski, A. M. (1995). What patients need to know about patch testing. Dermatology Nursing, 20(1), 20–26.</p>
<p>Nicol, N. H. (1987). Atopic dermatitis: The (wet) wrap-up. American Journal of Nursing, 87(12), 1560–1563.</p>
<p>Nicol, N. H. (2003). Dermatitis/eczemas. In M. J. Hill (Ed.), Dermatologic nursing essentials: A core curriculum (2nd ed., pp. 103–116). Pitman, NJ: Dermatology Nurses’ Association.</p>
<p>Nicol, N. H. (2005a). Atopic triad: Atopic dermatitis, allergic rhinitis and asthma. American Journal for Nurse Practitioners, (Suppl), 36–40.</p>
<p>Nicol, N. H. (2005b). Use of moisturizers in dermatologic disease: The role of healthcare providers in optimizing treatment outcomes. Cutis, 76(Suppl 6), 26–31.</p>
<p>Nicol, N. H. (2009). Assessment of the integumentary system. In J. M. Black, &amp; J. H. Hawks (Eds.), Medical-surgical nursing: Clinical management for positive outcomes (8th ed., pp. 1186–1198). Philadelphia, PA: WB Saunders Company.</p>
<p>Nicol, N. H., &amp; Baumeister, L. (1997). Topical corticosteroid therapy: Considerations for prescribing and use. Lippincott’s Primary Care Practice, 1(1), 62–69.</p>
<p>Nicol, N. H., &amp; Boguniewicz, M. (2008). Successful strategies in AD management. Dermatology Nursing, (Suppl), 3–19.</p>
<p>Nicol, N. H., Boguniewicz, M., Strand, M., &amp; Klinnert, M. D. (2014). Wet wrap therapy in children with moderate to severe atopic dermatitis in a multidisciplinary treatment program. The Journal of Allergy and Clinical Immunology. In Practice, 2(4), 400–406.</p>
<p>Nicol, N. H., &amp; Ersser, S. J. (2010). The role of the nurse educator in managing atopic dermatitis. In M. Boguniewicz (Ed.), Immunology and allergy clinics of North America: Atopic dermatitis (pp. 369–383). Philadelphia, PA: Saunders-</p>
<p>Elsevier.</p>
<p>Nicol, N. H., Hanifin, J. M., Tofte, S., &amp; Boguniewicz, M. (2003). Evolution in the treatment of atopic dermatitis: New approaches to managing a chronic skin disease. <em>Dermatology Nursing</em>, 15(Suppl 4), 3–19.</p>
<p>Nicol, N. H., &amp; Huether, S. E. (2014). Alterations of the integument in children. In S. E. Huether, K. L. McCance, V. L. Brasher, &amp; N. S. Rote (Eds.), <em>Pathophysiology—The biologic basics for disease in adults and children</em> (7th ed., pp. 1653–1667). St. Louis, MO: Mosby-Elsevier.</p>
<p>Nicol, N. H., &amp; Huether, S. E. (2012). Structure, function, and disorders of the integument. In S. E. Huether, K. L. McCance, V. L. Brasher, &amp; N. S. Rote (Eds.), <em>Understanding pathophysiology</em> (6th ed., pp. 1038–1069). St. Louis, MO: Mosby-Elsevier.</p>
<p>Nicol, N. H., &amp; Huether, S. E. (2016). Alterations of the integument in children. In S. E. Huether, K. L. McCance, V. L. Brasher, &amp; N. S. Rote (Eds.), <em>Understanding pathophysiology</em> (6th ed., pp. 1111–1122). St. Louis, MO: Mosby-Elsevier.</p>
<p>Odhiambo, J. A., Williams, H. C., Clayton, T. O., Robertson, C. F., Asher, M. I., &amp; the ISAAC Phase Three Study Group. (2009). Global variations in prevalence of eczema symptoms in children from ISAAC Phase Three. <em>Journal of Allergy and Clinical Immunology</em>, 124, 1251–1258.</p>
<p>Penzer, R., &amp; Ersser, S. J. (2010). <em>Principles of skin care</em>. Oxford, UK: Wiley-Blackwell.</p>
<p>Spergel, J. M. (2010). From atopic dermatitis to asthma: The atopic march. <em>Annals of Allergy, Asthma, and Immunology</em> 105, 99–109.</p>
<p>Spergel, J. M., &amp; Leung, D. Y. (2006). Safety of topical calcineurin inhibitors in atopic dermatitis: Evaluation of the evidence. <em>Current Allergy and Asthma Reports</em>, 6, 270–274.</p>
<p>Tuzun, Y., Wolf, R., Baglam, S., &amp; Engin, B. (2015). Diaper (napkin) dermatitis: A fold (intertriginous) dermatosis. <em>Clinics in Dermatology</em>, 33, 477–482.</p>
<p>Weinberg, S., Prose, N. S., &amp; Kristal, L. (2008). <em>Color atlas of pediatric dermatology</em> (4th ed.). New York, NY: McGraw-Hill.</p>
<p>Wolff, K., Johnson, R. A., &amp; Saavedra, A. P. (2013). Fitzpatrick’s color atlas and synopsis of clinical dermatology (7th ed.). New York, NY: McGraw-Hill.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="study-questions">STUDY QUESTIONS<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#study-questions" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<ol>
<li>The location of the cutaneous manifestations or symptoms of atopic dermatitis varies depending on the age of the patient.</li>
</ol>
<p>a. True
b. False</p>
<ol start="2">
<li>Atopic dermatitis is the most common chronic, relapsing inflammatory skin disease of children. Which of the following diseases is not usually associated with atopic dermatitis?</li>
</ol>
<p>a. Asthma
b. Allergic rhinitis
c. Food allergies
d. Discoid lupus</p>
<ol start="3">
<li>The infant with seborrheic dermatitis generally presents with all of the following signs and symptoms except:</li>
</ol>
<p>a. Erythematous papules
b. Greasy yellow scale
c. Intense pruritus</p>
<p>d. Rash on scalp and forehead</p>
<ol start="4">
<li>
<p>A parent can best prevent irritant diaper dermatitis in a healthy 6-month-old infant by:
a. Changing diapers frequently
b. Increasing dietary vitamin C intake
c. Using cloth diapers only
d. Using commercial diaper wipes regularly</p>
</li>
<li>
<p>Wet wrap therapy:
a. May promote skin dryness if not used with sufficient emollients
b. Should not be used over topical corticosteroids
c. Prevents the healing of excoriated lesions
d. Is not effective for patients with recalcitrant eczema</p>
</li>
<li>
<p>Which of the following is a frequently described characteristic of nummular eczema?
a. Coin-shaped lesions
b. Silver plaque lesions
c. Fish scale-like lesions
d. Facial tautness</p>
</li>
<li>
<p>Which of the following is most consistent with proper “soak and seal” method of skin care for atopic dermatitis?
a. Bath in tepid water for 15 minutes followed by application of moisturizer and then medication applied on top.
b. Shower in warm water followed by a thorough drying of the skin and then use of moisturizer to the entire body, waiting at least 2 hours to apply topical medications.
c. Bath in warm water followed by immediate application of anti-inflammatory medications to affected areas and then application of moisturizer to uninvolved areas.
d. Bath only twice weekly followed by application of topical anti-inflammatory medication to affected areas, then application of moisturizer over the medication.</p>
</li>
<li>
<p>Nummular eczema is an inflammatory skin usually affecting the:
a. Scalp
b. Upper extremities
c. Lower extremities
d. Torso</p>
</li>
<li>
<p>Patch testing is considered the gold standard to determine if a patient has:
a. Irritant contact dermatitis</p>
</li>
</ol>
<p>b. Allergic contact dermatitis
c. Atopic dermatitis
d. Nummular eczema</p>
<ol start="10">
<li>Lichenification is:
a. A prominent clinical feature only during the adult phase of atopic dermatitis
b. Most evident on the neck and face
c. An accentuation of skin markings associated with thickening of the skin
d. Seen only during acute flares of atopic dermatitis</li>
</ol>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="answers-to-study-questions">Answers to Study Questions:<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#answers-to-study-questions" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>1.a
2.d
3.c
4.a
5.a
6.a
7.c
8.c
9.b
10.c</p></div></div></div></div></div></div></div><div data-testid="stAppIframeResizerAnchor" data-iframe-height="true" class="st-emotion-cache-1dumvfu eht7o1d9"></div></section></div></div></div><div data-testid="portal" id="portal" class="st-emotion-cache-1q6lfs0 e19n7mk11"></div></div><div class=""></div></div>
  

</body></html>